## Supplement

## 2002 Canadian Sexually Transmitted Infections Surveillance Report



Suggested citation: Public Health Agency of Canada. 2002 Canadian Sexually Transmitted Infections Surveillance Report .
CCDR2005;3IS2:I-39.

This publication was produced by the Scientific Publication and Multimedia Services Section of the Communications Directorate.

To obtain additional copies or subscribe to the Canada Communicable Disease Report, please contact the Member Service Centre, Canadian Medical Association, 1867 Alta Vista Drive, Ottawa, ON, Canada KIG 3Y6, Tel.: (6I3) 73I-86IO Ext. 2307 or 888-855-2555 or by Fax: (6I3) 236-8864.

This publication can also be accessed electronically via Internet using a Web browser at http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc
© Her Majesty the Queen in Right of Canada, represented by the Minister of Health (2005)

## 2002 Canadian Sexually Transmitted Infections Surveillance Report

## TABLEOF CONTENTS

Foreword ..... iii
Executive Summary ..... V
Figure 1: Reported Cases of STI as a Proportion of all Notifiable Diseases in Canada, 2002 ..... vi
Genital Chlamydia ..... 1
Table 1: Number of Reported Cases and Rates of Genital Chlamydia Infection in Canada, 1992, 1997 and 2002 ..... 1
Table 2: Reported cases and rates of Genital Chlamydia by province/territory ..... 4
Table 3: Counts and Rates of Hospitalization for Ectopic Pregnancy by Year and Age Group, Canada, 1995-2000 ..... 6
Figure 1: Reported (Genital) Chlamydia Rates in Canada, 1992-2002 ..... 2
Figure 2: Reported Male (Genital) Chlamydia Rates in Canada by Selected Age Group, 1992-2002 ..... 2
Figure 3: Reported Famle (Genital) Chlamydia Rates in Canada by Selected AGe Group, 1992-2002 ..... 3
Figure 4: Reported Cases and Rates of Genital Chlamydia by Province/Territory, 2002 ..... 3
Figure 5: Reported Male Genital Chlamydia Rates in Canada by Province/Territory, 1997 and 2002 ..... 5
Figure 6: Reported Female Genital Chlamydia Rates in Canada by Province/Territory, 1997 and 2002 ..... 5
Gonorrhea ..... 7
Table 1: Percentage Increase in Number of Reported Male Gonorrhea Cases, Canada, 1997-2002 ..... 9
Table 2: Percentage Increase in Number of Reported Famale Gonorrhea Cases, Canada, 1997-2002. ..... 10
Table 3: Reported Cases and Rates by Province/Territory ..... 11
Table 4: Antimicrobial Susceptibility of N. Gonorrhoeae Strains Tested in Canada in 2002 ..... 14
Figure 1: Reported Gonorrhea Rates in Canada, 1980-2002 ..... 7
Figure 2: Reported Gonorrhea Rates in Canada by Sex and Age Group, 2002 ..... 8
Figure 3: Reported Male Gonorrhea Rates in Canada by Age Group, 1992-2002 ..... 8
Figure 4: Reported Famle Gonorrhea Rates in Canada by Age Group, 1992-2002 ..... 9
Figure 5: Reported Cases and Rates of Gonorrhea in Canada by Province/Territory, 2002 ..... 10
Figure 6: Reported Rate of Gonorrhea by Sex and Province/Territory, 2002 ..... 12
Figure 7: Reported Male Gonorrhea Rates in Canada by Province/Territory, 1997 and 2002 ..... 12
Figure 8: Reported Famle Gonorrhea Rates in Canada by Province/Territory, 1997 and 2002 ..... 13
Infectious Syphilis ..... 15
Table 1: Percentage Increase in Number of Reported Male Syphilis Cases, Canada, 1997-2002 ..... 17
Table 2: Percentage Increase in Number of Reported Female Syphilis Cases, Canada, 1997-2002 ..... 18
Table 3: "Syphilis-Free Status" by 3-Year Interval and Province/Territory, Canada, 1994-2002 ..... 19
Figure 1: Reported Infectious Syphilis Rates in Canada, 1993-2002 ..... 15
Figure 2: Reported Rate of Infectious Syphilis by Sex and Age Group, 2002 ..... 16
Figure 3: Reported Rates of Infectious Syphilis in Males, 1997 and 2002 ..... 17
Figure 4: Age Distribution of Reported Infectious Syphilis Cases in MSM, Canada, 1994-2002 ..... 18
Figure 5: Reported Rate of Infectious Syphilis among Females, by Age, 1997 and 2002 ..... 19
Figure 6: Reported Infectious Syphilis Cases and Rates in Canada by Province/Territory and Sex, 1993-2002 ..... 20
Figure 7: Reported Rates of Infectious Syphilis among Males by Province/Territory, 1997 and 2002 ..... 21
Figure 8: Reported Rates of Infectious Syphilis among Females by Province/Territory, 1997 and 2002 ..... 21
Technical Notes ..... 23
References ..... 25
Appendix 1
Table 1.1: Reported Genital Chlamydia Cases and Rates in Canada by Age Group and Sex, 1991-2002 ..... 26
Table1.2: Reported Genital Chlamydia Cases and Rates in Canada by Province/Territory and Sex, 1991-2002 ..... 28
Table 2.1: Reported Gonorrhea Cases and Rates in Canada by Age Group and Sex, 1980-2002 ..... 30
Table 2.2: Reported Gonorrhea Cases and Rates in Canada by Province/Territory and Sex, 1980-2002 ..... 33
Table 3.1: Reported Infectious Syphilis Cases and Rates in Canda by Age Group and Sex, 1993-2002 ..... 36
Table 3.2: Reported Infectious Syphilis Cases and Rates in Canada by Province/Territory and Sex, 1993-2002 ..... 38

## FOREWORD

The Sexual Health and Sexually Transmitted Infections section of the Public Health Agency of Canada is pleased to provide you with this latest version of the Sexually Transmitted Infections (STI) Surveillance Report. The term STI (sexually transmitted infection), now commonly used in place of STD (sexually transmitted disease), is more encompassing and includes infections that may be asymptomatic.

The timing of this report is ideal, as the Sexual Health and Sexually Transmitted Infections section is currently revising the national STI goals set in 1996, as well as revising the 1998 Canadian STD Guidelines. In addition, this section has continued its development of the Minimum Dataset in collaboration with the provinces and territories. Such a dataset would enhance the consistency and timeliness of data submission at the national level. However, none of these can be done effectively without a knowledge of the current national STI picture.

This publication focuses on basic epidemiologic information for diseases that are transmitted predominantly through sexual contact and that are nationally reportable to the Public Health Agency of Canada. The list of nationally reportable diseases was determined by a federal/provincial/territorial committee using a priority-setting process to determine which diseases should be routinely monitored. Criteria were developed with the objective of ensuring the best use of resources in the prevention and control of diseases that are a threat to Canadians. The STI included in this list are genital chlamydia, gonorrhea, and infectious syphilis. Other infections, such as genital herpes and human papillomavirus, are not reportable and therefore not included.

This report on Canadian trends in STI is intended for governments, health professionals, researchers, voluntary agencies that are involved in service provision and planning, and the general public. The goal is to provide information that can be used to support and
inform decision-making and programs aimed at improving the health of Canadians.

All surveillance systems have limitations; the following are the ones noted for our system. M any STI are asymptomatic, therefore some infections may go unnoticed, undiagnosed, and unreported. Furthermore, contact tracing is a critical activity in the prevention and control of STI, but recent increases in risky sexual behaviour, such as anonymous sex partnering, make contact tracing difficult. As a result, infections among anonymous contacts of cases may not be recognized and entered into the surveillance system. Among symptomatic individuals, only those who seek testing or medical care will be captured by this passive surveillance system. Because of these limitations, the counts in this report are likely an underestimate of the true burden of disease. However, the report does provide an estimate of the scope and trends of STI in Canada. Data up to 2001 have been finalized, but 2002 data are still subject to change because of reporting delays and other constraints of surveillance systems.

When reading this report, please keep in mind that small variability may exist between data reported by the Public Health Agency of Canada and data reported by individual provinces and territories. In such circumstances, provincial/territorial data are definitive, as their data are the most up to date.
This report, as well as our ongoing surveillance of STI, could not happen without the efforts of so many others:

- the Surveillance and Risk Assessment Division within the Public Health Agency of Canada, which maintains the Infectious Disease Reporting System from which counts of bacterial STI are derived;
- the National Microbiology Laboratory in Winnipeg, which provides data on antibioticresistant gonorrhea and has also contributed to sections of this report;
- the Data Development and Exchange Program at the Public Health Agency of Canada, which provided data on pelvic inflammatory disease as well as estimates of the number of births in Canada;
- the Field Surveillance Officers, located in several provinces and territories, who assist with data quality improvement and provide ongoing support to the Sexual Health and Sexually Transmitted Infections section;
- provincial and territorial health ministries. We gratefully acknowledge them for the timely manner in which they provide data to the Public Health Agency of Canada for their continued expert contributions to the national STI program.

Maureen Perrin, BA, ITMD
Senior Surveillance Analyst
Sexual Health and STI
Community Acquired Infections Division
Centre for Infectious Disease Prevention and Control
Cara Bowman, MHSc
Surveillance Analyst
Sexual Health and STI
Community Acquired Infections Division
Centre for Infectious Disease Prevention and Control

Susanne Shields, MSc
Head, STI and Behavioural Surveillance
Sexual Health and STI
Community Acquired Infections Division
Centre for Infectious Disease Prevention and Control
Barbara Jones
Acting M anager
Sexual Health and STI
Community Acquired Infections Division
Centre for Infectious Disease Prevention and Control
Thomas Wong, MD, MPH, CCFP, FRCPC
Director
Community Acquired Infections Division
Centre for Infectious Disease Prevention and Control

## EXECUTIVE SUMMARY

Since the last report, there have been continued increases in all three nationally reportable sexually transmitted infections (STI): chlamydia, gonorrhea, and infectious syphilis. This upward trend in STI rates has been reported since 1997.

The trend of increasing STI rates is one that has been reported to varying degrees in other industrialized countries. In the United Kingdom, rates of chlamydia infection have been rising since 1996 and those for gonorrhea infection since $1995{ }^{(1)}$. In 2002, rates of infectious syphilis were $73 \%$ higher among males and $33 \%$ higher among females than $2001^{(1)}$. With an exception in 2000, rates of chlamydia infection in the United States have risen steadily since 1996 ${ }^{(2)}$. However, unlike Canada, where rates have been steadily rising since 1998, rates of gonorrhea in the United States in 2002 were the lowest they had been in the previous 4 years. Also in the United States, rates of infectious syphilis have increased by $12.4 \%$ from 2001, which is much lower than the $66.7 \%$ increase observed in Canada.

There were 56241 cases of genital chlamydia in 2002, for a rate of 179.3 per 100000 population. This represents an $11.1 \%$ increase compared with the rate of 161.4 per 100000 in 2001 and a $57.5 \%$ increase above the rate in 1997. The number of reported cases of gonorrhea in 2002 was 7367 , for a rate of 23.5 per 100 000 population. This represents an increase of $7.9 \%$ compared with the 2001 rate of 21.8 per 100000 and
an increase of 57.3\% compared with the rate in 1997. In 2002, there were 463 cases of infectious syphilis reported, for a rate of 1.5 per 100000 population. This rate is $66.7 \%$ higher than that reported in 2001 ( 0.9 per 100000 population) and $284.9 \%$ higher than the rate reported in 1997. However, the percentage increase associated with infectious syphilis (compared with chlamydia and gonorrhea) must be interpreted with caution, as the case counts and rates of infectious syphilis are very small.

W ith a few exceptions, patterns of STI infection related to gender have remained fairly consistent. W omen continue to be disproportionately affected by chlamydia infection. Rates of gonorrhea and syphilis infection are still higher among men. For both chlamydia and gonorrhea, the males and females most at risk of infection are those between the ages of 15 and 29. The picture for syphilis, however, has changed. Among females, those most at risk continue to be between the ages of 20 and 39 , whereas the males most at risk are between the ages of 25 and 59, those in the 30 to 39 age group being at greatest risk.

In 2002, reported cases of chlamydia, gonorrhea, and syphilis accounted for $51 \%$ of all notifiable disease cases reported to Health Canada. This proportion has remained relatively stable over the years.

Figure 1: Reported Cases of STI as a Proportion of all Notifiable Diseases in Canada, 2002*


Source: Notifiable Diseases, Surveillance and Risk Assessment Division, Public Health Agency of Canada, 2004

## GENITALCHLAMYDIA

## (Chlamydia trachomatis)

- Genital chlamydia is the most commonly reported STI.
- The number of reported cases declined steadily when chlamydia became reportable in $1990^{(3)}$, reaching its lowest point in 1997.
- The picture has changed drastically over the last 5 years. The rate of chlamydia in Canada has reached an all-time high of 179.3 per 100000 in 2002, compared with 113.9 per 100000 in 1997.

Table 1: Number of Reported Cases and Rates of Genital Chlamydia Infection in Canada, 1992, 1997 and 2002

| Year | Number of <br> reported cases | Rate $^{1}$ |
| :--- | :---: | :---: |
| 1992 | 46365 | 163.4 |
| 1997 | 34144 | 113.9 |
| $2002^{2}$ | 56241 | 179.3 |

${ }^{1}$ Rate per 100000 population. Population estimates provided by Statistics Canada.
${ }^{2} 2002$ numbers are preliminary, and changes are anticipated.
Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI.

- The overall increase in the number of cases from 1997 to 2002 was $65 \%$. The male increase was $100 \%$, and the female increase was $52 \%$ over same period.
- Females have traditionally accounted for over $75 \%$ of all reported cases; a recent shift has seen that number drop slightly, to 69\%, in 2002.
- The reported rate remains significantly higher among females.


## Sex and Age Group Distribution

- Overall, the distribution of reported cases across age groups has remained fairly constant from 1997 to 2002 in spite of increased numbers.
- The majority of cases are aged 15 to 24 years.
- Among males, the consistently highest rate is in the age group 20-24, representing $38 \%$ of all male cases (see Figure 2).
- The 25-29 age group has the second highest rate of chlamydia among males.
- As of 2002, it appears that there is a divergence between 15-19 and 25- to 29-year-olds.
- The age group with the highest rate among females remains the 15-24 group (Figure 3).
- Those aged 20 to 24 now account for $37 \%$ of cases compared with $36 \%$ among those 15 to 19 years of age.


## Geographic Distribution

- In 2002, Ontario and Quebec reported the most cases of chlamydia (17 994 and 11112 respectively).
- To understand what a "case" means, note that an individual can have multiple cases of an infection, e.g. can be re-infected by an untreated partner.
- However, the highest reported rates of chlamydia are in the northern territories. As shown in Figure 4, the case counts are relatively small.
- Caution must be used in interpreting statistics from regions with small populations. Data based on small numbers of people are more prone to fluctuation and may inappropriately highlight very small changes in absolute cases as a large percentage change (may be unrelated to true changes in disease rate and be more difficult to interpret than data from larger populations).

Figure 1: Reported (Genital) Chlamydia Rates ${ }^{1}$ in Canada, 1992-2002 ${ }^{2}$

${ }^{1}$ Rate per 100000 population. Population estimates provided by Statistics Canada.
${ }^{2} 2002$ numbers are preliminary, and changes are anticipated.
Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI.

Figure 2: Reported Male (Genital) Chlamydia Rates ${ }^{1}$ in Canada by Selected Age Group, 1992-2002 ${ }^{2}$

${ }^{1}$ Rate per 100000 population. Population estimates provided by Statistics Canada.
${ }^{2} 2002$ numbers are preliminary, and changes are anticipated.
Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI.

Figure 3: Reported Female (Genital) Chlamydia Rates ${ }^{1}$ in Canada by Selected Age Group, 1992-2002²

${ }^{1}$ Rate per 100000 population. Population estimates provided by Statistics Canada.
${ }^{2} 2002$ numbers are preliminary, and changes are anticipated.
Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI.

Figure 4: Reported Cases and Rates ${ }^{1}$ of Genital Chlamydia by Province/Territory, 2002 ${ }^{2}$


[^0]- The Prairies, in particular Saskatchewan, have the highest reported rate of chlamydia outside of the northern region.
- The regional distribution of chlamydia cases, illustrated in Figure 4 for 2002, has remained fairly constant in recent years.
- The national rate of chlamydia continues to be driven by the larger, more populous regions in Canada (e.g. in Ontario, Quebec, and British Columbia, the number of cases has increased by at least 70\% from 1997 to 2002).
- Therefore, while increases are seen across most provinces/territories, rates of increase vary. The one exception is the Yukon, where the overall number of cases has actually decreased (Table 2).

Table 2: Reported Cases and Rates ${ }^{1}$ of Genital Chlamydia by Province/ Territory

|  | 1997 |  | $\mathbf{2 0 0 2}^{2}$ |  |  |
| :--- | ---: | ---: | ---: | ---: | ---: |
|  |  |  |  |  | $\%$ <br> change |
| NL | 335 | 60.5 | 522 | 100.5 | $56 \%$ |
| PE | 139 | 101.6 | 145 | 105.8 | $4 \%$ |
| NS | 1127 | 120.6 | 1574 | 168.5 | $40 \%$ |
| NB | 819 | 108.6 | 1313 | 175.0 | $60 \%$ |
| QC | 6380 | 87.4 | 11112 | 149.3 | $74 \%$ |
| ON | 10559 | 93.9 | 17994 | 148.4 | $70 \%$ |
| MB | 2587 | 227.6 | 3370 | 291.7 | $30 \%$ |
| SK | 2317 | 226.7 | 3613 | 362.9 | $56 \%$ |
| AB | 4547 | 160.3 | 7336 | 235.6 | $61 \%$ |
| BC | 4116 | 103.9 | 7701 | 187.2 | $87 \%$ |
| YT | 173 | 536.6 | 141 | 468.1 | $-18 \%$ |
| NT/NU* | 1045 | 1542.8 | 1420 | 2023.5 | $36 \%$ |
| Canada | $\mathbf{3 4} 144$ | $\mathbf{1 1 3 . 9}$ | $\mathbf{5 6 2 4 1}$ | $\mathbf{1 7 9 . 3}$ | $\mathbf{6 5 \%}$ |

${ }^{1}$ Rate per 100000 population. Population estimates provided by Statistics Canada.
${ }^{2} 2002$ numbers are preliminary, and changes are anticipated.
*The Northwest Territories was divided in April 1999 when Nunavut became a separate territory. To compare across time periods, these two territories have been combined.
Note: Small variability may exist between data reported by the provinces/territories and the Public Health Agency of Canada. Provincial/territorial data are definitive should a discrepancy exist.
Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI.

## Males

- Among males in 2002, Ontario has the largest number of cases (6 154), and N unavut had the highest reported rate (1833.4 per 100000 or 274 cases).
- Overall, there has been an increase in all provinces/territories since 1997, as illustrated in Figure 5 .
- The largest increase has occurred in British Columbia ( $135 \%$ from 1997 to 2002, 1002 to 2352 cases).


## Females

- In 2002, Yukon Territory is the only jurisdiction where there has been a reduction in the number of cases among females; however, rates continue to be high (Figure 6).
- The most cases are reported in Ontario (11 834), and the highest rate is in Nunavut ( 3958 per 100 000, as compared with the national average of 245 per 100000 ).
- Compared with males, the increase in female cases has been less dramatic between 1997 and 2002.
- Reported rates of chlamydia in British Columbia have increased the most of all regions: 72\% from 1997 to 2002 (from 3110 to 5348 cases respectively)


## Discussion

Surveillance systems capture only those cases in which an individual has presented to a health care professional and received a positive laboratory result for C. trachomatis. As a result, the true number of chlamydia cases in Canada is likely much higher than that reported. Lack of awareness, combined with lack of symptoms, further contributes to under-reporting. It is estimated that more than 50\% of males and $70 \%$ of females can be asymptomatic ${ }^{(4)}$, further diminishing the likelihood of testing.

The introduction of the nucleic acid amplification test (NAAT) has had an impact on chlamydia trends. This testing method, introduced in various regions of Canada in the late 1990s, permits the collection of urine-based samples instead of more invasive swabs.

Figure 5: Reported Male Genital Chlamydia Rates ${ }^{1}$ in Canada by Province/Territory, 1997 and $2002^{2}$

${ }^{1}$ Rate per 100000 population. Population estimates provided by Statistics Canada.
${ }^{2} 2002$ numbers are preliminary, and changes are anticipated.
Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI.

Figure 6: Reported Female Genital Chlamydia Rates ${ }^{1}$ in Canada by Province/Territory, 1997 and $2002^{2}$


[^1]The change in specimen collection removes a barrier to testing, especially for males. The minor shift in sex distribution may be partially explained by use of NAAT. However, it is the availability of non-invasive testing such as NAAT and effective, single-dose treatment for non-compliant individuals that favour the control and prevention of chlamydial infection.

NAAT alone does not adequately explain the persistent increase in reported cases of chlamydia. While almost every jurisdiction that has introduced NAAT has shown a subsequent increase in the number of cases in the following year, the expectation is that the increase will level off as transmission is reduced by improved detection and treatment. This trend has not yet been observed, suggesting that other factors, such as risk behaviours, point towards a true increase in disease incidence based on broader societal changes.

Untreated chlamydia can result in pelvic inflammatory disease (PID), which can lead to other complications such as tubal infertility and ectopic pregnancy (EP). It is estimated that in $20 \%$ to $25 \%$ of women untreated chlamydia will progress to PID, and these
women will be exposed to the additional risks of EP and tubal infertility ${ }^{(5)}$. EP occurs when a fertilized egg implants itself and the fetus develops outside the uterus. It is the leading cause of maternal death in the first trimester of pregnancy in industrialized countries. It can also lead to permanent sterility, affecting $20 \%$ to $60 \%$ of women who experience an $E P^{(6)}$. Chlamydia trachomatis infection is the primary infectious agent responsible, accounting for $33 \%{ }^{(7)}$ to $50 \%{ }^{(8)}$ of all EP .

The rate of hospitalization for EP in C anada seems to have declined among women 25 years and older (Table 3). This may be explained, in part, by the increased use of other methods to treat EP that do not require hospitalization ${ }^{(6)}$. Across years, rates of hospitalization for EP are highest among women between the ages of 35 and 44 and lowest in women under 25 .

Table 3: Counts and rates ${ }^{1}$ of hospitalization for ectopic pregnancy
by year and age group, Canada, 1995-2000

| Year |  |  |  |  |  | All women |
| :---: | :--- | :---: | :---: | :---: | :---: | :---: |
|  | Count | 322 | $\mathbf{2 0 - 2 4}$ | $\mathbf{2 5 - 3 4}$ | $\mathbf{3 5 - 4 4}$ | $\mathbf{1 5 - 3 4}$ |
|  | Rate | 13.2 | 14.3 | 1687 | 1520 | 7057 |
| 1996 | Count | 294 | 950 | 3877 | 1447 | 6568 |
|  | Rate | 13.1 | 13.7 | 16.6 | 28.4 | 17.5 |
| 1997 | Count | 289 | 923 | 3551 | 1423 | 6186 |
|  | Rate | 14.2 | 14.1 | 16.1 | 27.5 | 17.3 |
| 1998 | lount | 265 | 915 | 3305 | 1347 | 5832 |
|  | Rate | 13.0 | 14.2 | 15.5 | 25.6 | 16.6 |
| 1999 | Count | 261 | 846 | 2963 | 1264 | 5334 |
|  | Rate | 13.4 | 13.4 | 14.2 | 23.3 | 15.4 |
| 2000 | Count | 262 | 822 | 2630 | 1242 | 4956 |
|  | Rate | 14.6 | 13.5 | 13.0 | 22.5 | 14.8 |

${ }^{1}$ Rate per 1000 pregnancies. Pregnancies are calculated as the sum of live births, stillbirths, legally induced abortions, and ectopic pregnancies.
Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI.

## GONORRHEA

## (Neisseria gonorrhoeae)

- Like chlamydia, reported rates of gonorrhea have increased substantially after years of decline.
- At its lowest point in 1997, the reported rate was 14.9 per 100000
- As of 2002, this number has crept upwards to 23.5 per 100000 (see Figure 1)
- Rates of reported gonococcal infection remain consistently higher among men than women.
- Since 1997, reported cases have risen disproportionately across the sexes: by $74 \%$ in men and 52\% in women.


## Sex and Age Group Distribution

- The overall distribution of gonorrhea has remained relatively constant in 2002 as compared with other years.
- The most affected age group for females is 15 to 24 years (Figure 2).
- Males are somewhat older, as the highest rate occurs in 20- to 29-year-olds.
- A notable shift has occurred in reported male cases, indicating that the epidemic now affects older males.
- Since 1998, the rates among men in their 30s have been higher than among their adolescent counterparts (Figure 3).
- Furthermore, the greatest percentage increase in the number of cases from 1997 to 2002 was observed in men 40 years and older (Table 1).
- However, it is important to note that increases have been observed for all males aged 10 and up.

Figure 1: Reported Gonorrhea Rates ${ }^{1}$ in Canada, 1980-2002 ${ }^{2}$

${ }^{1}$ Rate per 100000 population. Population estimates provided by Statistics Canada.
${ }^{2} 2002$ numbers are preliminary, and changes are anticipated.
Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI.

Figure 2: Reported Gonorrhea Rates ${ }^{1}$ in Canada by Sex and Age Group, 2002 ${ }^{2}$

${ }^{1}$ Rate per 100000 population. Population estimates provided by Statistics Canada.
${ }^{2} 2002$ numbers are preliminary, and changes are anticipated.
Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI.

Figure 3: Reported Male Gonorrhea Rates ${ }^{1}$ in Canada by Age Group, 1992-2002 ${ }^{2}$


[^2]Table 1: Percentage Increase in Number of Reported Male Gonorrhea Cases, Canada, 1997-2002 ${ }^{1}$

| Age | $\mathbf{1 9 9 7}$ | $\mathbf{2 0 0 2}$ | Change |
| :---: | ---: | ---: | :---: |
| $0<1$ | 0 | 0 | $0 \%$ |
| $1-9$ | 0 | 0 | $0 \%$ |
| $10-14$ | 2 | 8 | $300 \%^{*}$ |
| $15-19$ | 333 | 472 | $42 \%$ |
| $20-24$ | 599 | 1121 | $87 \%$ |
| $25-29$ | 570 | 814 | $43 \%$ |
| $30-39$ | 765 | 1347 | $76 \%$ |
| $40-59$ | 337 | 768 | $128 \%$ |
| $60+$ | 23 | 60 | $161 \%$ |

${ }^{1} 2002$ numbers are preliminary, and changes are anticipated.
*Because case numbers are so small this increase should be interpreted with caution.
Note: Small variability may exist between data reported by the provinces/territories and the Public Health Agency of Canada. Provincial/territorial data are definitive should a discrepancy exist.
Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI.

- In 2002, more than $70 \%$ of reported female cases are under 25 years of age.
- This distribution of cases has been consistent over time.
- W omen aged 15 to 24 have the highest rates of gonorrhea (Figure 4), in contrast to older age groups in men.
- With the exception of women over 60 , the number of reported cases of gonorrhea has increased in all age groups.
- Other than the age group 1 to 9 , which has very few cases, the largest percentage increase was among females aged 40 to 59 ( 42 reported cases in 1997 compared with 97 in 2002, Table 2).

Figure 4: Reported Female Gonorrhea Rates ${ }^{1}$ in Canada by Age Group, 1992-2002 ${ }^{2}$


[^3]Table 2: Percentage Increase in Number of Reported Female Gonorrhea Cases, Canada, 1997-2002

| Age | $\mathbf{1 9 9 7}$ | $\mathbf{2 0 0 2}^{\mathbf{1}}$ | Change |
| :---: | ---: | ---: | :---: |
| $0<1$ | 0 | 1 | $\mathrm{n} / \mathrm{a}$ |
| $1-9$ | 2 | 5 | $150 \%$ |
| $10-14$ | 56 | 61 | $9 \%$ |
| $15-19$ | 716 | 1047 | $46 \%$ |
| $20-24$ | 578 | 872 | $51 \%$ |
| $25-29$ | 235 | 374 | $59 \%$ |
| $30-39$ | 184 | 301 | $64 \%$ |
| $40-59$ | 42 | 97 | $131 \%$ |
| $60+$ | 4 | 4 | $0 \%$ |

${ }^{1} 2002$ Numbers are preliminary, and changes are anticipated. N/A: not applicable
Note: Small variability may exist between data reported by the provinces/territories and the Public Health Agency of Canada. Provincial/territorial data are definitive should a discrepancy exist.
Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI.

## Geographic Distribution

- In 2002, the highest reported rates of gonorrhea are in the Northwest Territories and Nunavut (299.3 per 100000 and 267.9 per 100000 respectively)
- However, as shown in Figure 5, the number of cases is small, and the high rates are driven by small population numbers.
- Saskatchewan and M anitoba have the highest reported rates outside of the N orth.

Figure 5: Reported Cases and Rates ${ }^{1}$ of Gonorrhea by Province/Territory, $\mathbf{2 0 0 2}^{\text {² }}$


[^4]
## Table 3: Reported Cases and Rates1 by Province/Territory

|  | $\mathbf{1 9 9 7}$ |  | $\mathbf{2 0 0 2}^{2}$ |  |  |
| :--- | ---: | ---: | ---: | ---: | ---: |
|  | Cases | Rates | Cases*** | Rates | \% <br> change** |
| NL | 3 | 0.5 | 9 | 1.7 | $200 \%$ |
| PE | 1 | 0.7 | 0 | 0.0 | $-100 \%$ |
| NS | 108 | 11.6 | 199 | 21.3 | $84 \%$ |
| NB | 15 | 2.0 | 30 | 4.0 | $100 \%$ |
| QC | 545 | 7.5 | 878 | 11.8 | $61 \%$ |
| ON | 1931 | 17.2 | 3148 | 26.0 | $63 \%$ |
| MB | 518 | 45.6 | 635 | 55.0 | $23 \%$ |
| SK | 340 | 33.3 | 558 | 56.1 | $64 \%$ |
| AB | 406 | 14.3 | 980 | 31.5 | $141 \%$ |
| BC | 458 | 11.6 | 718 | 17.4 | $57 \%$ |
| YT | 0 | 0.0 | 11 | 36.5 | $\mathrm{n} / \mathrm{a}$ |
| NT/NU* | 150 | 221.5 | 201 | 286.4 | $34 \%$ |
| Canada | $\mathbf{4 4 7 7}$ | $\mathbf{1 4 . 9}$ | $\mathbf{7 3 6 7}$ | $\mathbf{2 3 . 5}$ | $\mathbf{6 5 \%}$ |

${ }^{1}$ Rate per 100000 population. Population estimates provided by Statistics Canada.
${ }^{2} 2002$ numbers are preliminary, and changes are anticipated.
*The Northwest Territories was divided in April 1999 when Nunavut became a separate territory. To compare across time periods, these two territories have been combined.
**Percentage change in number of cases.
***Numbers include cases where gender was not specified.
Note: small variability may exist between data reported by the provinces/territories and the Public Health Agency of Canada. Provincial/territorial data are definitive should a discrepancy exist.
Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI.

- Between 1997 and 2002, all jurisdictions except PEI have seen an increase in the number of reported cases of gonorrhea (see Table 3). However, because of small case numbers, this change for PEI should be interpreted with caution.
- The most substantial increase is in Alberta where there were 980 reported cases in 2002, up $141 \%$ from 1997.
- Other provinces also have substantial increases, but case counts are small.


## Geographic and Sex Distributions

- The national sex distribution, indicating that males make up about two-thirds of all reported gonorrhea cases, is not representative of all provinces and territories.
- Within larger provinces, such as Quebec, Ontario, and British Columbia, males do make up the bulk of reported gonorrhea cases (see Figure 6).
- In 2002, $84 \%$ of cases in British Columbia were male, the largest proportion of male cases in the country.
- Yukon rates appear quite high in Figure 6, but the total case count is 11 (compared with 718 in British Columbia).
- In other less populous jurisdictions, female rates are higher than rates reported among males.
- Nunavut, Nova Scotia, New Brunswick, and Saskatchewan have higher rates among females than males.
- The national picture is driven by trends in the more populous provinces such as Ontario, Quebec, and British Columbia.


## Males

- The male gonorrhea rate comparing 1997 and 2002 is shown in Figure 7.
- Note that Nunavut and the Northwest Territories have been combined to allow comparison over time. Because the rate is much higher than in other provinces/territories, Nunavut/N orthwest Territories is displayed in the inset graph to allow comparison of other jurisdictions.
- Outside of Nunavut and the Northwest Territories, M anitoba and Saskatchewan have consistently had the highest reported rates of male gonorrhea.
- The Yukon, which had no reported cases in 1997, has reported 8 male cases for 2002. The resulting rate should be interpreted with caution, given the low number.

Figure 6: Reported Rate ${ }^{1}$ of Gonorrhea by Sex and Province/Territory, 2002 ${ }^{2}$

${ }^{1}$ Rate per 100000 population. Population estimates provided by Statistics Canada.
${ }^{2} 2002$ numbers are preliminary, and changes are anticipated.
Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI.

Figure 7: Reported Male Gonorrhea Rates ${ }^{1}$ in Canada by Province/Territory, 1997 and $2002^{2}$


[^5]
## Females

- As with males, when comparing gonorrhea rates among females in 1997 and 2002 (see Figure 8), Nunavut and the Northwest Territories continue to have a much higher reported rate than other provinces/territories.
- In 2002, the Canadian rate was 17.5 per 100000 as compared with 302.5 per 100000 in Nunavut/Northwest Territories.
- To ease the comparison among other jurisdictions, N unavut and the N orthwest Territories have been included in the inset graph.
- Also as is the case with males, M anitoba and Saskatchewan show the highest gonorrhea rates among females outside of N unavut and the N orthwest Territories. However, between 1997 and 2002, Saskatchewan has surpassed M anitoba as the southern province/territory with the highest rate.


## Resistant Neisseria gonorrhoeae

- Antimicrobial resistance, increasing worldwide, is an issue particular to gonorrhea. Uncomplicated cases can be treated with a single dose of antimicrobial therapy. However, resistance of N . gonorrhoeae challenges the treatment, control, and prevention of this infection.
- In Canada, provincial laboratories submit to the National Microbiology Laboratory all gonococcal isol ates that have decreased susceptibility to at least one antibiotic.
- Penicillin- and tetracycline-resistant strains are documented worldwide, and recently fluoroquinolone resistance has become an issue.
- Once resistance rates reach between $3 \%$ and $5 \%$ (depending on the jurisdiction in Canada), that treatment (e.g. type of antibiotic, see Table 4) can no longer be recommended. For this reason, ongoing, accurate data on antimicrobial resistance and its associated risk factors (e.g. travel history, sexual practice) are needed.
- Table 4 outlines resistance in Canada for 2002.

Figure 8: Reported Female Gonorrhea Rates ${ }^{1}$ in Canada by Province/Territory, 1997 and $200 \mathbf{2}^{2}$


[^6]Table 4: Antimicrobial Susceptibility of N. Gonorrhoeae Strains Tested in Canada in 2002

| Antibiotic | Number of <br> strains resistant <br> to antibiotics | Resistance (\%) of <br> all cultured strains <br> in Canada* |
| :--- | :---: | :---: |
| Penicillin | 368 | 7.51 |
| Tetracycline | 830 | 16.93 |
| Erythromycin | 416 | 8.48 |
| Ciprofloxacin | 105 | 2.14 |

*Percentages are calculated using the number of specimens teted as the denominator: $\mathrm{n}=4,903$.
There is no resistant strain for spectinomycin, cefixime, or ceftriaxone.
Source: National Microbiology Laboratory, 2004

- Some strains have resistance to multiple antibiotics (e.g. penicillin, tetracycline, and erythromycin).
- Emergence of cephalosporin resistance is anticipated.
- The increasing use of NAAT to test for gonorrhea infection has implications for resistance trends, since this technology does not allow for resistance testing.
- An enhanced or sentinel surveillance system to track resistance trends may be needed. Such a system could incorporate epidemiologic data such as sex, age, and risk factors to help explain the resistance trends.


## Discussion

Asymptomatic infections likely result in under-diagnosis of cases ${ }^{(4)}$. Thus, trends noted in this report may not describe the full impact of gonorrhea infection in Canada. It is also unclear what impact new technology, such as NAAT, has had on observed gonorrhea infection rates. It is known that regional outbreaks of gonorrhea are helping to fuel the increasing rates.
Untreated gonorrhea infection may lead to pelvic inflammatory disease (PID) and its associated outcomes. However, the number of cases of PID associated with gonorrhea is much less than those attributed to untreated chlamydia infection.

At a national level, there are more reported cases of gonorrhea in men than women. However, males are more likely to be symptomatic than females and therefore would be more likely to present to the health care system for diagnosis and treatment. Furthermore, part of this higher incidence among men may be attributable to NAAT. Traditional diagnostic methods are particularly invasive for men, who, as a result, may be more deterred from seeking medical care than women. Non-invasive methods such as NAAT would thus likely motivate proportionately more men than women to be screened for gonorrhea infection.

## INFECTIOUSSYPHILIS

## (Treponema pallidum)

- Syphilis has been a notifiable disease in Canada since the $1920 \mathrm{~s}^{(9)}$. Disease progression is divided into the following stages: primary, secondary, early latent, late latent, and tertiary. There is al so latent syphilis of unknown duration.
- Prior to 1993, aggregate data were reported to the national level according to clinical manifestation, which categorizes syphilis stages into early symptomatic (primary and secondary syphilis) and other syphilis (early latent, late latent, Iatent of unknown duration, and tertiary).
- The alternative method of classification, based on infectivity, is more useful for disease surveillance as it enables estimation of the risk of disease transmission. Accordingly, syphilis is grouped as infectious syphilis (primary, secondary, and early latent), non-infectious syphilis (late latent and tertiary), and congenital syphilis ${ }^{(10)}$.
- Infectious syphilis is the least commonly reported STI.
- Like chlamydia and gonorrhea, rates of infectious syphilis have increased since 1997.
- The rate has increased 285\% from 1997 to 2002 (from 0.4 per 100000 to 1.5 per 100 000).
- Because case counts are relatively small, caution must be used when analyzing and interpreting trends in infectious syphilis data.

Figure 1: Reported Infectious Syphilis Rates ${ }^{1}$ in Canada, 1993-2002 ${ }^{2}$

${ }^{1}$ Rate per 100000 population. Population estimates provided by Statistics Canada.
${ }^{2} 2002$ numbers are preliminary, and changes are anticipated.
Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI.

## Sex and Age Group Distribution (Figure 2)

- Historically, there have been more reported cases of infectious syphilis among men than women. From 1993 until 2001, the female:male ratio was constant at approximately 1:1.3.
- The ratio changed dramatically in 2002 to 1:3.9, a sizeable increase in the reported number of cases among males.
- Since 1995, the age group with the highest incidence rate of infectious syphilis shifted, from the under 30 age group to those 30 and older.
- The shift is driven by the higher number of reported male cases, as the age distribution among women tends to be more evenly spread.
- Reported rates have increased $441 \%$ among males since 1997, whereas females have increased $80 \%$ over the same period. In 2002, males made up 79\% of all infectious syphilis cases as compared with just over 50\% before 1997.


## Males

- M ore than $85 \%$ of male cases of infectious syphilis occurred in those 30 years and older in 2002.
- Men aged 30 to 39 have the highest rate of infectious syphilis, at 6.6 per 100000 (Figure $3)$.
- There has been a dramatic increase since 2001, when the rate in this age group was 2.5 per 100000 ( $163 \%$ increase), and since 1997, when the rate was 1.0 per 100000 (560\% increase).
- Also notable in 2002, the 40- to 59-year age group has overtaken the 25 - to 29 -year age group and now has the second highest rate of infectious syphilis ( 3.2 vs. 2.8 per 100000 , respectively).
- However, because of differences in population size, the rate among males aged 25 to 29 is very close to that in the 40 to 59 age category.

Figure 2: Reported Rate ${ }^{1}$ of Infectious Syphilis by Sex and Age Group, 2002 ${ }^{2}$


[^7]Figure 3: Reported Rates ${ }^{1}$ of Infectious Syphilis in Males, 1997 and $\mathbf{2 0 0 2}^{2}$

${ }^{1}$ Rate per 100000 population. Population estimates provided by Statistics Canada.
${ }^{2} 2002$ numbers are preliminary, and changes are anticipated.
Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI.

Table 1: Percentage Increase in Number of Reported Male Syphilis Cases, Canada, 1997-2002

| Age | $\mathbf{1 9 9 7}$ | 2002 $^{\mathbf{1}}$ | \% Change |
| :---: | ---: | ---: | :---: |
| $0<1$ | 0 | 0 | $0 \%$ |
| $1-9$ | 0 | 0 | $0 \%$ |
| $10-14$ | 0 | 0 | $0 \%$ |
| $15-19$ | 1 | 5 | $400 \%$ |
| $20-24$ | 3 | 18 | $500 \%$ |
| $25-29$ | 8 | 30 | $275 \%$ |
| $30-39$ | 26 | 161 | $519 \%$ |
| $40-59$ | 26 | 143 | $450 \%$ |
| $60+$ | 1 | 11 | $1000 \%$ |

${ }^{1} 2002$ numbers are preliminary, and changes are anticipated. *Because case numbers are so small these increases should be interpreted with caution.
Note: Small variability may exist between data reported by the provinces/territories and the Public Health Agency of Canada. Provincial/territorial data are definitive should a discrepancy exist.
Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI.

## Men Who have Sex with Men (MSM)

- W orldwide, increasing rates of STI and an increasing prevalence of higher-risk sexual practices have been observed for MSM.
- Outbreaks of infectious syphilis in the MSM population have been investigated in Vancouver, Calgary, Ottawa, Toronto, and M ontreal.
- Between 1994 and 2001, the number of cases of infectious syphilis among MSM increased eight-fold ( 5 to 39 cases); in comparison, a four-fold increase was noted among heterosexual males over the same period
- The age distributions of infectious syphilis rates are different among heterosexual males and MSM.
- Among M SM , the most notable increases are in the 30 to 39 and 40 to 59 age groups (Figure 4).
- Among heterosexual males, increases have been observed in all ages 20 and up.

Figure 4: Age Distribution of Reported Infectious Syphilis Cases in MSM, Canada, 1994-2001


Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI - supplementary infromation. Source not included in routine surveillance.

## Females

- Compared with males, reported cases and rates of infectious syphilis among females are distributed much more evenly across age groups.
- The highest rates are in the 25 - to 29-year group ( 2.6 per 100000 ) followed by the 20 - to 24-year group ( 2.2 per 100000 ) in 2002.
- As with males, rates have increased in most ages since 1997.

Table 2: Percentage Increase in Number of Reported Female Syphilis Cases, Canada, 1997-2002

| Age | $\mathbf{1 9 9 7}^{190}$ | 2002 $^{\mathbf{1}}$ | \% Change |
| :---: | ---: | ---: | :---: |
| $0<1$ | 0 | 0 | $0 \%$ |
| $1-9$ | 0 | 0 | $0 \%$ |
| $10-14$ | 0 | 0 | $0 \%$ |
| $15-19$ | 3 | 6 | $100 \%$ |
| $20-24$ | 8 | 23 | $188 \%$ |
| $25-29$ | 13 | 27 | $108 \%$ |
| $30-39$ | 17 | 23 | $35 \%$ |
| $40-59$ | 8 | 14 | $75 \%$ |
| $60+$ | 1 | 1 | $0 \%$ |

${ }^{1} 2002$ numbers are preliminary, and changes are anticipated.
*Because case numbers are so small, these increases should be interpreted with caution.
Note: Small variability may exist between data reported by the provinces/territories versus the Public Health Agency of Canada. Provincial/ territorial data are definitive should a discrepancy exist.
Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI.

Figure 5: Reported Rate ${ }^{1}$ of Infectious Syphilis among Females, by Age, 1997 and $\mathbf{2 0 0 2}^{2}$

${ }^{1}$ Rate per 100000 population. Population estimates provided by Statistics Canada.
${ }^{2} 2002$ numbers are preliminary, and changes are anticipated.
Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI.

## Geographic Distribution

- In 2002, three provinces/territories in Canada reported no cases of syphilis for the previous 3 years (Table 3).
- However, outbreaks in certain parts of the country have driven the national rate to 1.5 per 100000.
- From 1998 until 2001, the national rate was driven predominantly by a large outbreak in Vancouver, BC. In 2002, this trend shifted slightly. Although $B C$ is still a large contributor to the national picture, outbreaks in Toronto and M ontreal are also having an impact, contributing $44 \%$ and $10 \%$ of cases respectively.

Table 3: "Syphilis-Free Status"1 by 3-Year Interval and Province/Territory, Canada, 1994-2002

| Province/ <br> Territory | 1994-1996 | 1997-1999 | 2000-2002 |
| :--- | :---: | :---: | :---: |
| NL |  | $\checkmark$ |  |
| PE |  | $\checkmark$ | $\checkmark$ |
| NS |  |  |  |
| NB |  | $\checkmark$ |  |
| QC |  |  |  |
| ON |  |  |  |
| MB |  |  |  |
| SK |  |  |  |
| AB |  |  |  |
| BC |  |  |  |
| YT |  | $\checkmark$ |  |
| NT |  | $\checkmark$ | $\checkmark$ |
| NU | - | - | $\checkmark$ |

[^8]- The highest reported rate of infectious syphilis is in the Yukon ( 19.9 per 100000 ), but this must be interpreted with caution as the total number of cases is very small ( $\mathrm{n}=6$ ).
- British Columbia has a reported rate of 4.5 per 100000 , the second highest in the country.
- The majority of cases are in Ontario ( $n=203$ ), British Columbia ( $n=187$ ), and Quebec ( $n=47$ ), which together account for $94 \%$ of all reported cases in Canada.


## Sex

- Among both males and females in 2002, infection rates are highest in the Yukon Territory (26.2 and 13.5 per 100000 respectively). However, caution is needed, as the actual case counts are very low (4 and 2 respectively).
- In Alberta, N ova Scotia, Ontario, and Quebec, rates among females were lower in 2002 than in 1997. Among males, this was noticed in Saskatchewan only (Figure 7).
- Again, caution is needed because of low case numbers. Overall, it appears that national trends may be driven by regional syphilis outbreaks and therefore may not accurately reflect regional rates of infectious syphilis.


## Congenital Syphilis

- Syphilis can be passed from mother to fetus transplacentally or during delivery if the newborn comes in contact with the genital lesion ${ }^{(11)}$.
- Syphilis can seriously complicate pregnancy, resulting in spontaneous abortion, stillbirth, or perinatal death. Children who do survive may suffer serious sequelae ${ }^{(11)}$, some of which may not become apparent for years ${ }^{(12)}$.
- A rise in the number of syphilitic babies born in the late 1980s and 1990s has been attributed to illicit drug use and the sex trade ${ }^{(11,12)}$. However, lack of prenatal care is the primary reason that cases of congenital syphilis continue to be reported globally ${ }^{(11)}$.

Figure 6: Reported Infectious Syphilis ${ }^{1}$ Cases and Rates ${ }^{2}$ in Canada by Province/Territory and Sex, 1993-2002

${ }^{1}$ Rate per 100000 population. Population estimates provided by Statistics Canada.
${ }^{2} 2002$ numbers are preliminary, and changes are anticipated.
Note: Small variability may exist between data reported by the provinces/territories and the Public Health Agency of Canada. Provincial/territorial data are definitive should a discrepancy exist.
Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI.

Figure 7: Reported Rates ${ }^{1}$ of Infectious Syphilis among Males by Province/Territory, 1997 and $200 \mathbf{2}^{2}$

${ }^{1}$ Rate per 100000 population. Population estimates provided by Statistics Canada.
${ }^{2} 2002$ numbers are preliminary, and changes are anticipated.
Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI.

Figure 8: Reported Rates ${ }^{1}$ of Infectious Syphilis among Females by Province/Territory, 1997 and $2002^{2}$


[^9]- Congenital syphilis has traditionally been divided into two syndromes ${ }^{(11)}$ :
- Early congenital syphilis: clinical manifestations occur within the first 2 years of life.
- Late congenital syphilis: clinical manifestations occur after 2 years and usually near puberty.
- Cases of early congenital syphilis in Canada are of low frequency. Between 1993 and 2002, the number of cases fluctuated between 1 and 3 each year.


## Discussion

Unlike gonorrhea and chlamydia, infectious syphilis is predominant in an older age group among both men and women. Although many current STI prevention and promotion efforts target adolescents and young adults who are at highest risk of acquiring chlamydia and gonorrhea, these efforts may not be appropriate for reaching those at greatest risk of syphilis. Efforts to reduce or prevent syphilis infection, therefore, need to target the older cohort of men and women most at risk of this infection.

The disproportionately high number of reported male cases, when interpreted using additional information from regional outbreaks, suggests that a significant proportion of syphilis transmission is occurring among MSM , although heterosexual transmission associated with the sex trade has also been reported.

Anonymous sexual partnering (for example, in bathhouses or via the internet) may help fuel outbreaks, and it makes timely partner notification difficult. A rapid response is important in containing transmission.

There are several challenges to the control of infectious syphilis in Canada. Infectious syphilis can be transmitted orally, a fact that many people may be unaware of ${ }^{[13)}$. As with other modes of transmission, the primary chancre is painless, resolves on its own, and may go unnoticed.

Bicillin (benzathine penicillin G) is currently the recommended treatment in C anada for infectious syphilis ${ }^{(4)}$. However, access to this drug in an effective and easy to administer form has become a problem since the Canadian distributor stopped distributing Bicillin in 2002. Alternatives are less optimal because of efficacy and/or compliance issues. Azithromycin has been used to treat some cases of infectious syphilis, but resistance has started to surface ${ }^{[14]}$.

An additional concern is that because syphilis has been rare for decades, there is now a new generation of clinicians who have never seen syphilis and may not know that they should look for it.

## TECHNICAL NOTES

## Commonly Used Terms/Definitions

## Asymptomatic

- Lack of symptoms of a sexually transmitted infection; symptom-free (the opposite of "symptomatic", see below).
Case
- A case is a person in the population who has had a diagnosis of an infection (for our purposes, an STI). An individual may be a case more than once if he or she is re-infected (e.g. by an untreated partner). At the national level, all cases of STI are laboratory confirmed.


## Gonococcal infection

- Another term for gonorrhea.


## NAAT

- Nucleic Acid Amplification Test. It is a relatively newer method of testing for infection of various pathogens, including Chlamydia trachomatis and Neisseria gonorrhoeae. Unlike previous methods, which required a piece of tissue for testing, NAAT can be used on urine samples.

Outbreak

- The occurrence of a higher-than-expected number of cases in a community.

Rate

- A rate is calculated as the number of cases in a population (e.g. a geographic region or a specific sex) divided by the total number of people in that population.


## STD

- Sexually transmitted disease. This is the traditional term for infections that can be spread through sexual contact with an infected person. However, some STDs can be spread
though non-sexual methods, such as injection drug use.

STI

- Sexually transmitted infection. This term is commonly used in place of STD, because it includes infections that may be asymptomatic.


## Surveillance

- This is the ongoing collection, analysis, and feedback of data that are collected systematically.


## Symptomatic

- Showing the symptoms of a disease or infection


## Population Standardization

A review of historical data was undertaken prior to publication of this report. Normally, the last 2 years of surveillance data are updated to account for reporting delays and any data cleaning that may have been undertaken at the provincial/territorial level. The population denominators, used to calculate rates, have been reviewed and updated to reflect the most recent and accurate population estimates.

Numerators have been reviewed and updated to correct historical errors where possible for gonorrhea and chlamydia. Because of the relatively small numbers and as a result of recent analyses, infectious syphilis numerators have been updated for all reported years. Please see footnotes on specific tables for more detail.

Overall Canadian trends have not been greatly affected by this update. While there are substantial changes in particular cells, primarily attributable to the denominator update, Canadian rates have shifted by less than $1 \%$ for all three infections.

## Improvements to National Surveillance of Sexually Transmitted Infections

There are many challenges to monitoring STI at the national level. For a case to be entered into this surveillance system, an infected individual must experience symptoms and seek medical care. Because of the asymptomatic nature of most infections, many infected persons will not realize that they have an STI and thus not seek medical treatment. Some additional cases are identified through contact tracing of an individual with a diagnosed infection. However, the increasing prevalence of anonymous sexual partnering makes contact tracing more difficult.

Furthermore, not all STI are nationally notifiable. Although other STI, such as herpes, may be monitored at the provincial/territorial level, the data are incomplete at the national level.

Technical differences between the provinces/territories and the Public Health Agency of Canada may introduce problems that can delay the timely reporting of case information. Furthermore, because many
provinces/territories use different software to maintain their data, not all submit the same data in the same format to the national level. Some submit aggregate case counts (by age, sex, and disease). Others submit case-level data with age and gender information. However, other fields, such as risk factor information, are completed to varying degrees, and different categories may be used in some fields (e.g. ethnicity).

There are several ways of getting around these limitations. W ork is under way to implement a minimum dataset. This standardized data format, agreed upon by the provinces and territories, would identify required information and incorporate a consistent set of categories.

Case-by-case reporting by all provinces and territories would enhance the national picture of STI. Risk factor data at the national level are currently incomplete, prohibiting in-depth analysis to help explain observed trends.

## REFERENCES

1. Health Protection Agency, SCIEH, ISD, National Public Health Service for W ales, CDSC Northern Ireland and the UASSG. Renewing the focus. HIV and other sexually transmitted infections in the United Kingdom in 2002. London: Health Protection Agency, November 2003.
2. Centers for Disease for Disease Control and Prevention. Sexually transmitted disease surveillance, 2002. Atlanta, GA: U.S. Department of Health and Human Services, September 2003.
3. Doherty J. Establishing priorities for national communicable disease surveillance. Can J Infect Dis 2000;11(1):21-4.
4. Health Canada. Canadian STD guidelines, 1998 edition. Ottawa: Minister of Public W orks and Government Services Canada, 1998.
5. Health Canada. National goals for the prevention and control of sexually transmitted diseases in Canada, chlamydia. URL:
http://www.hc-sc.gc.ca/pphb-dgspsp/publicat/cc dr-rmtc/97vol23/23s6nat/23s6d_e.html, November 1997. Accessed September 2004.
6. Health Canada. Perinatal health indicators for Canada: a resource manual. Ottawa: Minister of Public W orks and Government Services Canada, 2000.
7. Coste J, Bouyer J, Ughetto S et al. Ectopic pregnancy is again on the increase. Recent trends in the incidence of ectopic pregnancies in France (1992-2002). Human Reprod 2004;19(9):2014-18.
8. Egger M, Low $N$, Smith GD et al. Screening for chlamydial infections and the risk of ectopic pregnancy in a county in Sweden: ecological analysis. BMJ 1998;316:1776-80.
9. Notifiable Diseases On-line. Table 1: Current list of nationally notifiable diseases and year the first positive report was recorded. URL: http://dsol-smed.phac-aspc.gc.ca/dsol-smed/ndis /list_e.html\#tab1. Accessed October 22, 2004.
10. Health Canada. Sexually transmitted disease surveillance in Canada, 1995 annual report. CCDR 1998;24S1.
11. Genç M, Ledger WJ. Syphilis in pregnancy. Sex Transm Infect 2000;76:73-9.
12. Larkin JA, Lit L, Toney J, Haley JA. Recognizing and treating syphilis in pregnancy. M edscape W omen's Health 1998;3(1):5.
13. Ciesielski C, TabidzeI, Brown C. Transmission of primary and secondary syphilis by oral sex Chicago, Illinois, 1998-2002. M M W R 2004;53(41):966-68.
14. Lukehart SA, Godornes C, M olini BJ et al. M acrolide resistance in Treponema pallidum in the U nited States and Ireland. N Engl J Med 2004;351:154-8

## APPENDIXI

Table 1.1: Reported Genital Chlamydia Cases and Rates ${ }^{1}$ in Canada by Age Group and Sex, 1991-2002 ${ }^{2,3}$


${ }^{1}$ Rate per 100000 population. Population estimates provided by Statistics Canada (Source: Annual Demographic Statistics, 2000 Catalogue no. 91-213 and unpublished data).
${ }^{2} 2002$ data are preliminary and changes are anticipated.
${ }^{3}$ Data have been updated to rectify an historical discrepancy.
Source: Sexual Health and Sexually Transmitted Infections, Community Acquired Infections Division, Centre for Infectious Disease Prevention and
Control, Public Health Agency of Canada, 2003.

Table 1.2: Reported Genital Chlamydia Cases and Rates ${ }^{1}$ in Canada by Province/Territory and Sex, 1991-2002 ${ }^{2,3}$

|  |  |  | Province/Territory |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Year |  |  | Canada | NL | PE | NS | NB | QC | ON | MB | SK | AB | BC | YT | NT | $N U^{4}$ |
| 1991 | Cases | Male Female Total* | $\begin{array}{r} 8835 \\ 26918 \\ 45969 \end{array}$ | $\begin{array}{r} 74 \\ 518 \\ 594 \\ \hline \end{array}$ | $\begin{aligned} & 22 \\ & 73 \\ & 96 \\ & \hline \end{aligned}$ | $\begin{array}{r} 395 \\ 1832 \\ 2230 \\ \hline \end{array}$ | $\begin{aligned} & \hline 0 \\ & 0 \\ & 0 \\ & \hline \end{aligned}$ | 3311 9334 12681 | $\begin{array}{\|r} 2592 \\ 8515 \\ 11110 \\ \hline \end{array}$ | $\begin{aligned} & 1213 \\ & 3338 \\ & 4551 \\ & \hline \end{aligned}$ | $\begin{array}{r} 903 \\ 2388 \\ 3291 \\ \hline \end{array}$ | $\begin{array}{r} 0 \\ 0 \\ 6909 \\ \hline \end{array}$ | $\begin{array}{r} 10 \\ \\ \hline \\ 3261 \\ \hline \end{array}$ | $\begin{array}{r} \hline 53 \\ 144 \\ 198 \\ \hline \end{array}$ | $\begin{array}{r} 272 \\ 776 \\ 1048 \\ \hline \end{array}$ |  |
|  | Rate | Male Female Total* | $\begin{array}{r} \hline 63.6 \\ 190.4 \\ 164.0 \\ \hline \end{array}$ | $\begin{array}{r} \hline 25.5 \\ 179.3 \\ 102.5 \\ \hline \end{array}$ | $\begin{array}{r} 34.2 \\ 110.8 \\ 73.7 \end{array}$ | $\begin{array}{r} \hline 87.5 \\ 395.1 \\ 243.7 \\ \hline \end{array}$ | $\begin{aligned} & \hline 0.0 \\ & 0.0 \\ & 0.0 \\ & \hline \end{aligned}$ | $\begin{array}{r} 95.2 \\ 260.3 \\ 179.5 \\ \hline \end{array}$ | $\begin{array}{r} \hline 50.3 \\ 161.5 \\ 106.5 \\ \hline \end{array}$ | $\begin{aligned} & \hline 220.5 \\ & 596.7 \\ & 410.2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 180.8 \\ & 474.4 \\ & 328.2 \\ & \hline \end{aligned}$ | $\begin{array}{r} \hline 0.0 \\ 0.0 \\ 266.5 \\ \hline \end{array}$ | $\begin{array}{r\|} \hline 0.0 \\ 0.0 \\ 96.7 \\ \hline \end{array}$ | $\begin{gathered} 350.3 \\ --- \\ 684.8 \end{gathered}$ | $\begin{array}{rr} 850.1 \\ 2 & 681.9 \\ 1 & 720.0 \\ \hline \end{array}$ |  |
| 1992 | Cases | Male Female Total* | $\begin{array}{ll} 10 & 811 \\ 35 & 363 \\ 46 & 365 \end{array}$ | $\begin{array}{r} 32 \\ 417 \\ 450 \\ \hline \end{array}$ | $\begin{array}{r} 43 \\ 148 \\ 204 \\ \hline \end{array}$ | $\begin{array}{r} 325 \\ 1321 \\ 1646 \\ \hline \end{array}$ | $\begin{array}{rr}  & 230 \\ 11109 \\ 1339 \\ \hline \end{array}$ | $\begin{array}{\|r\|} \hline 2737 \\ 7595 \\ 10361 \\ \hline \end{array}$ | $\begin{array}{r} 2905 \\ 9915 \\ 12830 \end{array}$ | $\begin{array}{r} 865 \\ 2425 \\ 3290 \\ \hline \end{array}$ | $\begin{array}{r} 594 \\ 1814 \\ 2408 \\ \hline \end{array}$ | $\begin{aligned} & 1431 \\ & 4881 \\ & 6312 \\ & \hline \end{aligned}$ | $\begin{aligned} & 1386 \\ & 4910 \\ & 6434 \\ & \hline \end{aligned}$ | $\begin{array}{r} 46 \\ 146 \\ 192 \\ \hline \end{array}$ | $\begin{aligned} & \hline 217 \\ & 682 \\ & 899 \\ & \hline \end{aligned}$ |  |
|  | Rate | Male Female Total* | $\begin{array}{r} \hline 76.9 \\ 247.1 \\ 163.4 \\ \hline \end{array}$ | $\begin{array}{r} 11.0 \\ 144.0 \\ 77.6 \\ \hline \end{array}$ | $\begin{array}{r} 66.5 \\ 223.5 \\ 155.9 \\ \hline \end{array}$ | $\begin{array}{r} \hline 71.7 \\ 283.3 \\ 179.0 \\ \hline \end{array}$ | $\begin{array}{r} \hline 62.0 \\ 293.9 \\ 178.9 \\ \hline \end{array}$ | $\begin{array}{r} \hline 78.1 \\ 210.5 \\ 145.7 \\ \hline \end{array}$ | $\begin{array}{r} \hline 55.6 \\ 185.4 \\ 121.4 \\ \hline \end{array}$ | $\begin{aligned} & \hline 156.7 \\ & 432.1 \\ & 295.6 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 118.8 \\ & 359.8 \\ & 239.8 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 107.8 \\ & 373.5 \\ & 239.6 \\ & \hline \end{aligned}$ | $\begin{array}{r} \hline 80.1 \\ 282.2 \\ 185.4 \\ \hline \end{array}$ | 290.8 <br> --- <br> 634.9 |  |  |
| 1993 | Cases | Male Female Total* | $\begin{array}{ll} 10621 \\ 33 & 379 \\ 44 & 022 \end{array}$ | $\begin{array}{r} 51 \\ 412 \\ 463 \end{array}$ | $\begin{array}{r} \hline 24 \\ 110 \\ 139 \\ \hline \end{array}$ | $\begin{array}{r} 324 \\ 1134 \\ 1459 \end{array}$ | $\begin{array}{r} 179 \\ 887 \\ 1066 \\ \hline \end{array}$ | $\begin{aligned} & 2513 \\ & 7129 \\ & 9647 \\ & \hline \end{aligned}$ | $\begin{array}{r} 3504 \\ 10529 \\ 14041 \end{array}$ | $\begin{array}{r} 859 \\ 2400 \\ 3259 \\ \hline \end{array}$ | $\begin{array}{r} 644 \\ 1665 \\ 2309 \end{array}$ | $\begin{array}{lll} \hline 1 & 190 \\ 4 & 006 \\ 5 & 199 \\ \hline \end{array}$ | $\begin{array}{ll} 1 & 1051 \\ 4 & 251 \\ 5 & 302 \\ \hline \end{array}$ | $\begin{array}{r} 36 \\ 130 \\ 166 \\ \hline \end{array}$ | $\begin{aligned} & 246 \\ & 726 \\ & 972 \\ & \hline \end{aligned}$ |  |
|  | Rate | Male Female Total* | $\begin{array}{r} \hline 74.7 \\ 230.5 \\ 153.4 \\ \hline \end{array}$ | $\begin{array}{r} 17.6 \\ 142.1 \\ 79.8 \\ \hline \end{array}$ | $\begin{array}{r} 36.7 \\ 164.2 \\ 105.0 \\ \hline \end{array}$ | $\begin{array}{r} 71.3 \\ 241.8 \\ 158.0 \\ \hline \end{array}$ | $\begin{array}{r} 48.1 \\ 234.8 \\ 142.2 \\ \hline \end{array}$ | $\begin{array}{r} 71.2 \\ 196.2 \\ 134.6 \\ \hline \end{array}$ | $\begin{array}{r} \hline 66.4 \\ 194.5 \\ 131.3 \\ \hline \end{array}$ | $\begin{aligned} & 154.9 \\ & 425.6 \\ & 291.4 \\ & \hline \end{aligned}$ | $\begin{aligned} & 128.5 \\ & 329.2 \\ & 229.3 \\ & \hline \end{aligned}$ | $\begin{array}{r} \hline 88.4 \\ 302.3 \\ 194.7 \\ \hline \end{array}$ | $\begin{array}{r} 59.0 \\ 237.3 \\ 148.5 \\ \hline \end{array}$ | $\begin{aligned} & 225.0 \\ & 889.4 \\ & 542.1 \\ & \hline \end{aligned}$ | $\begin{array}{rr} \hline & 738.0 \\ 2 & 402.8 \\ 1 & 529.5 \end{array}$ |  |
| 1994 | Cases | Male Female Total* | $\begin{array}{ll} 10 & 006 \\ 31 & 176 \\ 41 & 235 \end{array}$ | $\begin{array}{r} 60 \\ 296 \\ 356 \end{array}$ | $\begin{array}{r} 22 \\ 85 \\ 109 \\ \hline \end{array}$ | $\begin{array}{r} 392 \\ 1052 \\ 1446 \\ \hline \end{array}$ | $\begin{aligned} & 174 \\ & 743 \\ & 917 \end{aligned}$ | $\begin{aligned} & 2043 \\ & 5783 \\ & 7837 \\ & \hline \end{aligned}$ | $\begin{array}{r} 3257 \\ 10196 \\ 13465 \\ \hline \end{array}$ | $\begin{array}{r} 815 \\ 2260 \\ 3075 \\ \hline \end{array}$ | $\begin{array}{r} 665 \\ 1832 \\ 2497 \\ \hline \end{array}$ | $\begin{aligned} & 1164 \\ & 3845 \\ & 5010 \end{aligned}$ | $\begin{aligned} & 1126 \\ & 4217 \\ & 5368 \end{aligned}$ | $\begin{array}{r} 37 \\ 116 \\ 153 \\ \hline \end{array}$ | $\begin{array}{r} 251 \\ 751 \\ 1002 \end{array}$ |  |
|  | Rate | Male Female Total* | $\begin{array}{r} \hline 69.6 \\ 212.8 \\ 142.0 \\ \hline \end{array}$ | $\begin{array}{r} \hline 20.9 \\ 102.9 \\ 61.9 \\ \hline \end{array}$ | $\begin{array}{r} 33.3 \\ 125.6 \\ 81.5 \end{array}$ | $\begin{array}{r} 86.1 \\ 223.4 \\ 156.1 \end{array}$ | $\begin{array}{r} 46.7 \\ 196.4 \\ 122.1 \end{array}$ | $\begin{array}{r} \hline 57.5 \\ 158.2 \\ 108.7 \\ \hline \end{array}$ | $\begin{array}{r} \hline 61.0 \\ 185.9 \\ 124.4 \end{array}$ | $\begin{aligned} & 146.3 \\ & 398.8 \\ & 273.6 \end{aligned}$ | $\begin{aligned} & 132.3 \\ & 361.2 \\ & 247.3 \end{aligned}$ | $\begin{array}{r} 85.4 \\ 286.5 \\ 185.2 \end{array}$ | $\begin{array}{r} \hline 61.4 \\ 228.3 \\ 145.8 \\ \hline \end{array}$ | $\begin{aligned} & 235.8 \\ & 808.2 \\ & 509.2 \end{aligned}$ | $\begin{array}{r} 734.8 \\ 2422.7 \\ 1537.8 \end{array}$ |  |
| 1995 | Cases | Male Female Total* | 9085 28451 37551 | $\begin{array}{r} 45 \\ 227 \\ 272 \end{array}$ | $\begin{array}{r} \hline 27 \\ 85 \\ 112 \end{array}$ | $\begin{array}{r} 282 \\ 884 \\ 1167 \end{array}$ | $\begin{aligned} & 164 \\ & 598 \\ & 762 \end{aligned}$ | $\begin{array}{ll} 1759 \\ 5 & 278 \\ 7048 \end{array}$ | $\begin{array}{r} 2931 \\ 9157 \\ 12090 \end{array}$ | $\begin{array}{r} 782 \\ 2226 \\ 3008 \end{array}$ | $\begin{array}{r} 612 \\ 1737 \\ 2344 \end{array}$ | $\begin{array}{ll} 1 & 167 \\ 3 & 851 \\ 5 & 018 \end{array}$ | $\begin{aligned} & 1057 \\ & 3602 \\ & 4660 \end{aligned}$ | $\begin{array}{r} 34 \\ 122 \\ 156 \end{array}$ | $\begin{aligned} & 225 \\ & 689 \\ & 914 \end{aligned}$ |  |
|  | Rate | Male Female Total* | $\begin{array}{r} \hline 62.5 \\ 192.0 \\ 127.9 \end{array}$ | $\begin{aligned} & 15.9 \\ & 79.8 \\ & 47.9 \end{aligned}$ | $\begin{array}{r} \hline 40.6 \\ 124.5 \\ 83.1 \end{array}$ | $\begin{array}{r} 61.9 \\ 187.3 \\ 125.8 \end{array}$ | $\begin{array}{r} 44.0 \\ 157.9 \\ 101.4 \end{array}$ | $\begin{array}{r} \hline 49.3 \\ 143.8 \\ 97.3 \end{array}$ | $\begin{array}{r} 54.2 \\ 164.7 \\ 110.3 \end{array}$ | $\begin{aligned} & 139.6 \\ & 390.8 \\ & 266.2 \end{aligned}$ | $\begin{aligned} & 121.3 \\ & 340.9 \\ & 231.1 \end{aligned}$ | $\begin{array}{r} 84.6 \\ 283.2 \\ 183.1 \end{array}$ | $\begin{array}{r} 56.1 \\ 189.7 \\ 123.1 \end{array}$ | $\begin{aligned} & 210.9 \\ & 826.3 \\ & 505.1 \end{aligned}$ | $\begin{array}{r} 645.0 \\ 2174.0 \\ 1372.9 \end{array}$ |  |
| 1996 | Cases | Male Female Total* | $\begin{array}{rr} \hline 8317 \\ 26 & 062 \\ 34399 \end{array}$ | $\begin{array}{r} \hline 60 \\ 219 \\ 279 \\ \hline \end{array}$ | $\begin{array}{r} 34 \\ 97 \\ 131 \\ \hline \end{array}$ | $\begin{array}{r} 200 \\ 873 \\ 1074 \\ \hline \end{array}$ | $\begin{aligned} & \hline 168 \\ & 665 \\ & 833 \\ & \hline \end{aligned}$ | $\begin{array}{ll} \hline 1640 \\ 5 & 006 \\ 6 & 655 \\ \hline \end{array}$ | $\begin{array}{\|rr\|} \hline 2578 \\ 8 & 025 \\ 10605 \\ \hline \end{array}$ | $\begin{array}{r} 598 \\ 1961 \\ 2559 \\ \hline \end{array}$ | $\begin{array}{r} 659 \\ 1577 \\ 2236 \\ \hline \end{array}$ | $\begin{aligned} & 1183 \\ & 3685 \\ & 4868 \end{aligned}$ | $\begin{array}{r} 917 \\ 3191 \\ 4116 \\ \hline \end{array}$ | $\begin{array}{r} 39 \\ 105 \\ 144 \\ \hline \end{array}$ | $\begin{aligned} & \hline 241 \\ & 658 \\ & 899 \\ & \hline \end{aligned}$ |  |
|  | Rate | Male Female Total* | $\begin{array}{r} \hline 56.6 \\ 174.0 \\ 115.9 \\ \hline \end{array}$ | $\begin{array}{\|} \hline 21.5 \\ 77.9 \\ 49.8 \\ \hline \end{array}$ | $\begin{array}{r} 50.6 \\ 140.6 \\ 96.2 \end{array}$ | $\begin{array}{r} \hline 43.8 \\ 184.0 \\ 115.3 \\ \hline \end{array}$ | $\begin{array}{r} \hline 44.9 \\ 175.4 \\ 110.6 \\ \hline \end{array}$ | $\begin{array}{r} \hline 45.7 \\ 135.8 \\ 91.5 \\ \hline \end{array}$ | $\begin{array}{r\|} \hline 47.1 \\ 142.5 \\ 95.5 \\ \hline \end{array}$ | $\begin{aligned} & \hline 106.3 \\ & 342.8 \\ & 225.6 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 129.9 \\ & 307.8 \\ & 219.3 \\ & \hline \end{aligned}$ | $\begin{array}{r} 84.5 \\ 267.0 \\ 175.1 \end{array}$ | $\begin{array}{r} \hline 47.4 \\ 163.8 \\ 106.0 \\ \hline \end{array}$ | $\begin{aligned} & \hline 234.1 \\ & 687.3 \\ & 450.9 \\ & \hline \end{aligned}$ | $\begin{array}{r} \hline 681.1 \\ 2044.4 \\ 1330.5 \end{array}$ |  |
| 1997 | Cases | Male Female Total* | $\begin{array}{r} 8714 \\ 25406 \\ 34144 \end{array}$ | $\begin{array}{r} 57 \\ 278 \\ 335 \end{array}$ | $\begin{array}{r} 39 \\ 100 \\ 139 \end{array}$ | $\begin{array}{r} 241 \\ 885 \\ 1127 \end{array}$ | $\begin{aligned} & 191 \\ & 625 \\ & 819 \end{aligned}$ | $\begin{aligned} & 1608 \\ & 4758 \\ & 6380 \end{aligned}$ | $\begin{array}{r} 2807 \\ 7750 \\ 10559 \end{array}$ | $\begin{array}{r} 601 \\ 1986 \\ 2587 \end{array}$ | $\begin{array}{r} 716 \\ 1601 \\ 2317 \end{array}$ | $\begin{aligned} & 1101 \\ & 3446 \\ & 4547 \end{aligned}$ | $\begin{aligned} & 1002 \\ & 3110 \\ & 4116 \end{aligned}$ | $\begin{array}{r} 34 \\ 139 \\ 173 \end{array}$ | $\begin{array}{r} 317 \\ 728 \\ 1045 \end{array}$ |  |
|  | Rate | Male Female Total* | $\begin{array}{r} 58.7 \\ 167.8 \\ 113.9 \end{array}$ | $\begin{array}{r\|} \hline 20.7 \\ 99.9 \\ 60.5 \\ \hline \end{array}$ | $\begin{array}{r} 57.8 \\ 144.1 \\ 101.6 \end{array}$ | $\begin{array}{r} 52.6 \\ 185.9 \\ 120.6 \\ \hline \end{array}$ | $\begin{array}{r} 51.0 \\ 164.4 \\ 108.6 \end{array}$ | $\begin{array}{r} 44.6 \\ 128.6 \\ 87.4 \\ \hline \end{array}$ | $\begin{array}{r} 50.6 \\ 135.9 \\ 93.9 \end{array}$ | $\begin{aligned} & 106.6 \\ & 346.7 \\ & 227.6 \end{aligned}$ | $\begin{aligned} & 140.8 \\ & 311.7 \\ & 226.7 \end{aligned}$ | $\begin{array}{r} 77.0 \\ 244.8 \\ 160.3 \\ \hline \end{array}$ | $\begin{array}{r} 50.6 \\ 156.4 \\ 103.9 \\ \hline \end{array}$ | $\begin{aligned} & 202.4 \\ & 900.4 \\ & 536.6 \end{aligned}$ | $\begin{array}{r} 894.0 \\ 2255.4 \\ 1542.8 \end{array}$ |  |
| 1998 | Cases | Male Female Total* | $\begin{aligned} & 11041 \\ & 27956 \\ & 39034 \end{aligned}$ | $\begin{array}{r} 81 \\ 294 \\ 375 \end{array}$ | $\begin{array}{r} 34 \\ 110 \\ 144 \end{array}$ | $\begin{array}{r} 271 \\ 938 \\ 1216 \end{array}$ | $\begin{aligned} & 224 \\ & 735 \\ & 959 \end{aligned}$ | $\begin{aligned} & 1982 \\ & 5268 \\ & 7264 \end{aligned}$ | $\begin{array}{r} 3727 \\ 8724 \\ 12458 \end{array}$ | $\begin{array}{r} 804 \\ 2148 \\ 2954 \end{array}$ | $\begin{array}{r} 787 \\ 1612 \\ 2399 \end{array}$ | $\begin{aligned} & 1361 \\ & 3834 \\ & 5195 \end{aligned}$ | $\begin{aligned} & 1340 \\ & 3422 \\ & 4769 \end{aligned}$ | $\begin{array}{r} 53 \\ 124 \\ 177 \end{array}$ | $\begin{array}{r} 377 \\ 747 \\ 1124 \end{array}$ |  |
|  | Rate | Male Female Total* | $\begin{array}{r} \hline 73.7 \\ 183.1 \\ 129.0 \\ \hline \end{array}$ | $\begin{array}{r} 29.9 \\ 107.0 \\ 68.8 \\ \hline \end{array}$ | $\begin{array}{r} \hline 50.5 \\ 158.1 \\ 105.2 \\ \hline \end{array}$ | $\begin{array}{r} \hline 59.0 \\ 196.6 \\ 129.9 \\ \hline \end{array}$ | $\begin{array}{r\|} \hline 60.0 \\ 193.4 \\ 127.3 \\ \hline \end{array}$ | $\begin{array}{r} \hline 54.9 \\ 142.0 \\ 99.2 \\ \hline \end{array}$ | $\begin{array}{r} \hline 66.4 \\ 151.2 \\ 109.4 \\ \hline \end{array}$ | $\begin{aligned} & \hline 142.5 \\ & 374.4 \\ & 259.6 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 154.5 \\ & 312.8 \\ & 234.1 \\ & \hline \end{aligned}$ | $\begin{array}{r} 92.8 \\ 266.2 \\ 178.7 \end{array}$ | $\begin{array}{r} 67.4 \\ 170.3 \\ 119.3 \end{array}$ | $\begin{aligned} & \hline 323.5 \\ & 819.1 \\ & 561.5 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 1070.6 \\ & 2315.2 \\ & 1665.7 \\ & \hline \end{aligned}$ |  |


${ }^{1}$ Rate per 100000 population. Population estimates provided by Statistics Canada (Source: Annual Demographic Statistics, 2000 Catalogue no. 91-213 and unpublished data).
${ }^{2} 2002$ data are preliminary and changes are anticipated.
${ }^{3}$ Data have been updated to rectify an historical discrepancy.
${ }^{4}$ Data prior to 2000 are not available because Nunavut became a Canadian territory in April 1999. Data for 1999 were included with NT.
*Total includes cases not specified for sex.
Source: Sexual Health and Sexually Transmitted Infections, Community Acquired Infections Division, Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada, 2003.

Table 2.1: Reported Gonorrhea Cases and Rates ${ }^{1}$ in Canada by Age Group and Sex, 1980-2002 ${ }^{2}$

|  |  |  | Age Group (years) |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Year |  |  | Canada | $0<1$ | 1-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-29 | 30-39 | 40-59 | 60+ | NS |
| 1980 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 32555 \\ 20485 \\ 231 \\ 53271 \end{array}$ | $\begin{array}{r} 10 \\ 18 \\ 0 \\ 28 \end{array}$ | $\begin{array}{r} 0 \\ 36 \\ 0 \\ 36 \end{array}$ | $\begin{array}{r} 6 \\ 34 \\ 0 \\ 40 \end{array}$ | $\begin{array}{r} 43 \\ 193 \\ 0 \\ 236 \end{array}$ | $\begin{array}{r} 3921 \\ 6075 \\ 1 \\ 9997 \end{array}$ | $\begin{array}{r} 10821 \\ 7234 \\ 0 \\ 18055 \end{array}$ | $\begin{array}{r} 7505 \\ 3280 \\ 1 \\ 10786 \end{array}$ | $\begin{array}{r} 6542 \\ 1962 \\ 0 \\ 8504 \end{array}$ | $\begin{array}{r} 2241 \\ 436 \\ 0 \\ 2677 \end{array}$ | $\begin{array}{r} 173 \\ 31 \\ 0 \\ 204 \end{array}$ | $\begin{array}{r} 1293 \\ 1186 \\ 229 \\ 2708 \end{array}$ |
|  | Rate | Male Female Total | $\begin{aligned} & 266.6 \\ & 166.5 \\ & 217.3 \end{aligned}$ | $\begin{array}{r} 5.3 \\ 10.1 \\ 7.7 \end{array}$ | $\begin{aligned} & 0.0 \\ & 5.2 \\ & 2.5 \end{aligned}$ | $\begin{aligned} & 0.6 \\ & 3.9 \\ & 2.2 \end{aligned}$ | $\begin{array}{r} 4.3 \\ 20.1 \\ 12.0 \end{array}$ | $\begin{aligned} & 317.8 \\ & 513.1 \\ & 413.5 \end{aligned}$ | $\begin{aligned} & 884.1 \\ & 602.5 \\ & 744.7 \end{aligned}$ | $\begin{aligned} & 678.2 \\ & 298.4 \\ & 489.0 \end{aligned}$ | $\begin{aligned} & 355.9 \\ & 110.0 \\ & 234.8 \end{aligned}$ | $\begin{aligned} & 89.4 \\ & 17.4 \\ & 53.4 \end{aligned}$ | $\begin{array}{r} 12.0 \\ 1.7 \\ 6.3 \end{array}$ |  |
| 1981 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 34337 \\ 21863 \\ 130 \\ 56330 \end{array}$ | $\begin{array}{r} 5 \\ 10 \\ 0 \\ 15 \end{array}$ | $\begin{array}{r} 5 \\ 28 \\ 0 \\ 33 \end{array}$ | $\begin{array}{r} 8 \\ 33 \\ 0 \\ 41 \end{array}$ | $\begin{array}{r} 54 \\ 219 \\ 0 \\ 273 \end{array}$ | $\begin{array}{r} 4435 \\ 6932 \\ 2 \\ 11369 \end{array}$ | $\begin{array}{r} 11991 \\ 8034 \\ 3 \\ 20028 \end{array}$ | $\begin{array}{r} 7906 \\ 3487 \\ 2 \\ 11395 \end{array}$ | $\begin{array}{r} 6959 \\ 2110 \\ 1 \\ 9070 \end{array}$ | $\begin{array}{r} 2179 \\ 476 \\ 0 \\ 2655 \end{array}$ | $\begin{array}{r} 149 \\ 33 \\ 0 \\ 182 \end{array}$ | $\begin{array}{r} 646 \\ 501 \\ 122 \\ 1269 \end{array}$ |
|  | Rate | Male Female Total | $\begin{aligned} & 278.0 \\ & 175.3 \\ & 227.0 \\ & \hline \end{aligned}$ | $\begin{aligned} & 2.7 \\ & 5.6 \\ & 4.1 \end{aligned}$ | $\begin{aligned} & 0.7 \\ & 4.0 \\ & 2.3 \end{aligned}$ | $\begin{aligned} & 0.9 \\ & 3.8 \\ & 2.3 \end{aligned}$ | $\begin{array}{r} 5.4 \\ 23.2 \\ 14.1 \\ \hline \end{array}$ | $\begin{aligned} & 366.2 \\ & 598.6 \\ & 479.9 \end{aligned}$ | $\begin{aligned} & 959.2 \\ & 654.7 \\ & 808.5 \end{aligned}$ | $\begin{aligned} & \hline 700.1 \\ & 310.8 \\ & 506.2 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 366.1 \\ & 113.9 \\ & 241.6 \\ & \hline \end{aligned}$ | $\begin{aligned} & 85.8 \\ & 18.8 \\ & 52.3 \end{aligned}$ | $\begin{array}{r} 10.0 \\ 1.8 \\ 5.4 \\ \hline \end{array}$ |  |
| 1982 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 32078 \\ 20893 \\ 101 \\ 53072 \end{array}$ | $\begin{array}{r} 5 \\ 8 \\ 0 \\ 13 \end{array}$ | $\begin{array}{r} 3 \\ 22 \\ 0 \\ 25 \end{array}$ | $\begin{array}{r} 1 \\ 32 \\ 0 \\ 33 \end{array}$ | $\begin{array}{r} 46 \\ 211 \\ 0 \\ 257 \end{array}$ | $\begin{array}{r} 4063 \\ 6563 \\ 0 \\ 10626 \end{array}$ | $\begin{array}{r} 11239 \\ 7816 \\ 3 \\ 19058 \end{array}$ | $\begin{array}{r} 7309 \\ 3363 \\ 2 \\ 10674 \end{array}$ | $\begin{array}{r} 6399 \\ 1899 \\ 0 \\ 8298 \end{array}$ | $\begin{array}{r} 2169 \\ 422 \\ 0 \\ 2591 \end{array}$ | $\begin{array}{r} 147 \\ 21 \\ 0 \\ 168 \end{array}$ | $\begin{array}{r} 697 \\ 536 \\ 96 \\ 1329 \end{array}$ |
|  | Rate | Male Female Total | $\begin{aligned} & 256.8 \\ & 165.5 \\ & 211.3 \end{aligned}$ | $\begin{aligned} & 2.6 \\ & 4.4 \\ & 3.5 \end{aligned}$ | $\begin{aligned} & 0.4 \\ & 3.1 \\ & 1.7 \end{aligned}$ | $\begin{aligned} & 0.1 \\ & 3.7 \\ & 1.8 \end{aligned}$ | $\begin{array}{r} 4.7 \\ 22.7 \\ 13.4 \end{array}$ | $\begin{aligned} & 345.9 \\ & 587.0 \\ & 463.5 \end{aligned}$ | $\begin{aligned} & 890.9 \\ & 634.0 \\ & 764.0 \end{aligned}$ | $\begin{aligned} & 627.9 \\ & 290.5 \\ & 459.8 \end{aligned}$ | $\begin{array}{r} 326.1 \\ 98.9 \\ 213.8 \end{array}$ | $\begin{aligned} & 84.4 \\ & 16.5 \\ & 50.5 \end{aligned}$ | $\begin{aligned} & 9.6 \\ & 1.1 \\ & 4.8 \end{aligned}$ |  |
| 1983 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 27006 \\ 18148 \\ 111 \\ 45265 \end{array}$ | $\begin{array}{r} 10 \\ 6 \\ 0 \\ 16 \end{array}$ | $\begin{array}{r} 2 \\ 19 \\ 0 \\ 21 \end{array}$ | $\begin{array}{r} 3 \\ 31 \\ 0 \\ 34 \end{array}$ | $\begin{array}{r} 32 \\ 185 \\ 0 \\ 217 \end{array}$ | $\begin{array}{r} 3223 \\ 5469 \\ 0 \\ 8692 \end{array}$ | $\begin{array}{r} 9455 \\ 6904 \\ 5 \\ 16364 \end{array}$ | $\begin{array}{r} 6186 \\ 2934 \\ 0 \\ 9120 \end{array}$ | $\begin{array}{r} 5592 \\ 1719 \\ 0 \\ 7311 \end{array}$ | $\begin{array}{r} 1801 \\ 414 \\ 2 \\ 2217 \end{array}$ | $\begin{array}{r} 116 \\ 25 \\ 0 \\ 141 \end{array}$ | $\begin{array}{r} 586 \\ 442 \\ 104 \\ 1132 \end{array}$ |
|  | Rate | Male Female Total | $\begin{aligned} & 214.2 \\ & 142.3 \\ & 178.4 \end{aligned}$ | $\begin{aligned} & 5.3 \\ & 3.3 \\ & 4.3 \end{aligned}$ | $\begin{aligned} & 0.3 \\ & 2.7 \\ & 1.4 \end{aligned}$ | $\begin{aligned} & 0.3 \\ & 3.5 \\ & 1.9 \end{aligned}$ | $\begin{array}{r} 3.3 \\ 20.1 \\ 11.5 \\ \hline \end{array}$ | $\begin{aligned} & 286.9 \\ & 512.4 \\ & 396.7 \end{aligned}$ | $\begin{aligned} & 743.2 \\ & 558.9 \\ & 652.6 \\ & \hline \end{aligned}$ | $\begin{aligned} & 518.7 \\ & 247.7 \\ & 383.7 \end{aligned}$ | $\begin{array}{r} 277.7 \\ 86.9 \\ 183.1 \end{array}$ | $\begin{aligned} & 69.0 \\ & 16.0 \\ & 42.6 \\ & \hline \end{aligned}$ | $\begin{aligned} & 7.4 \\ & 1.2 \\ & 3.9 \\ & \hline \end{aligned}$ |  |
| 1984 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 25852 \\ 17924 \\ 98 \\ 43874 \end{array}$ | $\begin{array}{r} 7 \\ 4 \\ 0 \\ 11 \end{array}$ | $\begin{array}{r} 2 \\ 22 \\ 0 \\ 24 \end{array}$ | $\begin{array}{r} 3 \\ 26 \\ 0 \\ 29 \end{array}$ | $\begin{array}{r} 51 \\ 240 \\ 0 \\ 291 \end{array}$ | $\begin{array}{r} 3094 \\ 5501 \\ 4 \\ 8599 \end{array}$ | $\begin{array}{r} 9024 \\ 6832 \\ 2 \\ 15858 \end{array}$ | $\begin{array}{r} 5966 \\ 2792 \\ 0 \\ 8758 \end{array}$ | $\begin{array}{r} 5226 \\ 1677 \\ 1 \\ 6904 \end{array}$ | $\begin{array}{r} 1828 \\ 365 \\ 0 \\ 2193 \end{array}$ | $\begin{array}{r} 98 \\ 23 \\ 0 \\ 121 \end{array}$ | $\begin{array}{r} 553 \\ 442 \\ 91 \\ 1086 \end{array}$ |
|  | Rate | Male Female Total | $\begin{aligned} & 203.2 \\ & 139.1 \\ & 171.3 \end{aligned}$ | $\begin{aligned} & 3.7 \\ & 2.2 \\ & 3.0 \end{aligned}$ | $\begin{aligned} & 0.3 \\ & 3.1 \\ & 1.6 \end{aligned}$ | $\begin{aligned} & 0.3 \\ & 3.0 \\ & 1.6 \end{aligned}$ | $\begin{array}{r} 5.3 \\ 26.4 \\ 15.6 \\ \hline \end{array}$ | $\begin{aligned} & 288.2 \\ & 540.0 \\ & 410.9 \end{aligned}$ | $\begin{aligned} & \hline 704.9 \\ & 553.6 \\ & 630.7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 491.8 \\ & 232.6 \\ & 362.9 \\ & \hline \end{aligned}$ | $\begin{array}{r} 252.6 \\ 82.1 \\ 168.0 \\ \hline \end{array}$ | $\begin{aligned} & 69.0 \\ & 13.9 \\ & 41.5 \\ & \hline \end{aligned}$ | $\begin{aligned} & 6.1 \\ & 1.1 \\ & 3.3 \\ & \hline \end{aligned}$ |  |
| 1985 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 23277 \\ 17399 \\ 61 \\ 40737 \end{array}$ | $\begin{array}{r} 8 \\ 5 \\ 0 \\ 13 \end{array}$ | $\begin{array}{r} 1 \\ 19 \\ 0 \\ 20 \end{array}$ | $\begin{array}{r} 4 \\ 26 \\ 0 \\ 30 \end{array}$ | $\begin{array}{r} 41 \\ 207 \\ 0 \\ 248 \end{array}$ | $\begin{array}{r} 2804 \\ 5448 \\ 2 \\ 8254 \end{array}$ | $\begin{array}{r} 8545 \\ 6445 \\ 3 \\ 14993 \end{array}$ | $\begin{array}{r} 5091 \\ 2666 \\ 1 \\ 7758 \end{array}$ | $\begin{array}{r} 4484 \\ 1598 \\ 0 \\ 6082 \end{array}$ | $\begin{array}{r} 1522 \\ 349 \\ 0 \\ 1871 \end{array}$ | $\begin{array}{r} 88 \\ 18 \\ 0 \\ 106 \end{array}$ | $\begin{array}{r} 689 \\ 618 \\ 55 \\ 1362 \end{array}$ |
|  | Rate | Male Female Total | $\begin{aligned} & 181.4 \\ & 133.7 \\ & 157.6 \end{aligned}$ | $\begin{aligned} & 4.2 \\ & 2.8 \\ & 3.5 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.1 \\ & 2.6 \\ & 1.4 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.4 \\ & 2.9 \\ & 1.7 \end{aligned}$ | $\begin{array}{r} 4.4 \\ 23.0 \\ 13.5 \\ \hline \end{array}$ | $\begin{aligned} & 270.5 \\ & 554.9 \\ & 409.0 \end{aligned}$ | $\begin{aligned} & 670.4 \\ & 526.6 \\ & 600.1 \\ & \hline \end{aligned}$ | $\begin{aligned} & 413.9 \\ & 220.2 \\ & 317.9 \end{aligned}$ | $\begin{array}{r} 210.6 \\ 75.8 \\ 143.5 \\ \hline \end{array}$ | $\begin{aligned} & 56.5 \\ & 13.1 \\ & 34.9 \\ & \hline \end{aligned}$ | $\begin{aligned} & 5.4 \\ & 0.8 \\ & 2.8 \end{aligned}$ |  |
| 1986 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 19458 \\ 15744 \\ 85 \\ 35287 \end{array}$ | $\begin{array}{r} 7 \\ 7 \\ 0 \\ 14 \end{array}$ | $\begin{array}{r} 1 \\ 23 \\ 0 \\ 24 \end{array}$ | $\begin{array}{r} 6 \\ 21 \\ 0 \\ 27 \end{array}$ | $\begin{array}{r} 34 \\ 227 \\ 0 \\ 261 \end{array}$ | $\begin{array}{r} 2715 \\ 5128 \\ 0 \\ 7843 \end{array}$ | $\begin{array}{r} 7042 \\ 5690 \\ 0 \\ 12732 \end{array}$ | $\begin{array}{r} 4542 \\ 2513 \\ 3 \\ 7058 \end{array}$ | $\begin{array}{r} 3413 \\ 1394 \\ 1 \\ 4808 \end{array}$ | $\begin{array}{r} 1164 \\ 320 \\ 0 \\ 1484 \end{array}$ | $\begin{array}{r} 100 \\ 28 \\ 0 \\ 128 \end{array}$ | $\begin{array}{r} 434 \\ 393 \\ 81 \\ 908 \end{array}$ |
|  | Rate | Male Female Total | $\begin{aligned} & 150.2 \\ & 119.7 \\ & 135.2 \end{aligned}$ | $\begin{aligned} & 3.7 \\ & 3.9 \\ & 3.8 \end{aligned}$ | $\begin{aligned} & 0.1 \\ & 3.2 \\ & 1.6 \end{aligned}$ | $\begin{aligned} & 0.6 \\ & 2.4 \\ & 1.5 \end{aligned}$ | $\begin{array}{r} 3.7 \\ 25.6 \\ 14.4 \end{array}$ | $\begin{aligned} & 266.0 \\ & 530.3 \\ & 394.6 \end{aligned}$ | $\begin{aligned} & 563.5 \\ & 475.6 \\ & 520.5 \end{aligned}$ | $\begin{aligned} & 362.5 \\ & 205.1 \\ & 284.8 \end{aligned}$ | $\begin{array}{r} 156.3 \\ 64.3 \\ 110.5 \\ \hline \end{array}$ | $\begin{aligned} & 42.3 \\ & 11.7 \\ & 27.1 \end{aligned}$ | $\begin{aligned} & 5.9 \\ & 1.3 \\ & 3.3 \end{aligned}$ |  |
| 1987 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 14755 \\ 12923 \\ 240 \\ 27918 \end{array}$ | $\begin{aligned} & 3 \\ & 6 \\ & 0 \\ & 9 \end{aligned}$ | $\begin{array}{r} 7 \\ 18 \\ 0 \\ 25 \end{array}$ | $\begin{array}{r} 4 \\ 30 \\ 0 \\ 34 \end{array}$ | $\begin{array}{r} 35 \\ 195 \\ 0 \\ 230 \end{array}$ | $\begin{array}{r} 2288 \\ 4357 \\ 1 \\ 6646 \end{array}$ | $\begin{array}{r} 5361 \\ 4578 \\ 0 \\ 9939 \end{array}$ | $\begin{array}{r} 3307 \\ 2017 \\ 0 \\ 5324 \end{array}$ | $\begin{array}{r} 2447 \\ 1084 \\ 0 \\ 3531 \end{array}$ | $\begin{array}{r} 897 \\ 298 \\ 0 \\ 1195 \end{array}$ | $\begin{array}{r} 74 \\ 17 \\ 0 \\ 91 \end{array}$ | $\begin{aligned} & 332 \\ & 323 \\ & 239 \\ & 894 \end{aligned}$ |
|  | Rate | Male Female Total | $\begin{array}{r} 112.4 \\ 97.0 \\ 105.6 \end{array}$ | $\begin{aligned} & 1.6 \\ & 3.3 \\ & 2.4 \end{aligned}$ | $\begin{aligned} & 0.9 \\ & 2.5 \\ & 1.7 \end{aligned}$ | $\begin{aligned} & 0.4 \\ & 3.3 \\ & 1.8 \end{aligned}$ | $\begin{array}{r} 3.8 \\ 21.9 \\ 12.6 \\ \hline \end{array}$ | $\begin{aligned} & 227.7 \\ & 456.9 \\ & 339.3 \end{aligned}$ | $\begin{aligned} & 443.5 \\ & 396.5 \\ & 420.6 \end{aligned}$ | $\begin{aligned} & 259.2 \\ & 162.5 \\ & 211.5 \end{aligned}$ | $\begin{array}{r} 109.6 \\ 48.9 \\ 79.4 \\ \hline \end{array}$ | $\begin{aligned} & 31.6 \\ & 10.6 \\ & 21.2 \end{aligned}$ | $\begin{aligned} & 4.3 \\ & 0.8 \\ & 2.3 \end{aligned}$ |  |


|  |  |  | Age Group (years) |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Year |  |  | Canada | $0<1$ | 1-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-29 | 30-39 | 40-59 | 60+ | NS |
| 1988 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 10381 \\ 9501 \\ 220 \\ 20102 \end{array}$ | $\begin{aligned} & 2 \\ & 5 \\ & 0 \\ & 7 \end{aligned}$ | $\begin{array}{r} 1 \\ 11 \\ 0 \\ 12 \end{array}$ | $\begin{array}{r} 4 \\ 25 \\ 0 \\ 29 \end{array}$ | $\begin{array}{r} 26 \\ 139 \\ 0 \\ 165 \end{array}$ | $\begin{array}{r} 1558 \\ 3209 \\ 0 \\ 4767 \end{array}$ | $\begin{array}{r} 3604 \\ 3293 \\ 0 \\ 6897 \end{array}$ | $\begin{array}{r} 2395 \\ 1531 \\ 0 \\ 3926 \end{array}$ | $\begin{array}{r} 1840 \\ 828 \\ 0 \\ 2668 \end{array}$ | $\begin{array}{r} 667 \\ 220 \\ 0 \\ 887 \end{array}$ | $\begin{array}{r} 48 \\ 14 \\ 0 \\ 62 \end{array}$ | $\begin{aligned} & 236 \\ & 226 \\ & 220 \\ & 682 \end{aligned}$ |
|  | Rate | $\begin{array}{\|l} \hline \text { Male } \\ \text { Female } \\ \text { Total } \end{array}$ | $\begin{aligned} & \hline 78.1 \\ & 70.3 \\ & 75.0 \\ & \hline \end{aligned}$ | $\begin{aligned} & 1.1 \\ & 2.8 \\ & 1.9 \end{aligned}$ | $\begin{aligned} & 0.1 \\ & 1.5 \\ & 0.8 \end{aligned}$ | $\begin{aligned} & 0.4 \\ & 2.7 \\ & 1.5 \end{aligned}$ | $\begin{array}{r} 2.8 \\ 15.5 \\ 9.0 \\ \hline \end{array}$ | $\begin{aligned} & 156.2 \\ & 338.7 \\ & 245.1 \end{aligned}$ | $\begin{aligned} & 312.5 \\ & 298.2 \\ & 305.5 \\ & \hline \end{aligned}$ | $\begin{aligned} & 185.3 \\ & 121.7 \\ & 153.9 \end{aligned}$ | $\begin{aligned} & 80.5 \\ & 36.4 \\ & 58.5 \end{aligned}$ | $\begin{array}{r} 22.8 \\ 7.6 \\ 15.2 \end{array}$ | 2.7 0.6 1.5 |  |
| 1989 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 10278 \\ 8778 \\ 54 \\ 19110 \end{array}$ | $\begin{array}{r} 7 \\ 3 \\ 0 \\ 10 \end{array}$ | $\begin{array}{r} 1 \\ 22 \\ 1 \\ 24 \end{array}$ | $\begin{array}{r} 2 \\ 18 \\ 0 \\ 20 \end{array}$ | $\begin{array}{r} 26 \\ 144 \\ 0 \\ 170 \end{array}$ | $\begin{array}{r} 1503 \\ 3083 \\ 1 \\ 4587 \end{array}$ | $\begin{array}{r} 3355 \\ 2850 \\ 3 \\ 6208 \end{array}$ | $\begin{array}{r} 2345 \\ 1445 \\ 2 \\ 3792 \end{array}$ | $\begin{array}{r} 2009 \\ 822 \\ 2 \\ 2833 \end{array}$ | $\begin{array}{r} 735 \\ 221 \\ 0 \\ 956 \end{array}$ | $\begin{array}{r} 54 \\ 10 \\ 0 \\ 64 \end{array}$ | $\begin{array}{r} 241 \\ 160 \\ 45 \\ 446 \end{array}$ |
|  | Rate | Male Female Total | $\begin{aligned} & 76.0 \\ & 63.8 \\ & 70.0 \end{aligned}$ | $\begin{aligned} & 3.6 \\ & 1.6 \\ & 2.6 \end{aligned}$ | $\begin{aligned} & 0.1 \\ & 3.0 \\ & 1.6 \end{aligned}$ | $\begin{aligned} & 0.2 \\ & 1.9 \\ & 1.1 \end{aligned}$ | $\begin{array}{r} \hline 2.7 \\ 15.9 \\ 9.2 \end{array}$ | $\begin{aligned} & 151.1 \\ & 326.2 \\ & 236.4 \end{aligned}$ | $\begin{aligned} & 301.4 \\ & 265.7 \\ & 284.0 \end{aligned}$ | $\begin{aligned} & 178.5 \\ & 113.0 \\ & 146.2 \end{aligned}$ | $\begin{aligned} & 85.1 \\ & 35.1 \\ & 60.2 \end{aligned}$ | $\begin{array}{r} 24.3 \\ 7.4 \\ 15.9 \end{array}$ | 3.0 0.4 1.5 |  |
| 1990 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 7681 \\ 6024 \\ 117 \\ 13822 \end{array}$ | $\begin{array}{r} 5 \\ 9 \\ 1 \\ 15 \end{array}$ | $\begin{array}{r} 1 \\ 13 \\ 0 \\ 14 \end{array}$ | $\begin{array}{r} 3 \\ 9 \\ 0 \\ 12 \end{array}$ | $\begin{array}{r} 21 \\ 139 \\ 0 \\ 160 \end{array}$ | $\begin{array}{r} 1140 \\ 2168 \\ 3 \\ 3311 \end{array}$ | $\begin{array}{r} 2373 \\ 1911 \\ 7 \\ 4291 \end{array}$ | $\begin{array}{r} 1791 \\ 918 \\ 1 \\ 2710 \end{array}$ | $\begin{array}{r} 1553 \\ 564 \\ 4 \\ 2121 \end{array}$ | $\begin{array}{r} 553 \\ 176 \\ 0 \\ 729 \end{array}$ | $\begin{array}{r} 57 \\ 10 \\ 0 \\ 67 \end{array}$ | $\begin{aligned} & 184 \\ & 107 \\ & 101 \\ & 392 \end{aligned}$ |
|  | Rate | Male Female Total | $\begin{aligned} & \hline 55.9 \\ & 43.1 \\ & 49.9 \\ & \hline \end{aligned}$ | $\begin{aligned} & 2.4 \\ & 4.6 \\ & 3.7 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 0.1 \\ & 1.7 \\ & 0.9 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 0.3 \\ & 1.0 \\ & 0.6 \\ & \hline \end{aligned}$ | $\begin{array}{r} 2.2 \\ 15.2 \\ 8.5 \\ \hline \end{array}$ | $\begin{aligned} & 114.6 \\ & 229.8 \\ & 170.8 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 219.5 \\ & 183.2 \\ & 202.0 \\ & \hline \end{aligned}$ | $\begin{array}{r} 136.9 \\ 72.0 \\ 104.9 \\ \hline \end{array}$ | $\begin{aligned} & 64.2 \\ & 23.4 \\ & 44.0 \\ & \hline \end{aligned}$ | $\begin{array}{r} 17.8 \\ 5.7 \\ 11.8 \\ \hline \end{array}$ | $\begin{aligned} & 3.0 \\ & 0.4 \\ & 1.6 \\ & \hline \end{aligned}$ |  |
| 1991 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 7086 \\ 5352 \\ 19 \\ 12457 \end{array}$ | $\begin{aligned} & 4 \\ & 2 \\ & 0 \\ & 6 \end{aligned}$ | $\begin{array}{r} 0 \\ 12 \\ 0 \\ 12 \end{array}$ | $\begin{aligned} & 0 \\ & 3 \\ & 0 \\ & 3 \end{aligned}$ | $\begin{array}{r} 22 \\ 109 \\ 0 \\ 131 \end{array}$ | $\begin{array}{r} 576 \\ 1082 \\ 0 \\ 1658 \end{array}$ | $\begin{array}{r} 1141 \\ 958 \\ 1 \\ 2100 \end{array}$ | $\begin{array}{r} 897 \\ 454 \\ 0 \\ 1351 \end{array}$ | $\begin{array}{r} 831 \\ 319 \\ 0 \\ 1150 \end{array}$ | $\begin{array}{r} 344 \\ 93 \\ 0 \\ 437 \end{array}$ | $\begin{array}{r} 41 \\ 5 \\ 0 \\ 46 \end{array}$ | $\begin{array}{r} 3230 \\ 2315 \\ 18 \\ 5563 \end{array}$ |
|  | Rate | Male Female Total | $\begin{aligned} & 51.0 \\ & 37.9 \\ & 44.4 \end{aligned}$ | $\begin{aligned} & 1.9 \\ & 1.0 \\ & 1.5 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 1.6 \\ & 0.8 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.3 \\ & 0.2 \end{aligned}$ | $\begin{array}{r} \hline 2.3 \\ 11.8 \\ 6.9 \end{array}$ | $\begin{array}{r} 58.1 \\ 115.5 \\ 86.0 \end{array}$ | $\begin{array}{r} 107.4 \\ 93.4 \\ 100.6 \end{array}$ | $\begin{aligned} & 70.6 \\ & 36.7 \\ & 53.9 \end{aligned}$ | $\begin{aligned} & 33.6 \\ & 13.0 \\ & 23.3 \end{aligned}$ | $\begin{array}{r} 10.7 \\ 2.9 \\ 6.8 \end{array}$ | 2.1 0.2 1.0 |  |
| 1992 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 5148 \\ 4093 \\ 12 \\ 9253 \end{array}$ | $\begin{array}{r} 8 \\ 7 \\ 0 \\ 15 \end{array}$ | $\begin{aligned} & 0 \\ & 9 \\ & 0 \\ & 9 \end{aligned}$ | $\begin{aligned} & 1 \\ & 6 \\ & 0 \\ & 7 \end{aligned}$ | $\begin{array}{r} 19 \\ 140 \\ 0 \\ 159 \end{array}$ | $\begin{array}{r} 781 \\ 1644 \\ 2 \\ 2427 \end{array}$ | $\begin{array}{r} 1485 \\ 1195 \\ 2 \\ 2682 \end{array}$ | $\begin{array}{r} 1175 \\ 582 \\ 4 \\ 1761 \end{array}$ | $\begin{array}{r} 1138 \\ 381 \\ 1 \\ 1520 \end{array}$ | $\begin{array}{r} 428 \\ 85 \\ 1 \\ 514 \end{array}$ | $\begin{array}{r} 51 \\ 12 \\ 0 \\ 63 \end{array}$ | $\begin{array}{r} 62 \\ 32 \\ 2 \\ 96 \end{array}$ |
|  | Rate | Male Female Total | $\begin{array}{l\|} \hline 36.6 \\ 28.6 \\ 32.6 \\ \hline \end{array}$ | $\begin{aligned} & 3.9 \\ & 3.6 \\ & 3.7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 1.2 \\ & 0.6 \end{aligned}$ | $\begin{aligned} & 0.1 \\ & 0.6 \\ & 0.4 \end{aligned}$ | $\begin{array}{r} 1.9 \\ 14.9 \\ 8.2 \end{array}$ | $\begin{array}{r} 78.8 \\ 175.4 \\ 125.9 \end{array}$ | $\begin{aligned} & \hline 140.8 \\ & 117.5 \\ & 129.5 \\ & \hline \end{aligned}$ | $\begin{aligned} & 95.5 \\ & 48.4 \\ & 72.4 \end{aligned}$ | $\begin{aligned} & \hline 45.3 \\ & 15.2 \\ & 30.3 \\ & \hline \end{aligned}$ | $\begin{array}{r} \hline 13.0 \\ 2.6 \\ 7.8 \\ \hline \end{array}$ | 2.6 0.5 1.4 |  |
| 1993 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 3738 \\ 3086 \\ 8 \\ 6832 \end{array}$ | $\begin{aligned} & 1 \\ & 0 \\ & 0 \\ & 1 \end{aligned}$ | $\begin{array}{r} 1 \\ 11 \\ 0 \\ 12 \end{array}$ | $\begin{aligned} & 3 \\ & 3 \\ & 1 \\ & 7 \end{aligned}$ | $\begin{array}{r} 8 \\ 88 \\ 1 \\ 97 \end{array}$ | $\begin{array}{r} 596 \\ 1185 \\ 2 \\ 1783 \end{array}$ | $\begin{array}{r} 1013 \\ 997 \\ 0 \\ 2010 \end{array}$ | $\begin{array}{r} 884 \\ 402 \\ 0 \\ 1286 \end{array}$ | $\begin{array}{r} 845 \\ 298 \\ 0 \\ 1143 \end{array}$ | $\begin{array}{r} 323 \\ 79 \\ 0 \\ 402 \end{array}$ | $\begin{array}{r} 26 \\ 4 \\ 1 \\ 31 \end{array}$ | $\begin{array}{r} 38 \\ 19 \\ 3 \\ 60 \end{array}$ |
|  | Rate | Male Female Total | $\begin{aligned} & 26.3 \\ & 21.3 \\ & 23.8 \end{aligned}$ | $\begin{aligned} & 0.5 \\ & 0.0 \\ & 0.3 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.1 \\ & 1.4 \\ & 0.7 \end{aligned}$ | $\begin{aligned} & 0.3 \\ & 0.3 \\ & 0.4 \end{aligned}$ | $\begin{aligned} & 0.8 \\ & 9.2 \\ & 5.0 \end{aligned}$ | $\begin{array}{r} 59.9 \\ 126.0 \\ 92.2 \\ \hline \end{array}$ | $\begin{aligned} & 96.9 \\ & 99.1 \\ & 98.0 \end{aligned}$ | $\begin{aligned} & 74.6 \\ & 34.8 \\ & 54.9 \end{aligned}$ | $\begin{aligned} & 33.0 \\ & 11.7 \\ & 22.4 \end{aligned}$ | $\begin{aligned} & 9.5 \\ & 2.3 \\ & 5.9 \end{aligned}$ | 1.3 0.2 0.7 |  |
| 1994 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 3478 \\ 2645 \\ 44 \\ 6167 \end{array}$ | $\begin{aligned} & 3 \\ & 1 \\ & 0 \\ & 4 \end{aligned}$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \\ & 4 \end{aligned}$ | $\begin{aligned} & 1 \\ & 3 \\ & 0 \\ & 4 \end{aligned}$ | $\begin{array}{r} 10 \\ 83 \\ 0 \\ 93 \end{array}$ | $\begin{array}{r} 433 \\ 947 \\ 2 \\ 1382 \end{array}$ | $\begin{array}{r} 796 \\ 817 \\ 2 \\ 1615 \end{array}$ | $\begin{array}{r} 821 \\ 363 \\ 1 \\ 1185 \end{array}$ | $\begin{array}{r} 971 \\ 293 \\ 4 \\ 1268 \end{array}$ | $\begin{array}{r} \hline 386 \\ 92 \\ 0 \\ 478 \end{array}$ | $\begin{array}{r} 34 \\ 7 \\ 0 \\ 41 \end{array}$ | $\begin{aligned} & 23 \\ & 35 \\ & 35 \\ & 93 \end{aligned}$ |
|  | Rate | Male Female Total | $\begin{aligned} & 24.2 \\ & 18.1 \\ & 21.2 \end{aligned}$ | $\begin{aligned} & 1.5 \\ & 0.5 \\ & 1.0 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.5 \\ & 0.2 \end{aligned}$ | $\begin{aligned} & 0.1 \\ & 0.3 \\ & 0.2 \end{aligned}$ | $\begin{aligned} & 1.0 \\ & 8.6 \\ & 4.7 \end{aligned}$ | $\begin{aligned} & 43.0 \\ & 99.5 \\ & 70.5 \end{aligned}$ | $\begin{aligned} & 76.9 \\ & 82.0 \\ & 79.5 \\ & \hline \end{aligned}$ | $\begin{aligned} & 71.9 \\ & 32.6 \\ & 52.5 \end{aligned}$ | $\begin{aligned} & 37.3 \\ & 11.4 \\ & 24.5 \end{aligned}$ | $\begin{array}{r} 11.0 \\ 2.6 \\ 6.8 \end{array}$ | 1.7 0.3 0.9 |  |
| 1995 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 3322 \\ 2385 \\ 8 \\ 5715 \end{array}$ | $\begin{aligned} & 3 \\ & 1 \\ & 0 \\ & 4 \end{aligned}$ | $\begin{aligned} & 2 \\ & 4 \\ & 0 \\ & 6 \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \\ & 2 \end{aligned}$ | $\begin{array}{r} 9 \\ 75 \\ 0 \\ 84 \end{array}$ | $\begin{array}{r} 425 \\ 888 \\ 2 \\ 1315 \end{array}$ | $\begin{array}{r} 769 \\ 761 \\ 0 \\ 1530 \end{array}$ | $\begin{array}{r} 710 \\ 347 \\ 2 \\ 1059 \end{array}$ | $\begin{array}{r} 980 \\ 243 \\ 1 \\ 1224 \end{array}$ | $\begin{array}{r} 360 \\ 51 \\ 1 \\ 412 \end{array}$ | $\begin{array}{r} 36 \\ 1 \\ 0 \\ 37 \end{array}$ | $\begin{array}{r} 28 \\ 12 \\ 2 \\ 42 \end{array}$ |
|  | Rate | Male <br> Female Total | $\begin{aligned} & 22.9 \\ & 16.1 \\ & 19.5 \end{aligned}$ | $\begin{aligned} & 1.5 \\ & 0.5 \\ & 1.0 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.2 \\ & 0.5 \\ & 0.4 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.2 \\ & 0.1 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.9 \\ & 7.7 \\ & 4.2 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 41.7 \\ & 92.2 \\ & 66.3 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 74.8 \\ & 76.9 \\ & 75.8 \\ & \hline \end{aligned}$ | $\begin{array}{r} \hline 63.9 \\ 32.0 \\ 48.3 \\ \hline \end{array}$ | $\begin{array}{r} 37.4 \\ 9.4 \\ 23.5 \end{array}$ | $\begin{array}{r} 10.0 \\ 1.4 \\ 5.7 \end{array}$ | 1.7 0.0 0.8 |  |


|  |  |  | Age Group (years) |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Year |  |  | Canada | $0<1$ | 1-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-29 | 30-39 | 40-59 | 60+ | S |
| 1996 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 2845 \\ 2168 \\ 10 \\ 5023 \end{array}$ | $\begin{aligned} & 1 \\ & 2 \\ & 0 \\ & 3 \end{aligned}$ | $\begin{aligned} & 2 \\ & 3 \\ & 0 \\ & 5 \end{aligned}$ | $\begin{aligned} & 1 \\ & 2 \\ & 0 \\ & 3 \end{aligned}$ | $\begin{array}{r} 5 \\ 64 \\ 0 \\ 69 \end{array}$ | $\begin{array}{r} 345 \\ 844 \\ 0 \\ 1189 \end{array}$ | $\begin{array}{r} 688 \\ 652 \\ 1 \\ 1341 \end{array}$ | $\begin{array}{r} 614 \\ 320 \\ 0 \\ 934 \end{array}$ | $\begin{array}{r} 820 \\ 210 \\ 4 \\ 1034 \end{array}$ | $\begin{array}{r} 320 \\ 60 \\ 0 \\ 380 \end{array}$ | $\begin{array}{r} 26 \\ 2 \\ 0 \\ 28 \end{array}$ | $\begin{array}{r} 23 \\ 9 \\ 5 \\ 37 \end{array}$ |
|  | Rate | Male Female Total | $\begin{aligned} & 19.4 \\ & 14.5 \\ & 16.9 \end{aligned}$ | $\begin{aligned} & 0.5 \\ & 1.1 \\ & 0.8 \end{aligned}$ | $\begin{aligned} & 0.2 \\ & 0.4 \\ & 0.3 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.1 \\ & 0.2 \\ & 0.1 \end{aligned}$ | $\begin{aligned} & 0.5 \\ & 6.5 \\ & 3.4 \end{aligned}$ | $\begin{aligned} & 33.3 \\ & 86.3 \\ & 59.1 \end{aligned}$ | 67.2 <br> 66.1 <br> 66.7 | $\begin{aligned} & 56.1 \\ & 29.9 \\ & 43.2 \\ & \hline \end{aligned}$ | $\begin{array}{r} 31.3 \\ 8.1 \\ 19.9 \end{array}$ | $\begin{aligned} & 8.6 \\ & 1.6 \\ & 5.1 \end{aligned}$ | 1.2 0.1 0.6 |  |
| 1997 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 2646 \\ 1822 \\ 9 \\ 4477 \end{array}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \\ & 2 \end{aligned}$ | $\begin{array}{r} 2 \\ 56 \\ 0 \\ 58 \end{array}$ | $\begin{array}{r} 333 \\ 716 \\ 0 \\ 1049 \end{array}$ | $\begin{array}{r} 599 \\ 578 \\ 2 \\ 1179 \end{array}$ | $\begin{array}{r} 570 \\ 235 \\ 0 \\ 805 \end{array}$ | $\begin{array}{r} 765 \\ 184 \\ 2 \\ 951 \end{array}$ | $\begin{array}{r} 337 \\ 42 \\ 0 \\ 379 \end{array}$ | $\begin{array}{r} 23 \\ 4 \\ 1 \\ 28 \end{array}$ | $\begin{array}{r} 17 \\ 5 \\ 4 \\ 26 \end{array}$ |
|  | Rate | Male Female Total | $\begin{aligned} & 17.8 \\ & 12.0 \\ & 14.9 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.2 \\ & 0.1 \end{aligned}$ | $\begin{aligned} & \hline 0.2 \\ & 5.7 \\ & 2.9 \\ & \hline \end{aligned}$ | $\begin{array}{r} 31.9 \\ 72.5 \\ 51.7 \\ \hline \end{array}$ | $\begin{aligned} & \hline 58.1 \\ & 58.2 \\ & 58.3 \\ & \hline \end{aligned}$ | $\begin{aligned} & 52.5 \\ & 22.1 \\ & 37.5 \\ & \hline \end{aligned}$ | $\begin{array}{r} 29.3 \\ 7.2 \\ 18.4 \end{array}$ | 8.7 1.1 4.9 | 1.1 0.1 0.6 |  |
| 1998 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 2921 \\ 1938 \\ 9 \\ 4868 \end{array}$ | $\begin{aligned} & 0 \\ & 3 \\ & 0 \\ & 3 \end{aligned}$ | $\begin{aligned} & 0 \\ & 5 \\ & 0 \\ & 5 \end{aligned}$ | $\begin{aligned} & 3 \\ & 3 \\ & 0 \\ & 6 \end{aligned}$ | $\begin{array}{r} 5 \\ 51 \\ 0 \\ 56 \end{array}$ | $\begin{array}{r} 327 \\ 799 \\ 0 \\ 1126 \end{array}$ | $\begin{array}{r} 665 \\ 575 \\ 2 \\ 1242 \end{array}$ | $\begin{array}{r} 571 \\ 245 \\ 0 \\ 816 \end{array}$ | $\begin{array}{r} 898 \\ 196 \\ 0 \\ 1094 \end{array}$ | $\begin{array}{r} 406 \\ 53 \\ 0 \\ 459 \end{array}$ | $\begin{array}{r} 32 \\ 5 \\ 0 \\ 37 \end{array}$ | $\begin{array}{r} 14 \\ 3 \\ 7 \\ 24 \end{array}$ |
|  | Rate | Male Female Total | $\begin{aligned} & 19.5 \\ & 12.7 \\ & 16.1 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 1.8 \\ & 0.9 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.7 \\ & 0.3 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.3 \\ & 0.3 \\ & 0.3 \end{aligned}$ | $\begin{aligned} & 0.5 \\ & 5.2 \\ & 2.8 \end{aligned}$ | $\begin{aligned} & 31.1 \\ & 80.2 \\ & 55.0 \end{aligned}$ | $\begin{aligned} & 64.0 \\ & 57.7 \\ & 61.0 \end{aligned}$ | $\begin{aligned} & 53.0 \\ & 23.3 \\ & 38.3 \\ & \hline \end{aligned}$ | $\begin{array}{r} 34.9 \\ 7.7 \\ 21.4 \end{array}$ | $\begin{array}{r} 10.2 \\ 1.3 \\ 5.7 \end{array}$ | 1.5 0.2 0.7 |  |
| 1999 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 3322 \\ 2054 \\ 5 \\ 5381 \end{array}$ | $\begin{aligned} & 1 \\ & 0 \\ & 0 \\ & 1 \end{aligned}$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \\ & 4 \end{aligned}$ | $\begin{aligned} & 1 \\ & 5 \\ & 0 \\ & 6 \end{aligned}$ | $\begin{array}{r} 2 \\ 49 \\ 0 \\ 51 \end{array}$ | $\begin{array}{r} 337 \\ 798 \\ 1 \\ 1136 \end{array}$ | $\begin{array}{r} 737 \\ 636 \\ 0 \\ 1373 \end{array}$ | $\begin{array}{r} 597 \\ 293 \\ 0 \\ 890 \end{array}$ | $\begin{array}{r} 1077 \\ 193 \\ 1 \\ 1271 \end{array}$ | $\begin{array}{r} 518 \\ 71 \\ 0 \\ 589 \end{array}$ | $\begin{array}{r} 45 \\ 2 \\ 0 \\ 47 \end{array}$ | $\begin{array}{r} 7 \\ 3 \\ 3 \\ 13 \end{array}$ |
|  | Rate | Male Female Total | $\begin{aligned} & 22.0 \\ & 13.3 \\ & 17.6 \end{aligned}$ | $\begin{aligned} & 0.6 \\ & 0.0 \\ & 0.3 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.6 \\ & 0.3 \end{aligned}$ | $\begin{aligned} & 0.1 \\ & 0.5 \\ & 0.3 \end{aligned}$ | $\begin{aligned} & 0.2 \\ & 5.0 \\ & 2.5 \\ & \hline \end{aligned}$ | $\begin{aligned} & 31.8 \\ & 79.5 \\ & 55.1 \end{aligned}$ | $\begin{aligned} & \hline 70.0 \\ & 63.0 \\ & 66.6 \\ & \hline \end{aligned}$ | $\begin{aligned} & 55.7 \\ & 28.0 \\ & 42.0 \\ & \hline \end{aligned}$ | $\begin{array}{r} 42.4 \\ 7.7 \\ 25.2 \end{array}$ | 12.6 1.7 7.1 | 2.0 0.1 0.9 |  |
| 2000 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 3829 \\ 2353 \\ 7 \\ 6189 \end{array}$ | $\begin{aligned} & 1 \\ & 1 \\ & 0 \\ & 2 \end{aligned}$ | $\begin{aligned} & 1 \\ & 1 \\ & 0 \\ & 2 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{array}{r} 6 \\ 47 \\ 0 \\ 53 \end{array}$ | $\begin{array}{r} 432 \\ 969 \\ 1 \\ 1402 \end{array}$ | $\begin{array}{r} 824 \\ 732 \\ 0 \\ 1556 \end{array}$ | $\begin{array}{r} 656 \\ 300 \\ 0 \\ 956 \end{array}$ | $\begin{array}{r} 1246 \\ 223 \\ 0 \\ 1469 \end{array}$ | $\begin{array}{r} 612 \\ 71 \\ 3 \\ 686 \end{array}$ | $\begin{array}{r} 46 \\ 6 \\ 0 \\ 52 \end{array}$ | 5 3 3 11 |
|  | Rate | Male Female Total | $\begin{aligned} & 25.1 \\ & 15.1 \\ & 20.1 \end{aligned}$ | $\begin{aligned} & 0.6 \\ & 0.6 \\ & 0.6 \end{aligned}$ | $\begin{aligned} & 0.1 \\ & 0.1 \\ & 0.1 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.6 \\ & 4.7 \\ & 2.6 \end{aligned}$ | $\begin{aligned} & 40.6 \\ & 96.0 \\ & 67.6 \end{aligned}$ | $\begin{aligned} & 77.3 \\ & 71.8 \\ & 74.6 \end{aligned}$ | $\begin{aligned} & 61.4 \\ & 28.7 \\ & 45.2 \\ & \hline \end{aligned}$ | $\begin{array}{r} 49.6 \\ 9.0 \\ 29.5 \end{array}$ | $\begin{array}{r} 14.4 \\ 1.7 \\ 8.0 \\ \hline \end{array}$ | 2.0 0.2 1.0 |  |
| 2001 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 4176 \\ 2571 \\ 9 \\ 6756 \end{array}$ | $\begin{aligned} & 0 \\ & 3 \\ & 0 \\ & 3 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 3 \\ & 0 \\ & 3 \end{aligned}$ | $\begin{array}{r} 4 \\ 58 \\ 0 \\ 62 \end{array}$ | $\begin{array}{r} 467 \\ 1007 \\ 2 \\ 1476 \end{array}$ | $\begin{array}{r} 980 \\ 852 \\ 2 \\ 1834 \end{array}$ | $\begin{array}{r} 740 \\ 310 \\ 1 \\ 1051 \end{array}$ | $\begin{array}{r} 1224 \\ 236 \\ 3 \\ 1463 \end{array}$ | $\begin{array}{r} 704 \\ 96 \\ 0 \\ 800 \end{array}$ | $\begin{array}{r} 53 \\ 4 \\ 0 \\ 57 \end{array}$ | 4 2 1 7 |
|  | Rate | Male Female Total | $\begin{aligned} & 27.2 \\ & 16.4 \\ & 21.8 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 1.9 \\ & 0.9 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.3 \\ & 0.1 \end{aligned}$ | $\begin{aligned} & 0.4 \\ & 5.7 \\ & 3.0 \\ & \hline \end{aligned}$ | $\begin{aligned} & 42.9 \\ & 97.9 \\ & 69.7 \end{aligned}$ | $\begin{aligned} & 90.8 \\ & 82.6 \\ & 86.9 \end{aligned}$ | $\begin{aligned} & 70.3 \\ & 30.4 \\ & 50.7 \\ & \hline \end{aligned}$ | $\begin{array}{r} 49.8 \\ 9.8 \\ 30.0 \\ \hline \end{array}$ | $\begin{array}{r} 16.1 \\ 2.2 \\ 9.1 \\ \hline \end{array}$ | 2.3 0.1 1.1 |  |
| 2002 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 4595 \\ 2766 \\ 6 \\ 7367 \end{array}$ | $\begin{aligned} & 0 \\ & 1 \\ & 0 \\ & 1 \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \\ & 2 \end{aligned}$ | $\begin{aligned} & 0 \\ & 3 \\ & 0 \\ & 3 \end{aligned}$ | $\begin{array}{r} 8 \\ 61 \\ 0 \\ 69 \end{array}$ | $\begin{array}{r} 472 \\ 1047 \\ 0 \\ 1519 \end{array}$ | $\begin{array}{r} 1121 \\ 872 \\ 1 \\ 1994 \end{array}$ | $\begin{array}{r} 814 \\ 374 \\ 0 \\ 1188 \end{array}$ | $\begin{array}{r} 1347 \\ 301 \\ 2 \\ 1650 \end{array}$ | $\begin{array}{r} 768 \\ 97 \\ 1 \\ 866 \end{array}$ | $\begin{array}{r} 60 \\ 4 \\ 0 \\ 64 \end{array}$ | 5 4 2 11 |
|  | Rate | Male Female Total | $\begin{aligned} & 29.6 \\ & 17.5 \\ & 23.5 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.6 \\ & 0.3 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.3 \\ & 0.1 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.3 \\ & 0.2 \end{aligned}$ | $\begin{aligned} & 0.7 \\ & 5.9 \\ & 3.3 \\ & \hline \end{aligned}$ | $\begin{array}{r} 43.2 \\ 101.3 \\ 71.4 \end{array}$ | $\begin{array}{r} 102.0 \\ 83.0 \\ 92.8 \end{array}$ | $\begin{aligned} & 76.5 \\ & 36.2 \\ & 56.7 \end{aligned}$ | $\begin{aligned} & 55.6 \\ & 12.6 \\ & 34.3 \end{aligned}$ | $\begin{array}{r} 17.1 \\ 2.1 \\ 9.6 \end{array}$ | 2.5 0.1 1.2 |  |

${ }^{1}$ Rate per 100000 population. Population estimates provided by Statistics Canada (Source: Annual Demographic Statistics, 2000 Catalogue no. 91-213 and unpublished data).
${ }^{2} 2002$ data are preliminary and changes are anticipated.
${ }^{3}$ Data have been updated to rectify an historical discrepancy.
Source: Sexual Health and Sexually Transmitted Infections, Community Acquired Infections Division, Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada, 2003.

Table 2.2: Reported Gonorrhea Cases and Rates ${ }^{1}$ in Canada by Province/Territory and Sex, 1980-2002 ${ }^{2}$

|  |  |  | Province/Territory |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Year |  |  | Canada | NL | PE | NS | NB | QC | ON | MB | SK | AB | BC | YT | NT | $N U^{3}$ |
| 1980 | Cases | Male Female Total* | $\begin{aligned} & 32555 \\ & 20485 \\ & 53271 \end{aligned}$ | $\begin{aligned} & 476 \\ & 276 \\ & 792 \\ & \hline \end{aligned}$ | $\begin{array}{r} 0 \\ 0 \\ 108 \end{array}$ | $\begin{array}{r} 692 \\ 753 \\ 1528 \end{array}$ | $\begin{aligned} & 222 \\ & 101 \\ & 323 \\ & \hline \end{aligned}$ | $\begin{aligned} & 2645 \\ & 1936 \\ & 4581 \end{aligned}$ | $\begin{array}{r} 9953 \\ 6093 \\ 16046 \end{array}$ | $\begin{aligned} & 2253 \\ & 1831 \\ & 4084 \end{aligned}$ | $\begin{array}{r} 1692 \\ 909 \\ 2601 \\ \hline \end{array}$ | $\begin{array}{r} 7025 \\ 4451 \\ 11476 \\ \hline \end{array}$ | $\begin{aligned} & 6470 \\ & 3513 \\ & 9983 \end{aligned}$ | $\begin{aligned} & 215 \\ & 128 \\ & 343 \\ & \hline \end{aligned}$ | $\begin{array}{r} 912 \\ 494 \\ 1406 \end{array}$ |  |
|  | Rate | Male Female Total* | $\begin{aligned} & 266.6 \\ & 166.5 \\ & 217.3 \end{aligned}$ | $\begin{array}{r} 164.5 \\ 97.5 \\ 138.3 \end{array}$ | $\begin{array}{r} 0.0 \\ 0.0 \\ 87.3 \end{array}$ | $\begin{aligned} & 163.2 \\ & 175.5 \\ & 179.2 \end{aligned}$ | $\begin{aligned} & 63.0 \\ & 28.6 \\ & 45.7 \end{aligned}$ | $\begin{aligned} & 82.1 \\ & 58.9 \\ & 70.4 \end{aligned}$ | $\begin{aligned} & 229.9 \\ & 138.0 \\ & 183.5 \end{aligned}$ | $\begin{aligned} & 439.5 \\ & 350.7 \\ & 394.7 \end{aligned}$ | $\begin{aligned} & 347.4 \\ & 189.2 \\ & 268.9 \end{aligned}$ | $\begin{aligned} & 625.7 \\ & 416.1 \\ & 523.4 \end{aligned}$ | $\begin{aligned} & 471.3 \\ & 256.4 \\ & 363.9 \end{aligned}$ | $\begin{aligned} & 1663.8 \\ & 1122.1 \\ & 1409.8 \end{aligned}$ | $\begin{aligned} & 3737.4 \\ & 2256.3 \\ & 3037.0 \end{aligned}$ |  |
| 1981 | Cases | Male Female Total* | $\begin{array}{\|l} \hline 34337 \\ 21863 \\ 56330 \\ \hline \end{array}$ | $\begin{aligned} & 485 \\ & 307 \\ & 813 \\ & \hline \end{aligned}$ | $\begin{array}{r} 0 \\ 0 \\ 92 \end{array}$ | $\begin{array}{r} 635 \\ 668 \\ 1320 \end{array}$ | $\begin{array}{r} 165 \\ 98 \\ 263 \\ \hline \end{array}$ | $\begin{aligned} & 3540 \\ & 2690 \\ & 6230 \end{aligned}$ | $\begin{array}{\|r} 10549 \\ 6651 \\ 17200 \end{array}$ | $\begin{aligned} & 2617 \\ & 2054 \\ & 4671 \end{aligned}$ | $\begin{array}{r} 1704 \\ 991 \\ 2695 \\ \hline \end{array}$ | $\begin{array}{r} 7234 \\ 4453 \\ 11687 \\ \hline \end{array}$ | $\begin{aligned} & 5939 \\ & 3168 \\ & 9107 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 291 \\ & 158 \\ & 449 \\ & \hline \end{aligned}$ | $\begin{array}{r} \hline 1178 \\ 625 \\ 1803 \\ \hline \end{array}$ |  |
|  | Rate | Male Female Total* | $\begin{aligned} & \hline 278.0 \\ & 175.3 \\ & 227.0 \\ & \hline \end{aligned}$ | $\begin{array}{l\|} \hline 167.2 \\ 107.8 \\ 141.4 \\ \hline \end{array}$ | $\begin{array}{r} \hline 0.0 \\ 0.0 \\ 74.3 \\ \hline \end{array}$ | $\begin{aligned} & 149.8 \\ & 155.1 \\ & 154.4 \end{aligned}$ | $\begin{aligned} & \hline 46.9 \\ & 27.7 \\ & 37.2 \\ & \hline \end{aligned}$ | $\begin{array}{r} 109.4 \\ 81.3 \\ 95.1 \end{array}$ | $\begin{aligned} & 242.1 \\ & 149.3 \\ & 195.2 \end{aligned}$ | $\begin{aligned} & 510.5 \\ & 392.2 \\ & 450.7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 347.2 \\ & 204.3 \\ & 276.2 \end{aligned}$ | $\begin{array}{r\|} \hline 614.7 \\ 398.5 \\ 509.4 \\ \hline \end{array}$ | $\begin{aligned} & 420.6 \\ & 224.4 \\ & 322.5 \end{aligned}$ | $\begin{aligned} & 2300.0 \\ & 1404.3 \\ & 1878.4 \end{aligned}$ | $\begin{aligned} & 4705.4 \\ & 2775.3 \\ & 3791.4 \end{aligned}$ |  |
| 1982 | Cases | Male Female Total* | $\begin{aligned} & 32078 \\ & 20893 \\ & 53072 \end{aligned}$ | $\begin{aligned} & 496 \\ & 257 \\ & 777 \end{aligned}$ | $\begin{array}{r} 0 \\ 0 \\ 59 \end{array}$ | $\begin{array}{r} 631 \\ 626 \\ 1275 \end{array}$ | $\begin{array}{r} 106 \\ 84 \\ 190 \\ \hline \end{array}$ | $\begin{aligned} & 3251 \\ & 2372 \\ & 5623 \end{aligned}$ | $\begin{array}{r} 10013 \\ 6371 \\ 16384 \end{array}$ | $\begin{aligned} & 2575 \\ & 2033 \\ & 4608 \end{aligned}$ | $\begin{array}{r} 1577 \\ 889 \\ 2466 \end{array}$ | $\begin{array}{r} 6717 \\ 4349 \\ 11066 \end{array}$ | $\begin{aligned} & 5403 \\ & 3223 \\ & 8626 \end{aligned}$ | $\begin{aligned} & 150 \\ & 108 \\ & 258 \end{aligned}$ | $\begin{array}{r} 1159 \\ 581 \\ 1740 \\ \hline \end{array}$ |  |
|  | Rate | Male Female Total* | $\begin{aligned} & \hline 256.8 \\ & 165.5 \\ & 211.3 \\ & \hline \end{aligned}$ | $\begin{array}{r} 171.3 \\ 90.2 \\ 135.2 \end{array}$ | $\begin{array}{r} 0.0 \\ 0.0 \\ 47.6 \\ \hline \end{array}$ | $\begin{aligned} & 147.9 \\ & 144.5 \\ & 148.3 \end{aligned}$ | $\begin{aligned} & 30.0 \\ & 23.6 \\ & 26.8 \\ & \hline \end{aligned}$ | $\begin{array}{r} 100.0 \\ 71.3 \\ 85.5 \end{array}$ | $\begin{aligned} & 227.0 \\ & 141.2 \\ & 183.6 \\ & \hline \end{aligned}$ | $\begin{aligned} & 497.1 \\ & 384.5 \\ & 440.2 \end{aligned}$ | $\begin{aligned} & 317.9 \\ & 181.0 \\ & 249.8 \end{aligned}$ | $\begin{aligned} & 554.6 \\ & 375.9 \\ & 467.3 \end{aligned}$ | $\begin{aligned} & 376.5 \\ & 224.2 \\ & 300.3 \end{aligned}$ | $\begin{array}{r} 1158.9 \\ 936.8 \\ 1054.3 \end{array}$ | $\begin{aligned} & 4443.8 \\ & 2479.3 \\ & 3514.1 \end{aligned}$ |  |
| 1983 | Cases | Male <br> Female <br> Total* | $\begin{aligned} & 27006 \\ & 18148 \\ & 45265 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 394 \\ & 279 \\ & 685 \\ & \hline \end{aligned}$ | $\begin{array}{r} 0 \\ 0 \\ 87 \end{array}$ | $\begin{array}{r} 564 \\ 594 \\ 1170 \end{array}$ | $\begin{array}{r} \hline 61 \\ 59 \\ 120 \\ \hline \end{array}$ | $\begin{array}{r} 3542 \\ 2360 \\ 5902 \\ \hline \end{array}$ | $\begin{array}{\|r} 9412 \\ 6183 \\ 15595 \end{array}$ | $\begin{aligned} & 2152 \\ & 1609 \\ & 3761 \\ & \hline \end{aligned}$ | $\begin{array}{r} 1295 \\ 734 \\ 2029 \\ \hline \end{array}$ | $\begin{aligned} & 4623 \\ & 3398 \\ & 8021 \\ & \hline \end{aligned}$ | $\begin{array}{r} 3774 \\ 2315 \\ 6089 \\ \hline \end{array}$ | $\begin{array}{r} \hline 89 \\ 58 \\ 147 \\ \hline \end{array}$ | $\begin{array}{r} 1100 \\ 559 \\ 1659 \\ \hline \end{array}$ |  |
|  | Rate | Male Female Total* | $\begin{array}{l\|} \hline 214.2 \\ 142.3 \\ 178.4 \\ \hline \end{array}$ | $\begin{array}{r} 135.1 \\ 96.9 \\ 118.2 \end{array}$ | $\begin{array}{r} \hline 0.0 \\ 0.0 \\ 69.4 \\ \hline \end{array}$ | $\begin{aligned} & 130.8 \\ & 135.6 \\ & 134.6 \\ & \hline \end{aligned}$ | $\begin{aligned} & 17.1 \\ & 16.4 \\ & 16.8 \\ & \hline \end{aligned}$ | $\begin{array}{r\|} \hline 108.6 \\ 70.6 \\ 89.4 \\ \hline \end{array}$ | $\begin{aligned} & \hline 210.5 \\ & 135.3 \\ & 172.5 \\ & \hline \end{aligned}$ | $\begin{aligned} & 409.7 \\ & 300.3 \\ & 354.5 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 257.5 \\ & 147.1 \\ & 202.5 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 379.3 \\ & 290.1 \\ & 335.6 \\ & \hline \end{aligned}$ | $\begin{array}{l\|} \hline 260.3 \\ 159.1 \\ 209.6 \\ \hline \end{array}$ | $\begin{aligned} & \hline 713.0 \\ & 520.9 \\ & 622.4 \\ & \hline \end{aligned}$ | $\begin{aligned} & 4090.6 \\ & 2316.3 \\ & 3251.4 \end{aligned}$ |  |
| 1984 | Cases | Male Female Total* | $\begin{aligned} & 25852 \\ & 17924 \\ & 43874 \end{aligned}$ | $\begin{aligned} & 383 \\ & 218 \\ & 617 \end{aligned}$ | $\begin{array}{r} 0 \\ 0 \\ 67 \\ \hline \end{array}$ | $\begin{array}{r} 643 \\ 684 \\ 1342 \end{array}$ | $\begin{aligned} & 139 \\ & 115 \\ & 254 \end{aligned}$ | $\begin{aligned} & 4197 \\ & 2793 \\ & 6990 \end{aligned}$ | $\begin{array}{r} 9119 \\ 6554 \\ 15673 \end{array}$ | $\begin{aligned} & 1897 \\ & 1453 \\ & 3350 \end{aligned}$ | $\begin{array}{r} 1198 \\ 614 \\ 1812 \end{array}$ | $\begin{aligned} & 3897 \\ & 2815 \\ & 6712 \\ & \hline \end{aligned}$ | $\begin{array}{r} 3334 \\ 2131 \\ 5465 \\ \hline \end{array}$ | $\begin{array}{r} 114 \\ 77 \\ 191 \\ \hline \end{array}$ | $\begin{array}{r} 931 \\ 470 \\ 1401 \end{array}$ |  |
|  | Rate | Male <br> Female <br> Total* | $\begin{aligned} & \hline 203.2 \\ & 139.1 \\ & 171.3 \\ & \hline \end{aligned}$ | $\begin{array}{r} \hline 131.3 \\ 75.6 \\ 106.3 \\ \hline \end{array}$ | $\begin{array}{r} \hline 0.0 \\ 0.0 \\ 52.9 \\ \hline \end{array}$ | $\begin{aligned} & 147.8 \\ & 154.7 \\ & 153.0 \end{aligned}$ | $\begin{aligned} & 38.8 \\ & 31.7 \\ & 35.2 \end{aligned}$ | $\begin{array}{r} 128.2 \\ 83.2 \\ 105.4 \end{array}$ | $\begin{aligned} & \hline 201.1 \\ & 141.3 \\ & 170.9 \\ & \hline \end{aligned}$ | $\begin{aligned} & 357.4 \\ & 268.5 \\ & 312.5 \end{aligned}$ | $\begin{aligned} & 235.2 \\ & 121.3 \\ & 178.4 \end{aligned}$ | $\begin{aligned} & \hline 320.7 \\ & 239.6 \\ & 280.8 \\ & \hline \end{aligned}$ | $\begin{aligned} & 227.0 \\ & 144.3 \\ & 185.5 \end{aligned}$ | $\begin{aligned} & 902.5 \\ & 682.5 \\ & 798.7 \end{aligned}$ | $\begin{aligned} & 3358.9 \\ & 1891.6 \\ & 2665.3 \end{aligned}$ |  |
| 1985 | Cases | Male Female Total* | $\begin{aligned} & 23277 \\ & 17399 \\ & 40737 \end{aligned}$ | $\begin{aligned} & \hline 357 \\ & 201 \\ & 568 \\ & \hline \end{aligned}$ | $\begin{array}{r} \hline 0 \\ 0 \\ 49 \\ \hline \end{array}$ | $\begin{array}{r} 506 \\ 677 \\ 1185 \\ \hline \end{array}$ | $\begin{aligned} & \hline 243 \\ & 264 \\ & 507 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 3749 \\ & 2678 \\ & 6427 \\ & \hline \end{aligned}$ | $\begin{array}{\|r\|} \hline 8462 \\ 6445 \\ 14907 \\ \hline \end{array}$ | $\begin{aligned} & 1813 \\ & 1373 \\ & 3186 \\ & \hline \end{aligned}$ | $\begin{array}{r} 1209 \\ 689 \\ 1898 \\ \hline \end{array}$ | $\begin{aligned} & 3175 \\ & 2515 \\ & 5690 \end{aligned}$ | $\begin{aligned} & 2819 \\ & 2103 \\ & 4922 \end{aligned}$ | $\begin{array}{r} 115 \\ 76 \\ 191 \end{array}$ | $\begin{array}{r} 829 \\ 378 \\ 1207 \\ \hline \end{array}$ |  |
|  | Rate | Male Female Total* | $\begin{array}{l\|} \hline 181.4 \\ 133.7 \\ 157.6 \\ \hline \end{array}$ | $\begin{array}{r} 122.7 \\ 69.7 \\ 98.0 \\ \hline \end{array}$ | $\begin{array}{r\|} \hline 0.0 \\ 0.0 \\ 38.4 \\ \hline \end{array}$ | $\begin{aligned} & 115.3 \\ & 151.7 \\ & 133.9 \\ & \hline \end{aligned}$ | $\begin{aligned} & 67.5 \\ & 72.5 \\ & 70.1 \end{aligned}$ | $\begin{array}{r} 114.0 \\ 79.3 \\ 96.4 \\ \hline \end{array}$ | $\begin{aligned} & 184.1 \\ & 137.1 \\ & 160.3 \\ & \hline \end{aligned}$ | $\begin{aligned} & 338.2 \\ & 251.4 \\ & 294.4 \end{aligned}$ | $\begin{aligned} & 235.2 \\ & 134.7 \\ & 185.1 \end{aligned}$ | $\begin{aligned} & \hline 260.7 \\ & 212.3 \\ & 236.8 \\ & \hline \end{aligned}$ | $\begin{aligned} & 190.2 \\ & 140.9 \\ & 165.5 \end{aligned}$ | $\begin{aligned} & 894.3 \\ & 660.6 \\ & 784.0 \\ & \hline \end{aligned}$ | $\begin{aligned} & 2888.3 \\ & 1470.8 \\ & 2218.7 \end{aligned}$ |  |
| 1986 | Cases | Male <br> Female Total* | $\begin{aligned} & 19458 \\ & 15744 \\ & 35287 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 250 \\ & 171 \\ & 435 \\ & \hline \end{aligned}$ | $\begin{array}{r} 0 \\ 0 \\ 67 \end{array}$ | $\begin{aligned} & \hline 389 \\ & 563 \\ & 952 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 263 \\ & 241 \\ & 506 \\ & \hline \end{aligned}$ | $\begin{array}{r} 3322 \\ 2522 \\ 5844 \\ \hline \end{array}$ |  | $\begin{aligned} & 1715 \\ & 1314 \\ & 3029 \\ & \hline \end{aligned}$ | $\begin{array}{r} 1073 \\ 664 \\ 1737 \\ \hline \end{array}$ | $\begin{aligned} & 2588 \\ & 2294 \\ & 4882 \\ & \hline \end{aligned}$ | $\begin{aligned} & 1984 \\ & 1586 \\ & 3570 \\ & \hline \end{aligned}$ | $\begin{array}{r} \hline 118 \\ 68 \\ 186 \\ \hline \end{array}$ | $\begin{array}{r} 884 \\ 550 \\ 1436 \end{array}$ |  |
|  | Rate | Male <br> Female Total* | $\begin{aligned} & \hline 150.2 \\ & 119.7 \\ & 135.2 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 86.5 \\ & 59.5 \\ & 75.5 \\ & \hline \end{aligned}$ | $\begin{array}{r} \hline 0.0 \\ 0.0 \\ 52.2 \\ \hline \end{array}$ | $\begin{array}{r} \hline 88.2 \\ 125.6 \\ 107.0 \\ \hline \end{array}$ | $\begin{array}{l\|} \hline 73.0 \\ 66.0 \\ 69.8 \\ \hline \end{array}$ | $\begin{array}{r\|} \hline 100.4 \\ 74.2 \\ 87.1 \\ \hline \end{array}$ | $\begin{aligned} & \hline 147.3 \\ & 121.0 \\ & 134.0 \\ & \hline \end{aligned}$ | $\begin{array}{r} 317.0 \\ 238.6 \\ 277.5 \\ \hline \end{array}$ | $\begin{aligned} & \hline 208.2 \\ & 129.2 \\ & 168.8 \\ & \hline \end{aligned}$ | $\begin{aligned} & 210.7 \\ & 190.8 \\ & 200.8 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 132.7 \\ & 105.1 \\ & 118.8 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 913.9 \\ & 587.8 \\ & 759.8 \\ & \hline \end{aligned}$ | $\begin{aligned} & 3061.7 \\ & 2129.9 \\ & 2625.4 \end{aligned}$ |  |
| 1987 | Cases | Male Female Total* | $\begin{aligned} & 14755 \\ & 12923 \\ & 27918 \end{aligned}$ | $\begin{aligned} & 152 \\ & 102 \\ & 258 \end{aligned}$ | $\begin{aligned} & 13 \\ & 20 \\ & 39 \\ & \hline \end{aligned}$ | $\begin{aligned} & 251 \\ & 356 \\ & 609 \end{aligned}$ | $\begin{aligned} & 268 \\ & 203 \\ & 471 \\ & \hline \end{aligned}$ | $\begin{aligned} & 1973 \\ & 1697 \\ & 3897 \end{aligned}$ | $\begin{aligned} & 5077 \\ & 4596 \\ & 9673 \end{aligned}$ | $\begin{aligned} & 1585 \\ & 1306 \\ & 2891 \end{aligned}$ | $\begin{array}{r} 968 \\ 816 \\ 1784 \\ \hline \end{array}$ | $\begin{aligned} & 2158 \\ & 1949 \\ & 4107 \\ & \hline \end{aligned}$ | $\begin{aligned} & 1565 \\ & 1355 \\ & 2920 \end{aligned}$ | $\begin{array}{r} 68 \\ 57 \\ 125 \\ \hline \end{array}$ | $\begin{array}{r} 677 \\ 466 \\ 1144 \\ \hline \end{array}$ |  |
|  | Rate | Male Female Total* | $\begin{array}{r\|} \hline 112.4 \\ 97.0 \\ 105.6 \\ \hline \end{array}$ | $\begin{aligned} & 52.7 \\ & 35.6 \\ & 44.9 \end{aligned}$ | $\begin{aligned} & 20.3 \\ & 30.9 \\ & 30.3 \end{aligned}$ | $\begin{aligned} & 56.7 \\ & 78.9 \\ & 68.2 \end{aligned}$ | $\begin{aligned} & 74.1 \\ & 55.4 \\ & 64.7 \end{aligned}$ | $\begin{aligned} & 59.0 \\ & 49.4 \\ & 57.5 \end{aligned}$ | $\begin{array}{r} \hline 106.5 \\ 94.3 \\ 100.3 \\ \hline \end{array}$ | $\begin{aligned} & 291.3 \\ & 235.8 \\ & 263.3 \end{aligned}$ | $\begin{aligned} & 187.4 \\ & 158.1 \\ & 172.7 \end{aligned}$ | $\begin{aligned} & 175.4 \\ & 161.7 \\ & 168.6 \end{aligned}$ | $\begin{array}{r} \hline 103.0 \\ 88.5 \\ 95.7 \end{array}$ | $\begin{aligned} & 502.3 \\ & 468.4 \\ & 486.2 \end{aligned}$ | $\begin{aligned} & 2332.6 \\ & 1791.3 \\ & 2078.6 \end{aligned}$ |  |
| 1988 | Cases | Male <br> Female <br> Total* | $\begin{array}{r} 10381 \\ 9501 \\ 20102 \\ \hline \end{array}$ | $\begin{array}{r} 89 \\ 59 \\ 151 \\ \hline \end{array}$ | $\begin{aligned} & 10 \\ & 13 \\ & 23 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 197 \\ & 346 \\ & 543 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 104 \\ & 139 \\ & 243 \\ & \hline \end{aligned}$ | $\begin{aligned} & 1342 \\ & 1227 \\ & 2785 \end{aligned}$ | $\begin{aligned} & \hline 4149 \\ & 3680 \\ & 7829 \\ & \hline \end{aligned}$ | $\begin{array}{r} 1115 \\ 903 \\ 2018 \\ \hline \end{array}$ | $\begin{array}{r} 669 \\ 601 \\ 1270 \\ \hline \end{array}$ | $\begin{aligned} & \hline 1285 \\ & 1272 \\ & 2557 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 1119 \\ & 1015 \\ & 2135 \\ & \hline \end{aligned}$ | $\begin{array}{r} 62 \\ 38 \\ 100 \\ \hline \end{array}$ | $\begin{aligned} & \hline 240 \\ & 208 \\ & 448 \\ & \hline \end{aligned}$ |  |
|  | Rate | Male <br> Female <br> Total* | $\begin{array}{\|l\|} \hline 78.1 \\ 70.3 \\ 75.0 \\ \hline \end{array}$ | $\begin{array}{\|l\|} \hline 30.9 \\ 20.6 \\ 26.3 \\ \hline \end{array}$ | $\begin{aligned} & \hline 15.6 \\ & 20.0 \\ & 17.8 \\ & \hline \end{aligned}$ | $\begin{array}{\|l\|} \hline 44.4 \\ 76.3 \\ 60.5 \\ \hline \end{array}$ | $\begin{aligned} & \hline 28.7 \\ & 37.8 \\ & 33.3 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 39.8 \\ & 35.4 \\ & 40.7 \\ & \hline \end{aligned}$ | 85.3 73.9 79.5 | $\begin{aligned} & \hline 204.1 \\ & 162.5 \\ & 183.1 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 130.2 \\ & 116.8 \\ & 123.5 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 103.7 \\ & 104.7 \\ & 104.2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 72.1 \\ & 64.9 \\ & 68.5 \end{aligned}$ | $\begin{aligned} & \hline 443.0 \\ & 301.0 \\ & 375.6 \\ & \hline \end{aligned}$ |  |  |


|  |  |  | Province/Territory |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Year |  |  | Canada | NL | PE | NS | NB | QC | ON | MB | SK | AB | BC | YT | NT | NU ${ }^{3}$ |
| 1989 | Cases | Male Female Total* | $\begin{array}{r\|r} 10278 \\ 8778 \\ 19110 \end{array}$ | $\begin{aligned} & 41 \\ & 37 \\ & 80 \\ & \hline \end{aligned}$ | $\begin{array}{r} 5 \\ 10 \\ 15 \\ \hline \end{array}$ | $\begin{aligned} & 156 \\ & 295 \\ & 451 \end{aligned}$ | $\begin{array}{r} 61 \\ 87 \\ 148 \\ \hline \end{array}$ | $\begin{array}{r} 948 \\ 694 \\ 1694 \end{array}$ | $\begin{aligned} & 5169 \\ & 4081 \\ & 9250 \\ & \hline \end{aligned}$ | $\begin{array}{r} 819 \\ 721 \\ 1540 \\ \hline \end{array}$ | $\begin{array}{r} 551 \\ 449 \\ 1000 \\ \hline \end{array}$ | $\begin{array}{r} 1015 \\ 962 \\ 1977 \end{array}$ | $\begin{array}{r} 781 \\ 712 \\ 1493 \end{array}$ | $\begin{aligned} & 62 \\ & 35 \\ & 97 \\ & \hline \end{aligned}$ | $\begin{array}{r} 670 \\ 695 \\ 1365 \\ \hline \end{array}$ |  |
|  | Rate | Male Female Total* | $\begin{array}{l\|} \hline 76.0 \\ 63.8 \\ 70.0 \\ \hline \end{array}$ | $\begin{array}{l\|} \hline 14.2 \\ 12.9 \\ 13.9 \\ \hline \end{array}$ | $\begin{array}{r\|} \hline 7.8 \\ 15.2 \\ 11.5 \\ \hline \end{array}$ | $\begin{array}{l\|} \hline 34.9 \\ 64.5 \\ 49.9 \\ \hline \end{array}$ | $\begin{array}{l\|} \hline 16.7 \\ 23.5 \\ 20.1 \\ \hline \end{array}$ | $\begin{array}{\|l\|} \hline 27.8 \\ 19.7 \\ 24.4 \\ \hline \end{array}$ | $\begin{array}{r\|} \hline 103.4 \\ 79.8 \\ 91.5 \\ \hline \end{array}$ | $\begin{aligned} & 149.7 \\ & 129.6 \\ & 139.6 \\ & \hline \end{aligned}$ | $\begin{array}{r\|} \hline 108.3 \\ 87.9 \\ 98.1 \\ \hline \end{array}$ | $\begin{array}{l\|} \hline 80.6 \\ 77.8 \\ 79.2 \\ \hline \end{array}$ | $\begin{array}{l\|} \hline 49.0 \\ 44.4 \\ 46.7 \\ \hline \end{array}$ | $\begin{aligned} & \hline 435.5 \\ & 271.7 \\ & 357.7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 2232.7 \\ & 2572.5 \\ & 2393.7 \end{aligned}$ |  |
| 1990 | Cases | Male Female Total* | $\begin{array}{r} 7681 \\ 6024 \\ 13822 \end{array}$ | $\begin{aligned} & 27 \\ & 22 \\ & 49 \\ & \hline \end{aligned}$ | $\begin{array}{r} 6 \\ 3 \\ 10 \end{array}$ | $\begin{aligned} & 120 \\ & 190 \\ & 310 \end{aligned}$ | $\begin{aligned} & 36 \\ & 26 \\ & 62 \end{aligned}$ | $\begin{array}{r} 1182 \\ 695 \\ 1966 \\ \hline \end{array}$ | $\begin{aligned} & 3569 \\ & 2552 \\ & 6148 \end{aligned}$ | $\begin{array}{r} 571 \\ 508 \\ 1079 \end{array}$ | $\begin{aligned} & 448 \\ & 455 \\ & 903 \\ & \hline \end{aligned}$ | $\begin{array}{r} 625 \\ 630 \\ 1255 \end{array}$ | $\begin{array}{r} 818 \\ 682 \\ 1500 \end{array}$ | $\begin{aligned} & 48 \\ & 37 \\ & 85 \end{aligned}$ | $\begin{aligned} & 231 \\ & 224 \\ & 455 \\ & \hline \end{aligned}$ |  |
|  | Rate | Male Female Total* | 55.9 43.1 49.9 | 9.3 7.6 8.5 | $\begin{aligned} & 9.3 \\ & 4.6 \\ & 7.7 \end{aligned}$ | $\begin{array}{r\|} \hline 26.7 \\ 41.3 \\ 34.1 \\ \hline \end{array}$ | $\begin{aligned} & \hline 9.8 \\ & 7.0 \\ & 8.4 \\ & \hline \end{aligned}$ | $\begin{array}{r\|} \hline 34.3 \\ 19.6 \\ 28.1 \\ \hline \end{array}$ | $\begin{aligned} & 70.1 \\ & 49.0 \\ & 59.7 \end{aligned}$ | $\begin{array}{r} \hline 104.2 \\ 91.1 \\ 97.6 \\ \hline \end{array}$ | $\begin{aligned} & \hline 89.2 \\ & 90.1 \\ & 89.7 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 48.6 \\ & 49.9 \\ & 49.3 \\ & \hline \end{aligned}$ | $\begin{array}{l\|} \hline 49.9 \\ 41.3 \\ 45.6 \\ \hline \end{array}$ | $\begin{aligned} & \hline 329.7 \\ & 279.9 \\ & 306.0 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 746.0 \\ & 801.7 \\ & 772.4 \\ & \hline \end{aligned}$ |  |
| 1991 | Cases | Male Female Total* | $\begin{array}{r} 7086 \\ 5352 \\ 12457 \end{array}$ | $\begin{aligned} & 10 \\ & 15 \\ & 25 \\ & \hline \end{aligned}$ | $\begin{aligned} & 3 \\ & 3 \\ & 6 \end{aligned}$ | $\begin{aligned} & 105 \\ & 189 \\ & 294 \\ & \hline \end{aligned}$ | $\begin{array}{r} 32 \\ 21 \\ 53 \\ \hline \end{array}$ | $\begin{array}{r} 953 \\ 417 \\ 1380 \\ \hline \end{array}$ | $\begin{aligned} & 3100 \\ & 2274 \\ & 5381 \end{aligned}$ | $\begin{array}{r} 697 \\ 598 \\ 1295 \end{array}$ | $\begin{aligned} & 442 \\ & 404 \\ & 846 \\ & \hline \end{aligned}$ | $\begin{array}{r} 757 \\ 630 \\ 1387 \end{array}$ | $\begin{array}{r} 744 \\ 584 \\ 1330 \end{array}$ | $\begin{aligned} & 44 \\ & 33 \\ & 77 \\ & \hline \end{aligned}$ | $\begin{aligned} & 199 \\ & 184 \\ & 383 \\ & \hline \end{aligned}$ |  |
|  | Rate | Male Female Total* | $\begin{array}{l\|} \hline 51.0 \\ 37.9 \\ 44.4 \\ \hline \end{array}$ | $\begin{aligned} & 3.4 \\ & 5.2 \\ & 4.3 \\ & \hline \end{aligned}$ | $\begin{aligned} & 4.7 \\ & 4.6 \\ & 4.6 \end{aligned}$ | $\begin{aligned} & \hline 23.3 \\ & 40.8 \\ & 32.1 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 8.7 \\ & 5.6 \\ & 7.1 \\ & \hline \end{aligned}$ | $\begin{array}{l\|} \hline 27.4 \\ 11.6 \\ 19.5 \\ \hline \end{array}$ | $\begin{aligned} & 60.2 \\ & 43.1 \\ & 51.6 \end{aligned}$ | $\begin{aligned} & \hline 126.7 \\ & 106.9 \\ & 116.7 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 88.5 \\ & 80.3 \\ & 84.4 \\ & \hline \end{aligned}$ | $\begin{aligned} & 57.9 \\ & 49.0 \\ & 53.5 \\ & \hline \end{aligned}$ | $\begin{array}{r\|} \hline 44.2 \\ 34.5 \\ 39.4 \\ \hline \end{array}$ | $\begin{aligned} & 290.8 \\ & 239.4 \\ & 266.3 \end{aligned}$ | $\begin{aligned} & 622.0 \\ & 635.9 \\ & 628.6 \\ & \hline \end{aligned}$ |  |
| 1992 | Cases | Male Female Total* | $\begin{aligned} & 5148 \\ & 4093 \\ & 9253 \\ & \hline \end{aligned}$ | $\begin{array}{r} 9 \\ 4 \\ 13 \\ \hline \end{array}$ | $\begin{aligned} & 2 \\ & 1 \\ & 3 \end{aligned}$ | $\begin{array}{r} \hline 69 \\ 126 \\ 196 \\ \hline \end{array}$ | $\begin{array}{r} 15 \\ 9 \\ 24 \end{array}$ | $\begin{aligned} & 618 \\ & 264 \\ & 891 \\ & \hline \end{aligned}$ | $\begin{aligned} & 2188 \\ & 1707 \\ & 3897 \\ & \hline \end{aligned}$ | $\begin{array}{r} 702 \\ 557 \\ 1259 \\ \hline \end{array}$ | $\begin{aligned} & \hline 360 \\ & 357 \\ & 717 \\ & \hline \end{aligned}$ | $\begin{array}{r} 598 \\ 576 \\ 1174 \\ \hline \end{array}$ | $\begin{aligned} & 456 \\ & 336 \\ & 792 \\ & \hline \end{aligned}$ | $\begin{array}{r} 8 \\ 5 \\ 13 \end{array}$ | $\begin{aligned} & \hline 123 \\ & 151 \\ & 274 \\ & \hline \end{aligned}$ |  |
|  | Rate | Male Female Total* | $\begin{aligned} & \hline 36.6 \\ & 28.6 \\ & 32.6 \\ & \hline \end{aligned}$ | $\begin{aligned} & 3.1 \\ & 1.4 \\ & 2.2 \end{aligned}$ | $\begin{aligned} & 3.1 \\ & 1.5 \\ & 2.3 \end{aligned}$ | $\begin{aligned} & 15.2 \\ & 27.0 \\ & 21.3 \end{aligned}$ | $\begin{aligned} & 4.0 \\ & 2.4 \\ & 3.2 \end{aligned}$ | $\begin{array}{r\|} 17.6 \\ 7.3 \\ 12.5 \end{array}$ | $\begin{aligned} & 41.9 \\ & 31.9 \\ & 36.9 \end{aligned}$ | $\begin{array}{r} 127.2 \\ 99.3 \\ 113.1 \end{array}$ | $\begin{aligned} & 72.0 \\ & 70.8 \\ & 71.4 \end{aligned}$ | $\begin{aligned} & 45.0 \\ & 44.1 \\ & 44.6 \end{aligned}$ | $\begin{array}{\|l\|} \hline 26.4 \\ 19.3 \\ 22.8 \\ \hline \end{array}$ | $\begin{aligned} & 50.6 \\ & 34.7 \\ & 43.0 \end{aligned}$ | $\begin{aligned} & 375.5 \\ & 509.2 \\ & 439.0 \end{aligned}$ |  |
| 1993 | Cases | Male Female Total* | $\begin{aligned} & 3738 \\ & 3086 \\ & 6832 \end{aligned}$ | $\begin{aligned} & 2 \\ & 1 \\ & 3 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 29 \\ & 61 \\ & 90 \\ & \hline \end{aligned}$ | $\begin{aligned} & 6 \\ & 2 \\ & 8 \end{aligned}$ | $\begin{aligned} & 458 \\ & 217 \\ & 680 \end{aligned}$ | $\begin{aligned} & 1691 \\ & 1341 \\ & 3035 \end{aligned}$ | $\begin{aligned} & 487 \\ & 436 \\ & 923 \end{aligned}$ | $\begin{aligned} & 247 \\ & 243 \\ & 490 \\ & \hline \end{aligned}$ | $\begin{aligned} & 427 \\ & 404 \\ & 831 \end{aligned}$ | $\begin{aligned} & 312 \\ & 254 \\ & 566 \end{aligned}$ | $\begin{array}{r} 9 \\ 14 \\ 23 \end{array}$ | $\begin{array}{r} 70 \\ 113 \\ 183 \end{array}$ |  |
|  | Rate | Male Female Total* | $\begin{array}{r\|} \hline 26.3 \\ 21.3 \\ 23.8 \\ \hline \end{array}$ | $\begin{array}{l\|} \hline 0.7 \\ 0.3 \\ 0.5 \\ \hline \end{array}$ | $\begin{aligned} & \hline 0.0 \\ & 0.0 \\ & 0.0 \\ & \hline \end{aligned}$ | $\begin{array}{r} \hline 6.4 \\ 13.0 \\ 9.7 \\ \hline \end{array}$ | $\begin{aligned} & \hline 1.6 \\ & 0.5 \\ & 1.1 \\ & \hline \end{aligned}$ | $\begin{array}{r\|} \hline 13.0 \\ 6.0 \\ 9.5 \\ \hline \end{array}$ | $\begin{array}{\|} \hline 32.0 \\ 24.8 \\ 28.4 \\ \hline \end{array}$ | $\begin{array}{\|} \hline 87.8 \\ 77.3 \\ 82.5 \\ \hline \end{array}$ | $\begin{aligned} & 49.3 \\ & 48.1 \\ & 48.7 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 31.7 \\ & 30.5 \\ & 31.1 \\ & \hline \end{aligned}$ | $\begin{array}{l\|} \hline 17.5 \\ 14.2 \\ 15.8 \\ \hline \end{array}$ | $\begin{aligned} & \hline 56.2 \\ & 95.8 \\ & 75.1 \\ & \hline \end{aligned}$ | $\begin{array}{l\|} \hline 210.0 \\ 374.0 \\ 288.0 \\ \hline \end{array}$ |  |
| 1994 | Cases | Male Female Total* | $\begin{aligned} & 3478 \\ & 2645 \\ & 6167 \\ & \hline \end{aligned}$ | $\begin{aligned} & 1 \\ & 2 \\ & 3 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 13 \\ & 22 \\ & 35 \\ & \hline \end{aligned}$ | $\begin{array}{r} 6 \\ 7 \\ 13 \end{array}$ | $\begin{aligned} & \hline 504 \\ & 225 \\ & 735 \\ & \hline \end{aligned}$ | $\begin{aligned} & 1760 \\ & 1328 \\ & 3123 \end{aligned}$ | $\begin{aligned} & 394 \\ & 335 \\ & 729 \\ & \hline \end{aligned}$ | $\begin{aligned} & 188 \\ & 189 \\ & 377 \end{aligned}$ | $\begin{aligned} & \hline 266 \\ & 240 \\ & 506 \\ & \hline \end{aligned}$ | $\begin{aligned} & 298 \\ & 189 \\ & 490 \\ & \hline \end{aligned}$ | $\begin{array}{r} 7 \\ 6 \\ 13 \end{array}$ | $\begin{array}{r} \hline 41 \\ 102 \\ 143 \\ \hline \end{array}$ |  |
|  | Rate | Male Female Total* | $\begin{aligned} & \hline 24.2 \\ & 18.1 \\ & 21.2 \\ & \hline \end{aligned}$ | $\begin{array}{l\|} \hline 0.3 \\ 0.7 \\ 0.5 \\ \hline \end{array}$ | $\begin{aligned} & \hline 0.0 \\ & 0.0 \\ & 0.0 \\ & \hline \end{aligned}$ | $\begin{array}{r} 2.9 \\ 4.7 \\ 3.8 \\ \hline \end{array}$ | $\begin{array}{l\|} \hline 1.6 \\ 1.9 \\ 1.7 \\ \hline \end{array}$ | $\begin{array}{r\|} \hline 14.2 \\ 6.2 \\ 10.2 \\ \hline \end{array}$ | $\begin{array}{\|} \hline 32.9 \\ 24.2 \\ 28.8 \\ \hline \end{array}$ | $\begin{aligned} & \hline 70.7 \\ & 59.1 \\ & 64.9 \\ & \hline \end{aligned}$ | $\begin{array}{r} 37.4 \\ 37.3 \\ 37.3 \\ \hline \end{array}$ | $\begin{aligned} & \hline 19.5 \\ & 17.9 \\ & 18.7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 16.2 \\ & 10.2 \\ & 13.3 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 44.6 \\ & 41.8 \\ & 43.3 \\ & \hline \end{aligned}$ | $\begin{aligned} & 120.0 \\ & 329.0 \\ & 219.5 \\ & \hline \end{aligned}$ |  |
| 1995 | Cases | Male Female Total* | $\begin{aligned} & 3322 \\ & 2385 \\ & 5715 \end{aligned}$ | $\begin{aligned} & 2 \\ & 2 \\ & 4 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 15 \\ & 23 \\ & 38 \end{aligned}$ | $\begin{array}{r} 7 \\ 7 \\ 14 \end{array}$ | $\begin{aligned} & 425 \\ & 165 \\ & 595 \end{aligned}$ | $\begin{aligned} & 1719 \\ & 1264 \\ & 2983 \end{aligned}$ | $\begin{aligned} & \hline 376 \\ & 282 \\ & 658 \end{aligned}$ | $\begin{aligned} & 208 \\ & 178 \\ & 386 \end{aligned}$ | $\begin{aligned} & 223 \\ & 177 \\ & 400 \end{aligned}$ | $\begin{aligned} & 296 \\ & 193 \\ & 492 \end{aligned}$ | $\begin{array}{r} 11 \\ 9 \\ 20 \end{array}$ | $\begin{array}{r} 40 \\ 85 \\ 125 \end{array}$ |  |
|  | Rate | Male <br> Female Total* | $\begin{aligned} & 22.9 \\ & 16.1 \\ & 19.5 \end{aligned}$ | $\begin{array}{l\|} \hline 0.7 \\ 0.7 \\ 0.7 \\ \hline \end{array}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 3.3 \\ & 4.9 \\ & 4.1 \end{aligned}$ | $\begin{aligned} & 1.9 \\ & 1.8 \\ & 1.9 \end{aligned}$ | $\begin{array}{r} 11.9 \\ 4.5 \\ 8.2 \\ \hline \end{array}$ | $\begin{aligned} & 31.8 \\ & 22.7 \\ & 27.2 \end{aligned}$ | $\begin{aligned} & 67.1 \\ & 49.5 \\ & 58.2 \end{aligned}$ | $\begin{aligned} & 41.2 \\ & 34.9 \\ & 38.1 \end{aligned}$ | $\begin{aligned} & 16.2 \\ & 13.0 \\ & 14.6 \end{aligned}$ | $\begin{aligned} & 15.7 \\ & 10.2 \\ & 13.0 \end{aligned}$ | $\begin{aligned} & 68.2 \\ & 61.0 \\ & 64.8 \end{aligned}$ | $\begin{aligned} & 114.7 \\ & 268.2 \\ & 187.8 \end{aligned}$ |  |
| 1996 | Cases | Male Female Total* | $\begin{aligned} & 2845 \\ & 2168 \\ & 5023 \end{aligned}$ | $\begin{aligned} & 2 \\ & 0 \\ & 2 \end{aligned}$ | $\begin{aligned} & 1 \\ & 0 \\ & 1 \end{aligned}$ | $\begin{aligned} & 30 \\ & 67 \\ & 97 \end{aligned}$ | $\begin{aligned} & 10 \\ & 31 \\ & 41 \end{aligned}$ | $\begin{aligned} & 325 \\ & 144 \\ & 478 \end{aligned}$ | $\begin{aligned} & 1304 \\ & 1008 \\ & 2312 \end{aligned}$ | $\begin{aligned} & 305 \\ & 249 \\ & 554 \end{aligned}$ | $\begin{aligned} & 216 \\ & 188 \\ & 404 \end{aligned}$ | $\begin{aligned} & 247 \\ & 225 \\ & 472 \end{aligned}$ | $\begin{aligned} & 354 \\ & 172 \\ & 527 \end{aligned}$ | $\begin{array}{r} 3 \\ 7 \\ 10 \end{array}$ | $\begin{array}{r} 48 \\ 77 \\ 125 \end{array}$ |  |
|  | Rate | Male Female Total* | $\begin{array}{\|r\|} \hline 19.4 \\ 14.5 \\ 16.9 \\ \hline \end{array}$ | $\begin{array}{l\|} \hline 0.7 \\ 0.0 \\ 0.4 \\ \hline \end{array}$ | $\begin{aligned} & \hline 1.5 \\ & 0.0 \\ & 0.7 \\ & \hline \end{aligned}$ | $\begin{array}{r\|} \hline 6.6 \\ 14.1 \\ 10.4 \\ \hline \end{array}$ | $\begin{aligned} & 2.7 \\ & 8.2 \\ & 5.4 \\ & \hline \end{aligned}$ | $\begin{array}{l\|} \hline 9.1 \\ 3.9 \\ 6.6 \\ \hline \end{array}$ | $\begin{aligned} & 23.8 \\ & 17.9 \\ & 20.8 \end{aligned}$ | $\begin{aligned} & \hline 54.2 \\ & 43.5 \\ & 48.8 \\ & \hline \end{aligned}$ | $\begin{aligned} & 42.6 \\ & 36.7 \\ & 39.6 \end{aligned}$ | $\begin{aligned} & 17.6 \\ & 16.3 \\ & 17.0 \end{aligned}$ | $\begin{array}{r\|} \hline 18.3 \\ 8.8 \\ 13.6 \\ \hline \end{array}$ | $\begin{aligned} & 18.0 \\ & 45.8 \\ & 31.3 \end{aligned}$ | $\begin{aligned} & 135.7 \\ & 239.2 \\ & 185.0 \end{aligned}$ |  |
| 1997 | Cases | Male Female Total* | $\begin{aligned} & 2646 \\ & 1822 \\ & 4477 \end{aligned}$ | $\begin{aligned} & 2 \\ & 1 \\ & 3 \end{aligned}$ | $\begin{aligned} & 1 \\ & 0 \\ & 1 \end{aligned}$ | $\begin{array}{r} 33 \\ 75 \\ 108 \end{array}$ | $\begin{array}{r} 4 \\ 11 \\ 15 \end{array}$ | $\begin{aligned} & 402 \\ & 136 \\ & 545 \end{aligned}$ | $\begin{array}{r} 1147 \\ 783 \\ 1931 \end{array}$ | $\begin{aligned} & 249 \\ & 269 \\ & 518 \end{aligned}$ | $\begin{aligned} & 176 \\ & 166 \\ & 342 \\ & \hline \end{aligned}$ | $\begin{aligned} & 218 \\ & 188 \\ & 406 \end{aligned}$ | $\begin{aligned} & 344 \\ & 113 \\ & 458 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{array}{r} 70 \\ 80 \\ 150 \end{array}$ |  |
|  | Rate | Male Female Total* | 17.8 <br> 12.0 <br> 14.9 | $\begin{array}{l\|} \hline 0.7 \\ 0.4 \\ 0.5 \\ \hline \end{array}$ | $\begin{aligned} & 1.5 \\ & 0.0 \\ & 0.7 \end{aligned}$ | $\begin{array}{r\|} \hline 7.2 \\ 15.8 \\ 11.6 \\ \hline \end{array}$ | $\begin{array}{l\|} \hline 1.1 \\ 2.9 \\ 2.0 \\ \hline \end{array}$ | $\begin{array}{r\|} \hline 11.2 \\ 3.7 \\ 7.5 \\ \hline \end{array}$ | $\begin{array}{\|r\|} \hline 20.7 \\ 13.7 \\ 17.2 \\ \hline \end{array}$ | $\begin{aligned} & 44.2 \\ & 47.0 \\ & 45.6 \end{aligned}$ | $\begin{array}{r\|} \hline 34.6 \\ 32.3 \\ 33.5 \\ \hline \end{array}$ | $\begin{aligned} & 15.2 \\ & 13.4 \\ & 14.3 \end{aligned}$ | $\begin{array}{r\|} \hline 17.4 \\ 5.7 \\ 11.6 \\ \hline \end{array}$ | 0.0 0.0 0.0 | $\begin{aligned} & 197.4 \\ & 247.8 \\ & 221.5 \end{aligned}$ |  |


${ }^{1}$ Rate per 100000 population. Population estimates provided by Statistics Canada (Source: Annual Demographic Statistics, 2000 Catalogue no. $91-213$ and unpublished data).
${ }^{2} 2002$ data are preliminary and changes are anticipated.
${ }^{3}$ Data prior to 2000 are not available because Nunavut became a Canadian territory in April 1999. Data for 1999 were included with NT.
*Total includes cases not specified for sex.
Source: Sexual Health and Sexually Transmitted Infections, Community Acquired Infections Division, Centre for Infectious Disease Prevention and
Control, Public Health Agency of Canada, 2003.

Table 3.1: Reported Infectious Syphilis ${ }^{1}$ Cases and Rates ${ }^{2}$ in Canada by Age Group and Sex, 1993-2002 ${ }^{3,4}$

|  |  |  | Age Group (years) |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Year |  |  | Canada | $0<1$ | 1-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-29 | 30-39 | 40-59 | 60+ | NS |
| 1993 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 97 \\ 76 \\ 4 \\ 177 \end{array}$ | $\begin{aligned} & 0 \\ & 1 \\ & 0 \\ & 1 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{array}{r} 2 \\ 13 \\ 1 \\ 16 \end{array}$ | $\begin{array}{r} 14 \\ 24 \\ 0 \\ 38 \end{array}$ | $\begin{array}{r} 16 \\ 10 \\ 0 \\ 26 \end{array}$ | $\begin{array}{r} 30 \\ 15 \\ 1 \\ 46 \end{array}$ | $\begin{array}{r} 29 \\ 7 \\ 1 \\ 37 \end{array}$ | $\begin{array}{r} 6 \\ 6 \\ 0 \\ 12 \end{array}$ | 0 0 1 1 |
|  | Rate | Male Female Total | $\begin{aligned} & 0.7 \\ & 0.5 \\ & 0.6 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.5 \\ & 0.3 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.2 \\ & 1.4 \\ & 0.8 \end{aligned}$ | $\begin{aligned} & 1.3 \\ & 2.4 \\ & 1.9 \end{aligned}$ | 1.4 0.9 1.1 | $\begin{aligned} & 1.2 \\ & 0.6 \\ & 0.9 \end{aligned}$ | $\begin{aligned} & 0.9 \\ & 0.2 \\ & 0.5 \end{aligned}$ | 0.3 0.2 0.3 |  |
| 1994 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 112 \\ 71 \\ 5 \\ 188 \end{array}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{array}{r} 3 \\ 9 \\ 0 \\ 12 \end{array}$ | $\begin{array}{r} 15 \\ 17 \\ 1 \\ 33 \end{array}$ | $\begin{array}{r} 19 \\ 14 \\ 1 \\ 34 \end{array}$ | $\begin{array}{r} 31 \\ 15 \\ 1 \\ 47 \end{array}$ | $\begin{array}{r} 32 \\ 11 \\ 0 \\ 43 \end{array}$ | $\begin{array}{r} 12 \\ 5 \\ 1 \\ 18 \end{array}$ | $\begin{aligned} & 0 \\ & 0 \\ & 1 \\ & 1 \end{aligned}$ |
|  | Rate | Male Female Total | $\begin{aligned} & 0.8 \\ & 0.5 \\ & 0.6 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.3 \\ & 0.9 \\ & 0.6 \end{aligned}$ | $\begin{aligned} & 1.4 \\ & 1.7 \\ & 1.6 \end{aligned}$ | $\begin{aligned} & 1.7 \\ & 1.3 \\ & 1.5 \end{aligned}$ | $\begin{aligned} & 1.2 \\ & 0.6 \\ & 0.9 \end{aligned}$ | $\begin{aligned} & 0.9 \\ & 0.3 \\ & 0.6 \end{aligned}$ | 0.6 0.2 0.4 |  |
| 1995 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 95 \\ 52 \\ 0 \\ 147 \end{array}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{array}{r} 1 \\ 9 \\ 0 \\ 10 \end{array}$ | $\begin{array}{r} 16 \\ 11 \\ 0 \\ 27 \end{array}$ | $\begin{array}{r} 13 \\ 10 \\ 0 \\ 23 \end{array}$ | $\begin{array}{r} 31 \\ 14 \\ 0 \\ 45 \end{array}$ | $\begin{array}{r} 27 \\ 8 \\ 0 \\ 35 \end{array}$ | $\begin{aligned} & 6 \\ & 0 \\ & 0 \\ & 6 \end{aligned}$ | 1 0 0 1 |
|  | Rate | Male Female Total | $\begin{aligned} & 0.7 \\ & 0.4 \\ & 0.5 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.1 \\ & 0.9 \\ & 0.5 \end{aligned}$ | $\begin{aligned} & 1.6 \\ & 1.1 \\ & 1.3 \end{aligned}$ | 1.2 0.9 1.0 | $\begin{aligned} & 1.2 \\ & 0.5 \\ & 0.9 \end{aligned}$ | 0.7 0.2 0.5 | 0.3 0.0 0.1 |  |
| 1996 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 74 \\ 45 \\ 0 \\ 119 \end{array}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | 3 6 0 9 | 7 8 0 15 | 12 12 0 24 | 28 12 0 40 | 20 5 0 25 | 3 2 0 5 | 1 0 0 1 |
|  | Rate | Male Female Total | $\begin{aligned} & 0.5 \\ & 0.3 \\ & 0.4 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.3 \\ & 0.6 \\ & 0.4 \end{aligned}$ | $\begin{aligned} & 0.7 \\ & 0.8 \\ & 0.7 \end{aligned}$ | 1.1 1.1 1.1 | $\begin{aligned} & 1.1 \\ & 0.5 \\ & 0.8 \end{aligned}$ | $\begin{aligned} & 0.5 \\ & 0.1 \\ & 0.3 \end{aligned}$ | 0.1 0.1 0.1 |  |
| 1997 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 65 \\ 50 \\ 0 \\ 115 \end{array}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 1 \\ & 3 \\ & 0 \\ & 4 \end{aligned}$ | $\begin{array}{r} 3 \\ 8 \\ 0 \\ 11 \end{array}$ | $\begin{array}{r} 8 \\ 13 \\ 0 \\ 21 \end{array}$ | $\begin{array}{r} 26 \\ 17 \\ 0 \\ 43 \end{array}$ | $\begin{array}{r} 26 \\ 8 \\ 0 \\ 34 \end{array}$ | $\begin{aligned} & 1 \\ & 1 \\ & 0 \\ & 2 \end{aligned}$ | 0 0 0 0 |
|  | Rate | Male Female Total | $\begin{aligned} & 0.4 \\ & 0.3 \\ & 0.4 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.1 \\ & 0.3 \\ & 0.2 \end{aligned}$ | $\begin{aligned} & 0.3 \\ & 0.8 \\ & 0.5 \end{aligned}$ | 0.7 1.2 1.0 | $\begin{aligned} & 1.0 \\ & 0.7 \\ & 0.8 \end{aligned}$ | 0.7 0.2 0.4 | 0.0 0.0 0.0 |  |
| 1998 | Cases | Male Female Unspecified Total | $\begin{array}{r} 110 \\ 67 \\ 0 \\ 177 \end{array}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & \hline 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 2 \\ & 6 \\ & 0 \\ & 8 \end{aligned}$ | $\begin{array}{r} 4 \\ 8 \\ 0 \\ 12 \end{array}$ | $\begin{array}{r} 13 \\ 10 \\ 0 \\ 23 \end{array}$ | $\begin{array}{r} 41 \\ 26 \\ 0 \\ 67 \end{array}$ | $\begin{array}{r} 39 \\ 14 \\ 0 \\ 53 \end{array}$ | $\begin{array}{r} 11 \\ 3 \\ 0 \\ 14 \end{array}$ | 0 0 0 0 |
|  | Rate | Male Female Total | $\begin{aligned} & 0.7 \\ & 0.4 \\ & 0.6 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.2 \\ & 0.6 \\ & 0.4 \end{aligned}$ | $\begin{aligned} & 0.4 \\ & 0.8 \\ & 0.6 \end{aligned}$ | $\begin{aligned} & 1.2 \\ & 0.9 \\ & 1.1 \end{aligned}$ | $\begin{aligned} & 1.6 \\ & 1.0 \\ & 1.3 \end{aligned}$ | $\begin{aligned} & 1.0 \\ & 0.3 \\ & 0.7 \end{aligned}$ | 0.5 0.1 0.3 |  |
| 1999 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 113 \\ 78 \\ 0 \\ 191 \end{array}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 1 \\ & 8 \\ & 0 \\ & 9 \end{aligned}$ | $\begin{array}{r} 13 \\ 12 \\ 0 \\ 25 \end{array}$ | $\begin{array}{r} 11 \\ 14 \\ 0 \\ 25 \end{array}$ | $\begin{array}{r} 36 \\ 19 \\ 0 \\ 55 \end{array}$ | $\begin{array}{r} 41 \\ 22 \\ 0 \\ 63 \end{array}$ | $\begin{array}{r} 11 \\ 3 \\ 0 \\ 14 \end{array}$ | 0 0 0 0 |
|  | Rate | Male Female Total | 0.7 0.5 0.6 | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.1 \\ & 0.8 \\ & 0.4 \end{aligned}$ | $\begin{aligned} & 1.2 \\ & 1.2 \\ & 1.2 \end{aligned}$ | 1.0 1.3 1.2 | $\begin{aligned} & 1.4 \\ & 0.8 \\ & 1.1 \end{aligned}$ | 1.0 0.5 0.8 | 0.5 0.1 0.3 |  |


|  |  |  | Age Group (years) |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Year |  |  | Canada | $0<1$ | 1-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-29 | 30-39 | 40-59 | 60+ | NS |
| 2000 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 114 \\ 60 \\ 0 \\ 174 \end{array}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 5 \\ & 0 \\ & 5 \end{aligned}$ | $\begin{array}{r} 3 \\ 9 \\ 0 \\ 12 \end{array}$ | $\begin{array}{r} 12 \\ 8 \\ 0 \\ 20 \end{array}$ | $\begin{array}{r} 44 \\ 23 \\ 0 \\ 67 \end{array}$ | $\begin{array}{r} 44 \\ 13 \\ 0 \\ 57 \end{array}$ | $\begin{array}{r} 11 \\ 2 \\ 0 \\ 13 \end{array}$ | 0 0 0 0 |
|  | Rate | Male Female Total | $\begin{aligned} & 0.7 \\ & 0.4 \\ & 0.6 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.5 \\ & 0.2 \end{aligned}$ | $\begin{aligned} & 0.3 \\ & 0.9 \\ & 0.6 \end{aligned}$ | $\begin{aligned} & 1.1 \\ & 0.8 \\ & 0.9 \end{aligned}$ | $\begin{aligned} & 1.8 \\ & 0.9 \\ & 1.3 \end{aligned}$ | $\begin{aligned} & 1.0 \\ & 0.3 \\ & 0.7 \end{aligned}$ | $\begin{aligned} & 0.5 \\ & 0.1 \\ & 0.3 \end{aligned}$ |  |
| 2001 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 184 \\ 103 \\ 0 \\ 287 \end{array}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{array}{r} 4 \\ 10 \\ 0 \\ 14 \end{array}$ | $\begin{array}{r} 21 \\ 25 \\ 0 \\ 46 \end{array}$ | $\begin{array}{r} 20 \\ 21 \\ 0 \\ 41 \end{array}$ | $\begin{array}{r} 62 \\ 23 \\ 0 \\ 85 \end{array}$ | $\begin{array}{r} 60 \\ 22 \\ 0 \\ 82 \end{array}$ | $\begin{array}{r} 16 \\ 2 \\ 0 \\ 18 \end{array}$ | 1 0 0 1 |
|  | Rate | Male Female Total | $\begin{aligned} & 1.2 \\ & 0.7 \\ & 0.9 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.4 \\ & 1.0 \\ & 0.7 \end{aligned}$ | $\begin{aligned} & 1.9 \\ & 2.4 \\ & 2.2 \end{aligned}$ | $\begin{aligned} & 1.9 \\ & 2.1 \\ & 2.0 \end{aligned}$ | $\begin{aligned} & 2.5 \\ & 1.0 \\ & 1.7 \end{aligned}$ | 1.4 0.5 0.9 | $\begin{aligned} & 0.7 \\ & 0.1 \\ & 0.3 \end{aligned}$ |  |
| 2002 | Cases | Male <br> Female <br> Unspecified <br> Total | $\begin{array}{r} 368 \\ 94 \\ 1 \\ 463 \end{array}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{array}{r} 5 \\ 6 \\ 0 \\ 11 \end{array}$ | $\begin{array}{r} 18 \\ 23 \\ 0 \\ 41 \end{array}$ | $\begin{array}{r} 30 \\ 27 \\ 0 \\ 57 \end{array}$ | $\begin{array}{r} 161 \\ 23 \\ 1 \\ 185 \end{array}$ | $\begin{array}{r} 143 \\ 14 \\ 0 \\ 157 \end{array}$ | $\begin{array}{r} 11 \\ 1 \\ 0 \\ 12 \end{array}$ | 0 0 0 0 |
|  | Rate | Male Female Total | $\begin{aligned} & 2.4 \\ & 0.6 \\ & 1.5 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 0.0 \\ & 0.0 \\ & 0.0 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 0.0 \\ & 0.0 \\ & 0.0 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.5 \\ & 0.6 \\ & 0.5 \end{aligned}$ | 1.6 2.2 1.9 | $\begin{aligned} & 2.8 \\ & 2.6 \\ & 2.7 \end{aligned}$ | 6.6 1.0 3.8 | 3.2 0.3 1.7 | 0.5 0.0 0.2 |  |

${ }^{1}$ Infectious syphilis: early symptomatic (primary and secondary) syphilis + early latent syphilis.
${ }^{2}$ Rate per 100000 population. Population estimates provided by Statistics Canada (Source: Annual Demographic Statistics, 2000 Catalogue no. 91-213 and unpublished data).
${ }^{3} 2002$ data are preliminary and changes are anticipated.
${ }^{4}$ As part of a review of historical data, all case counts (numerators) for infectious syphilis have been updated as of J anuary 2004.
Source: Sexual Health and Sexually Transmitted Infections, Community Acquired Infections Division, Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada, 2003.

Table 3.2: Reported Infectious Syphilis ${ }^{1}$ Cases and Rates ${ }^{2}$ in Canada by Province/Territory and Sex, 1993-2002 ${ }^{3,4}$

|  |  |  | Province/Territory |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Year |  |  | Canada | NL | PE | NS | NB | QC | ON | MB | SK | AB | BC | YT | NT | $N U^{5}$ |
| 1993 | Cases |  | $\begin{array}{r} 97 \\ 76 \\ 177 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{array}{r} 6 \\ 9 \\ 15 \end{array}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{array}{r} 11 \\ 6 \\ 17 \end{array}$ | $\begin{array}{r} 58 \\ 53 \\ 115 \\ \hline \end{array}$ | $\begin{aligned} & 2 \\ & 1 \\ & 3 \end{aligned}$ | $\begin{aligned} & 3 \\ & 2 \\ & 5 \end{aligned}$ | $\begin{aligned} & 5 \\ & 1 \\ & 6 \end{aligned}$ | $\begin{array}{r} 12 \\ 4 \\ 16 \end{array}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ |  |
|  | Rate |  | $\begin{aligned} & \hline 0.7 \\ & 0.5 \\ & 0.6 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 1.3 \\ & 1.9 \\ & 1.6 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 0.0 \\ & 0.0 \\ & 0.0 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.3 \\ & 0.2 \\ & 0.2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 1.1 \\ & 1.0 \\ & 1.1 \end{aligned}$ | $\begin{aligned} & 0.4 \\ & 0.2 \\ & 0.3 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.6 \\ & 0.4 \\ & 0.5 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.4 \\ & 0.1 \\ & 0.2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.7 \\ & 0.2 \\ & 0.4 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 0.0 \\ & 0.0 \\ & 0.0 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ |  |
| 1994 | Cases |  | $\begin{array}{r} 112 \\ 71 \\ 188 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 1 \\ & 1 \end{aligned}$ | $\begin{aligned} & 0 \\ & 1 \\ & 1 \end{aligned}$ | $\begin{aligned} & 11 \\ & 13 \\ & 24 \end{aligned}$ | $\begin{aligned} & 2 \\ & 2 \\ & 4 \end{aligned}$ | $\begin{array}{r} 16 \\ 4 \\ 20 \end{array}$ | $\begin{aligned} & 55 \\ & 35 \\ & 93 \\ & \hline \end{aligned}$ | 3 1 4 | $\begin{array}{r} 11 \\ 7 \\ 18 \end{array}$ | 5 3 8 | 9 3 14 | 0 1 1 | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ |  |
|  | Rate | Male Female Total* | $\begin{aligned} & 0.8 \\ & 0.5 \\ & 0.6 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.3 \\ & 0.2 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 1.5 \\ & 0.7 \end{aligned}$ | $\begin{aligned} & 2.4 \\ & 2.8 \\ & 2.6 \end{aligned}$ | $\begin{aligned} & 0.5 \\ & 0.5 \\ & 0.5 \end{aligned}$ | $\begin{aligned} & 0.5 \\ & 0.1 \\ & 0.3 \end{aligned}$ | $\begin{aligned} & 1.0 \\ & 0.6 \\ & 0.9 \end{aligned}$ | $\begin{aligned} & 0.5 \\ & 0.2 \\ & 0.4 \end{aligned}$ | $\begin{aligned} & 2.2 \\ & 1.4 \\ & 1.8 \end{aligned}$ | $\begin{aligned} & 0.4 \\ & 0.2 \\ & 0.3 \end{aligned}$ | $\begin{aligned} & 0.5 \\ & 0.2 \\ & 0.4 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 7.0 \\ & 3.3 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ |  |
| 1995 | Cases |  | $\begin{array}{r} 95 \\ 52 \\ 147 \\ \hline \end{array}$ | $\begin{aligned} & 1 \\ & 0 \\ & 1 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & \hline 1 \\ & 0 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{aligned} & 1 \\ & 0 \\ & 1 \end{aligned}$ | $\begin{array}{r} 6 \\ 8 \\ 14 \end{array}$ | $\begin{aligned} & 58 \\ & 28 \\ & 86 \\ & \hline \end{aligned}$ | 3 1 4 | $\begin{array}{r} 9 \\ 10 \\ 19 \end{array}$ | $\begin{aligned} & 3 \\ & 1 \\ & 4 \end{aligned}$ | $\begin{array}{r} 13 \\ 4 \\ 17 \end{array}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ |  |
|  | Rate |  | $\begin{aligned} & 0.7 \\ & 0.4 \\ & 0.5 \end{aligned}$ | $\begin{aligned} & 0.4 \\ & 0.0 \\ & 0.2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.2 \\ & 0.0 \\ & 0.1 \end{aligned}$ | $\begin{aligned} & 0.3 \\ & 0.0 \\ & 0.1 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.2 \\ & 0.2 \\ & 0.2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 1.1 \\ & 0.5 \\ & 0.8 \end{aligned}$ | $\begin{aligned} & 0.5 \\ & 0.2 \end{aligned}$ $0.4$ | $\begin{aligned} & 1.8 \\ & 2.0 \\ & 1.9 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.2 \\ & 0.1 \\ & 0.1 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.7 \\ & 0.2 \\ & 0.4 \end{aligned}$ | $\begin{aligned} & \hline 0.0 \\ & 0.0 \\ & 0.0 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \\ & \hline \end{aligned}$ |  |
| 1996 | Cases | Male Female Total* | $\begin{array}{r} 74 \\ 45 \\ 119 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 1 \\ & 2 \\ & 3 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{array}{r} 10 \\ 2 \\ 12 \end{array}$ | $\begin{aligned} & 41 \\ & 32 \\ & 73 \\ & \hline \end{aligned}$ | $\begin{aligned} & 1 \\ & 0 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{aligned} & 4 \\ & 5 \\ & 9 \end{aligned}$ | $\begin{aligned} & 1 \\ & 0 \\ & 1 \end{aligned}$ | $\begin{array}{r} 16 \\ 4 \\ 20 \end{array}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ |  |
|  | Rate | Male Female Total* | $\begin{aligned} & 0.5 \\ & 0.3 \\ & 0.4 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.2 \\ & 0.4 \\ & 0.3 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.3 \\ & 0.1 \\ & 0.2 \end{aligned}$ | $\begin{aligned} & 0.7 \\ & 0.6 \\ & 0.7 \end{aligned}$ | $\begin{aligned} & 0.2 \\ & 0.0 \\ & 0.1 \end{aligned}$ | $\begin{aligned} & 0.8 \\ & 1.0 \\ & 0.9 \end{aligned}$ | $\begin{aligned} & 0.1 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.8 \\ & 0.2 \\ & 0.5 \end{aligned}$ | $\begin{aligned} & \hline 0.0 \\ & 0.0 \\ & 0.0 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ |  |
| 1997 | Cases | Male Female Total* | $\begin{array}{r} 65 \\ 50 \\ 115 \end{array}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 1 \\ & 1 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | 4 3 7 | $\begin{aligned} & 28 \\ & 21 \\ & 49 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 1 \\ & 1 \\ & 2 \end{aligned}$ | $\begin{aligned} & 3 \\ & 4 \\ & 7 \end{aligned}$ | $\begin{aligned} & 29 \\ & 20 \\ & 49 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ |  |
|  | Rate | Male Female Total* | $\begin{aligned} & 0.4 \\ & 0.3 \\ & 0.4 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.2 \\ & 0.1 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.1 \\ & 0.1 \\ & 0.1 \end{aligned}$ | $\begin{aligned} & 0.5 \\ & 0.4 \\ & 0.4 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.2 \\ & 0.2 \\ & 0.2 \end{aligned}$ | $\begin{aligned} & 0.2 \\ & 0.3 \\ & 0.2 \end{aligned}$ | $\begin{aligned} & 1.5 \\ & 1.0 \\ & 1.2 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ |  |
| 1998 | Cases |  | $\begin{array}{r} 110 \\ 67 \\ 177 \\ \hline \end{array}$ | $\begin{aligned} & \hline 0 \\ & 0 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 0 \\ & 0 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} & 1 \\ & 1 \\ & 2 \end{aligned}$ | $\begin{aligned} & \hline 0 \\ & 0 \\ & 0 \\ & \hline \end{aligned}$ | 2 2 4 | $\begin{aligned} & 25 \\ & 16 \\ & 41 \\ & \hline \end{aligned}$ | 2 1 3 | 4 2 6 | 6 0 6 | $\begin{array}{r} 70 \\ 45 \\ 115 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \end{aligned}$ | 0 0 0 |  |
|  | Rate |  | $\begin{aligned} & 0.7 \\ & 0.4 \\ & 0.6 \end{aligned}$ | $\begin{array}{l\|} \hline 0.0 \\ 0.0 \\ 0.0 \\ \hline \end{array}$ | $\begin{aligned} & \hline 0.0 \\ & 0.0 \\ & 0.0 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 0.2 \\ & 0.2 \\ & 0.2 \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline 0.0 \\ & 0.0 \\ & 0.0 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0.1 \\ & 0.1 \\ & 0.1 \end{aligned}$ | $\begin{aligned} & 0.4 \\ & 0.3 \\ & 0.4 \end{aligned}$ | $\begin{aligned} & 0.4 \\ & 0.2 \\ & 0.3 \end{aligned}$ | $\begin{aligned} & 0.8 \\ & 0.4 \\ & 0.6 \end{aligned}$ | $\begin{aligned} & \hline 0.4 \\ & 0.0 \\ & 0.2 \\ & \hline \end{aligned}$ | $\begin{aligned} & 3.5 \\ & 2.2 \\ & 2.9 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & \hline 0.0 \\ & 0.0 \\ & 0.0 \\ & \hline \end{aligned}$ |  |
| 1999 | Cases |  | $\begin{array}{r} 113 \\ 78 \\ 191 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 1 \\ & 0 \\ & 1 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | 2 2 4 | $\begin{aligned} & \hline 37 \\ & 17 \\ & 54 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & \hline 0 \\ & 1 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{aligned} & 2 \\ & 0 \\ & 2 \end{aligned}$ | $\begin{array}{r} 71 \\ 58 \\ 129 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ |  |
|  | Rate |  | $\begin{aligned} & 0.7 \\ & 0.5 \\ & 0.6 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.2 \\ & 0.0 \\ & 0.1 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.1 \\ & 0.1 \\ & 0.1 \end{aligned}$ | $\begin{aligned} & 0.7 \\ & 0.3 \\ & 0.5 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.2 \\ & 0.1 \end{aligned}$ | $\begin{aligned} & 0.1 \\ & 0.0 \\ & 0.1 \end{aligned}$ | $\begin{aligned} & 3.5 \\ & 2.9 \\ & 3.2 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | 0.0 0.0 0.0 |  |


|  |  |  | Province/Territory |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Year |  |  | Canada | NL | PE | NS | NB | QC | ON | MB | SK | AB | BC | YT | NT | NU ${ }^{5}$ |
| 2000 | Cases | Male Female Total* | $\begin{array}{r} 114 \\ 60 \\ 174 \end{array}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 1 \\ & 1 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 5 \\ & 2 \\ & 7 \end{aligned}$ | $\begin{aligned} & 29 \\ & 14 \\ & 43 \end{aligned}$ | $\begin{aligned} & 0 \\ & 1 \\ & 1 \end{aligned}$ | $\begin{aligned} & 1 \\ & 0 \\ & 1 \end{aligned}$ | $\begin{array}{r} 13 \\ 2 \\ 15 \end{array}$ | $\begin{aligned} & 59 \\ & 36 \\ & 95 \end{aligned}$ | $\begin{array}{r} 7 \\ 4 \\ 11 \end{array}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ |
|  | Rate | Male <br> Female <br> Total* | $\begin{aligned} & 0.7 \\ & 0.4 \\ & 0.6 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.2 \\ & 0.1 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.1 \\ & 0.1 \\ & 0.1 \end{aligned}$ | $\begin{aligned} & 0.5 \\ & 0.2 \\ & 0.4 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.2 \\ & 0.1 \end{aligned}$ | $\begin{aligned} & 0.2 \\ & 0.0 \\ & 0.1 \end{aligned}$ | $\begin{aligned} & 0.9 \\ & 0.1 \\ & 0.5 \end{aligned}$ | $\begin{aligned} & 2.9 \\ & 1.8 \\ & 2.3 \end{aligned}$ | $\begin{aligned} & 44.4 \\ & 27.0 \\ & 36.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ |
| 2001 | Cases | Male Female Total* | $\begin{aligned} & 184 \\ & 103 \\ & 287 \end{aligned}$ | $\begin{aligned} & 0 \\ & 1 \\ & 1 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{array}{r} 15 \\ 0 \\ 15 \end{array}$ | $\begin{array}{r} 37 \\ 9 \\ 46 \end{array}$ | $\begin{aligned} & 1 \\ & 0 \\ & 1 \end{aligned}$ | $\begin{aligned} & 2 \\ & 1 \\ & 3 \end{aligned}$ | $\begin{array}{r} 13 \\ 7 \\ 20 \end{array}$ | $\begin{array}{r} 103 \\ 76 \\ 179 \end{array}$ | $\begin{array}{r} 13 \\ 9 \\ 22 \end{array}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ |
|  | Rate | Male <br> Female <br> Total* | $\begin{aligned} & 1.2 \\ & 0.7 \\ & 0.9 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.4 \\ & 0.2 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.4 \\ & 0.0 \\ & 0.2 \end{aligned}$ | $\begin{aligned} & 0.6 \\ & 0.1 \\ & 0.4 \end{aligned}$ | $\begin{aligned} & 0.2 \\ & 0.0 \\ & 0.1 \end{aligned}$ | $\begin{aligned} & 0.4 \\ & 0.2 \\ & 0.3 \end{aligned}$ | $\begin{aligned} & 0.8 \\ & 0.5 \\ & 0.7 \end{aligned}$ | $\begin{aligned} & 5.1 \\ & 3.7 \\ & 4.4 \end{aligned}$ | $\begin{aligned} & 84.9 \\ & 60.8 \\ & 73.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ |
| 2002 | Cases | Male Female Total* | $\begin{array}{r} 368 \\ 94 \\ 463 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 1 \\ & 0 \\ & 1 \end{aligned}$ | $\begin{aligned} & 1 \\ & 1 \\ & 2 \end{aligned}$ | $\begin{array}{r} 47 \\ 0 \\ 47 \end{array}$ | $\begin{array}{r} 191 \\ 12 \\ 203 \end{array}$ | $\begin{aligned} & 4 \\ & 2 \\ & 6 \end{aligned}$ | $\begin{aligned} & 0 \\ & 1 \\ & 1 \end{aligned}$ | $\begin{array}{r} 7 \\ 3 \\ 10 \end{array}$ | $\begin{array}{r} 113 \\ 73 \\ 187 \\ \hline \end{array}$ | $\begin{aligned} & 4 \\ & 2 \\ & 6 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ |
|  | Rate | Male Female Total* | $\begin{aligned} & 2.4 \\ & 0.6 \\ & 1.5 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.2 \\ & 0.0 \\ & 0.1 \end{aligned}$ | $\begin{aligned} & 0.3 \\ & 0.3 \\ & 0.3 \end{aligned}$ | $\begin{aligned} & 1.3 \\ & 0.0 \\ & 0.6 \end{aligned}$ | $\begin{aligned} & 3.2 \\ & 0.2 \\ & 1.7 \end{aligned}$ | $\begin{aligned} & 0.7 \\ & 0.3 \\ & 0.5 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.2 \\ & 0.1 \end{aligned}$ | $\begin{aligned} & 0.4 \\ & 0.2 \\ & 0.3 \end{aligned}$ | $\begin{aligned} & 5.5 \\ & 3.5 \\ & 4.5 \end{aligned}$ | $\begin{aligned} & 26.2 \\ & 13.5 \\ & 19.9 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ | $\begin{aligned} & 0.0 \\ & 0.0 \\ & 0.0 \end{aligned}$ |

${ }^{1}$ Infectious syphilis: early symptomatic (primary and secondary) syphilis + early latent syphilis.
${ }^{2}$ Rate per 100000 population. Population estimates provided by Statistics Canada (Source: Annual Demographic Statistics, 2000 Catalogue no. 91-213 and unpublished data).
${ }^{3} 2002$ data are preliminary and changes are anticipated.
${ }^{4}$ As part of a review of historical data, all case counts (numerators) for infectious syphilis have been updated as of J anuary 2004.
${ }^{5}$ Data prior to 2000 are not available because Nunavut became a Canadian territory in April 1999. Data for 1999 were included with NT.
*Total includes cases not specified for sex.
Source: Sexual Health and Sexually Transmitted Infections, Community Acquired Infections Division, Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada, 2003.


[^0]:    ${ }^{1}$ Rate per 100000 population. Population estimates provided by Statistics Canada.
    ${ }^{2} 2002$ numbers are preliminary, and changes are anticipated.
    Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI.

[^1]:    ${ }^{1}$ Rate per 100000 population. Population estimates provided by Statistics Canada.
    ${ }^{2} 2002$ numbers are preliminary, and changes are anticipated.
    Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI.

[^2]:    ${ }^{1}$ Rate per 100000 population. Population estimates provided by Statistics Canada.
    ${ }^{2} 2002$ numbers are preliminary, and changes are anticipated.
    Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI.

[^3]:    ${ }^{1}$ Rate per 100000 population. Population estimates provided by Statistics Canada.
    ${ }^{2} 2002$ numbers are preliminary, and changes are anticipated.
    Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI.

[^4]:    ${ }^{1}$ Rate per 100000 population. Population estimates provided by Statistics Canada.
    ${ }^{2} 2002$ numbers are preliminary, and changes are anticipated.
    Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI.

[^5]:    ${ }^{1}$ Rate per 100000 population. Population estimates provided by Statistics Canada.
    ${ }^{2} 2002$ numbers are preliminary, and changes are anticipated.
    Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI.

[^6]:    ${ }^{1}$ Rate per 100000 population. Population estimates provided by Statistics Canada.
    ${ }^{2} 2002$ numbers are preliminary, and changes are anticipated.
    *The Northwest Territories was divided in April 1999 when Nunavut became a separate territory. To compare across time periods, these 2 territories have been combined.
    Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI.

[^7]:    'Rate per 100000 population. Population estimates provided by Statistics Canada.
    ${ }^{2} 2002$ numbers are preliminary, and changes are anticipated.
    Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI.

[^8]:    ${ }^{1}$ "Syphilis-free" indicates that no cases of infectious syphilis were reported in that jurisdiction.
    ${ }^{2} 2002$ numbers are preliminary, and changes are anticipated.
    Note: Small variability may exist between data reported by the provinces/territories and the Public Health Agency of Canada. Provincial/territorial data are definitive should a discrepancy exist.
    Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI.

[^9]:    ${ }^{1}$ Rate per 100000 population. Population estimates provided by Statistics Canada.
    ${ }^{2} 2002$ numbers are preliminary, and changes are anticipated.
    Source: Public Health Agency of Canada, Centre for Infectious Disease Prevention and Control, Community Acquired Infections Division, Sexual Health and STI.

